



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Mitsuru Shiraishi

Serial No. 10/524,452

Group Art Unit 1625

Filed August 29, 2005

Examiner CHANG, CELIA C

For : FUSED BENZENE DERIVATIVE AND USE

TRANSLATOR'S DECLARATION

Honorable Commissioner of Patents and Trademarks

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

I, Ritsuko Arimura, declare:

That I am well acquainted with both the Japanese and English languages;

That the attached document represents a true English translation of Japanese Patent Application No. 2002-235275 (filing date August 12, 2002); and

That I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 26th day of January, 2009.

... *Ritsuko Arimura* ...
Ritsuko Arimura



(Translation)

J A P A N P A T E N T O F F I C E

This is to certify that the annexed is a true copy of the following application as filed with this Office.

Date of Application : August 12, 2002

Application Number : 235275/2002

The country code and number
of your priority application,
to be used for filing abroad
under the Paris Convention, is

JP2002-235275

Applicant(s) : Takeda Pharmaceutical Company Limited

Commissioner, Japan Patent Office

【Document】 Petition for Patent

【Reference Number】 B02251

【Submission Date】 August 12, 2002

【To】 Commissioner of the Patent Office

【International Classification】 A61K 31/00

A61K 31/33

【Inventor】

【Address】 33-26, Tsukaguchicho 4-chome, Amagasaki-shi,
Hyogo 661-0002, Japan

【Name】 SHIRAISHI Mitsuru

【Inventor】

【Address】 12-4, Kikawanishi 1-chome, Yodogawa-Ku, Osaka-
shi, Osaka 532-0013, Japan

【Name】 HARA Takahito

【Inventor】

【Address】 4-102-301, Gakuenhigashimachi 1-chome, Nishi-Ku,
Kobe-shi, Hyogo 651-2102, Japan

【Name】 KUSAKA Masami

【Inventor】

【Address】 2-15-203, Taishocho Ibaraki-shi, Osaka 567-0867,
Japan

【Name】 KANZAKI Naoyuki

【Inventor】

【Address】 8-23-309, Tennou 1-chome, Ibaraki-shi, Osaka
567-0876, Japan

【Name】 YAMAMOYO Satoshi

【Inventor】

【Address】 17-23, Hinoikecho, Nishinomiya-shi, Hyogo 662-
0084, Japan

【Name】 MIYAWAKI Toshio

【Applicant】

【Identification Number】 000002934

【Name】 Takeda Pharmaceutical Company Limited

【Agent】

【Identification Number】 100114041

【Patent Attorney】

【Name】 Shuichi Takahashi

【Appointed Agent】

【Identification Number】 100106323

【Patent Attorney】

【Name】 Akira Sekiguchi


【Official Fee】

【Deposit Ledger Number】 005142

【Payment Amount】 ¥21,000

【List of the Annexed Documents】

【Document】 Claims	One copy
【Document】 Specification	One copy
【Document】 Abstract	One copy
【Number of General Power of Attorney】	9909276
【Number of General Power of Attorney】	0203423




【Document】 Specification

【Title of the Invention】 FUSED BENZENE DERIVATIVE AND USE

【What is Claimed is】

【Claim 1】 A compound represented by the general formula:



5 [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X^1 represents a carbon atom, X^2 represents a carbon atom, an oxygen atom or a group represented by the formula $S(O)_k$ (wherein k represents 0, 1 or 2), Y^1 represents a group represented by the formula CR^2R^3 (wherein R^2 and R^3 are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), Y^2 represents a group represented by the formula CR^4R^5 (wherein R^4 and R^5 are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), a nitrogen atom, an oxygen atom or a group represented by the formula $S(O)_m$ (wherein m represents 0, 1 or 2), or when Ring B is a further optionally substituted bicyclic ring, CR^2 in Y^1 or CR^4 or the nitrogen atom in Y^2 may constitute a part of Ring B, and R^1 represents an electron-withdrawing group, or a salt thereof.


【Claim 2】 The compound according to claim 1, wherein Ring A is an optionally substituted benzene ring.

【Claim 3】 The compound according to claim 1, wherein Ring B is an optionally substituted pyrrolidine ring, an optionally

5 **【Claim 4】** The compound according to claim 1, wherein R¹ is a cyano group, a nitro group, a halogen atom, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or a C₁₋₆ alkyl group substituted with 1 to 5 halogen atoms.


10 **【Claim 5】** The compound according to claim 1, wherein the
substituent on Ring A or Ring B except for R², R³, R⁴ and R⁵ is 1
to 6 groups selected from the group consisting of (1) a hydrogen
atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group,
(5) a hydroxy group, (6) an optionally substituted amino group,
15 (7) an optionally esterified or amidated carboxyl group, (8) an
optionally substituted C₁₋₆ alkyl group, (9) an optionally
substituted C₁₋₆ acyl group, (10) an optionally substituted C₁₋₆
alkoxy group, (11) a group represented by the formula R⁶S(O)_p
(wherein R⁶ represents an optionally substituted C₁₋₆ alkyl group,
20 and p represents 0, 1 or 2), (12) an oxo group, (13) a
hydroxyimino group, (14) an optionally substituted C₁₋₆
alkoxyimino group and (15) an optionally substituted C₁₋₄
alkylenedioxy group.

[Claim 6] A compound represented by the general formula:




25 R'
[wherein R⁷ represents a cyano group, a nitro group, a halogen
atom, an optionally substituted acyl group, an optionally
esterified or amidated carboxyl group or a C₁₋₆ alkyl group
substituted with 1 to 5 halogen atoms, R⁸ and R⁹ are the same or
30 different and each represents (1) a hydrogen atom, (2) a cyano

group, (3) a nitro group, (4) a C₁₋₆ alkyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (5) a C₁₋₆ acyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (6) a C₁₋₆ alkoxy group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group or (7) an optionally esterified or amidated carboxyl group, q represents 0, 1 or 2, Z¹ represents a carbonyl group, a carbon atom substituted with a hydroxyimino group or an optionally substituted C₁₋₆ alkoxyimino group, a carbon atom substituted with a C₁₋₄ alkylenedioxy group or a group represented by the formula:




(wherein R¹⁰ and R¹¹ are the same or different and each represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group, (5) a hydroxy group, (6) a C₁₋₆ alkyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (7) a C₁₋₆ acyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (8) a C₁₋₆ alkoxy group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (9) an amino group optionally substituted with a C₁₋₆ alkyl group and/or a C₁₋₆ acyl group or (10) an optionally esterified or amidated carboxyl group), and Z² represents an oxygen atom, a sulfur atom, SO, SO₂, a carbonyl group, a carbon atom substituted with a hydroxyimino group or an optionally substituted C₁₋₆ alkoxyimino group, an amino group optionally substituted with a C₁₋₆ alkyl group or a C₁₋₆ acyl group, a carbon atom substituted with a C₁₋₄ alkylenedioxy group or a group represented by the formula:




(wherein R¹² and R¹³ are the same or different and each represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group, (5) a hydroxy group, (6) a C₁₋₆ alkyl group optionally substituted with a halogen atom, a hydroxy group or a

C₁₋₆ alkoxy group, (7) a C₁₋₆ acyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (8) a C₁₋₆ alkoxy group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group, (9) an amino group optionally substituted with a C₁₋₆ alkyl group and/or a C₁₋₆ acyl group or (10) an optionally esterified or amidated carboxyl group)] or a salt thereof.

10 **[Claim 7]** A method for preparing the compound according to claim 1 or a salt thereof, comprising subjecting a compound represented by the general formula:



[wherein Ring A^a represents an optionally substituted 5- to 8-membered ring, Ring C^a represents a further optionally substituted benzene ring, X^{1a} represents a carbon atom, X^{2a} represents a carbon atom, an oxygen atom or a group represented by the formula S(O)_{k^a} (wherein k^a represents 0, 1 or 2), R^{1a} represents an electron-withdrawing group, and M represents a leaving group] or a salt thereof, and a compound represented by the general formula:



20 [wherein Ring B^a represents a further optionally substituted 4- to 10-membered ring, Y^{1a} represents a group represented by the formula CR^{2a}R^{3a} (wherein R^{2a} and R^{3a} are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), and Y^{2a} represents a group represented by the formula CR^{4a}R^{5a} (wherein R^{4a} and R^{5a} are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an

optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), a nitrogen atom, an oxygen atom or a group represented by the formula $S(O)_m^a$ (wherein m^a represents 0, 1 or 2), or when Ring
5 B is a further optionally substituted bicyclic ring, CR^2 in Y^1 or CR^4 or the nitrogen atom in Y^2 may constitute a part of Ring B] or a salt thereof to a reaction, and if desired, eliminating the protective group.

【Claim 8】 A prodrug of the compound according to claim 1 or 6.

10 【Claim 9】 A pharmaceutical composition comprising the compound according to claim 1 or 6 or a salt or a prodrug thereof.

【Claim 10】 The pharmaceutical composition according to claim 9, which is an androgen receptor agonist.

15 【Claim 11】 The pharmaceutical composition according to claim 9, which is an agent for preventing and/or treating hypogonadism.

【Claim 12】 The pharmaceutical composition according to claim 9, which is an agent for preventing and/or treating osteoporosis.

20 【Claim 13】 The pharmaceutical composition according to claim 9, which is an agent for preventing and/or treating hormone-resistant cancer.

【Claim 14】 The pharmaceutical composition according to claim 13, wherein the hormone-resistant cancer is LHRH agonist-resistant cancer.

25 【Claim 15】 The pharmaceutical composition according to claim 13 or 14, wherein the cancer is prostate cancer.

【Claim 16】 A method for preventing and/or treating hormone-resistant cancer, comprising administering an effective amount of an androgen receptor agonist to a mammal.

30 【Claim 17】 An agent for preventing and/or treating hormone-resistant cancer, comprising an androgen receptor agonist.

【Claim 18】 The agent according to claim 17, wherein the androgen receptor agonist is a non-steroidal compound.

【Detailed Description of the Invention】

【0001】

【Technical Field of the Invention】

The present invention relates to a condensed benzene derivative useful as an androgen receptor modulator and a method for preparing the same, etc.

5 **【0002】**

【Prior Art】

Androgens synthesized in the testis and the adrenal cortex, bind to an androgen receptor at the target organ, and exert various physiological activities. Natural androgens all belong
10 to C19 steroids chemically. The chief androgen among them is testosterone, which is synthesized at testis, incorporated into target cells and has strong physiological activity. For females, the adrenal cortex is a major source for androgens.

Androgens have actions of developing and maintaining the
15 functions of reproductive organs (prostate, seminal vesicle, epididymis, vas deferens, etc.), sexual differentiation at fetal stage, formation of sperm, expression of secondary sexual characteristics (induction of masculinization for muscle/backbone, voice, fat distribution, etc.), promoting protein anabolism at
20 muscle, etc., and actions for bone metabolism, etc. Therefore, insufficiency of androgen such as androgen deficiency by testis function disorders and castration, etc. is linked to various diseases and decrease of QOL (quality of life). For this, androgen supplement therapy is usually carried out. In addition
25 to testosterone, synthetic androgens having different balance of androgen action have been investigated, and applied in clinical practice.

On the other hand, in the case that androgens are associated with the progress of diseases, androgen deprivation therapy is
30 carried out. For example, for androgen-dependent prostate cancer, testosterone level is lowered by castration operation or GnRH agonist administration, to increase therapeutic effects.

【0003】

【Problems to be Solved by the Invention】

In the case of androgen supplements, testosterone or synthetic androgens are usually used. However, these substances have steroid backbones, and sometimes give a great burden to the liver, or exhibit actions of other steroid hormones. Therefore,
 5 an androgen receptor modulator having non-steroidal backbone (especially, agonist) is considered to be useful for improving diseases by deficient androgen actions (hypogonadism, etc.) and in diseases which is expected to be improved by actions of androgen (osteoporosis, etc.).

10 Furthermore, the present inventors have investigated and found that if the testosterone level is lowered by a castration operation or GnRH agonist administration, there may be cancer acquiring growth ability under such a lowered testosterone, and in such cancer, androgen agonists exhibit anti-tumor actions
 15 conversely.

Therefore, the object of the present invention is to provide an androgen receptor modulator (especially, agonist) having a non-steroidal backbone, to solve such problems.


【0004】

20 【Means of Solving the Problems】

The present inventors have made extensive studies considering the above-mentioned circumstances, and as a result, have found that a compound represented by the general formula (I) has excellent action as an androgen receptor modulator capable of
 25 accomplishing the above-mentioned objects, and reached completion of the present invention.

That is, the present invention relates to:

[1] A compound represented by the general formula:



[wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X^1 represents a carbon atom, X^2 represents a carbon atom, an oxygen atom or a group represented by the formula $S(O)_k$ (wherein k represents 0, 1 or 2), Y^1 represents a group represented by the formula CR^2R^3 (wherein R^2 and R^3 are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), Y^2 represents a group represented by the formula CR^4R^5 (wherein R^4 and R^5 are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), a nitrogen atom, an oxygen atom or a group represented by the formula $S(O)_m$ (wherein m represents 0, 1 or 2), or when Ring B is a further optionally substituted bicyclic ring, CR^2 in Y^1 or CR^4 or the nitrogen atom in Y^2 may constitute a part of Ring B, and R^1 represents an electron-withdrawing group, or a salt thereof;

[2] The compound as described in the above-mentioned [1], wherein Ring A is an optionally substituted benzene ring;


[3] The compound as described in the above-mentioned [1], wherein Ring B is an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring, an optionally substituted piperazine ring, an optionally substituted morpholine ring, an optionally substituted thiomorpholine ring or an optionally substituted perhydroazepine ring;

[4] The compound as described in the above-mentioned [1], wherein R^1 is a cyano group, a nitro group, a halogen atom, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or a C_{1-6} alkyl group substituted with 1 to 5 halogen atoms;

[5] The compound as described in the above-mentioned [1],


wherein the substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 is 1 to 6 groups selected from the group consisting of (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group, (5) a hydroxy group, (6) an optionally substituted amino group, (7) an optionally esterified or amidated carboxyl group, (8) an optionally substituted C_{1-6} alkyl group, (9) an optionally substituted C_{1-6} acyl group, (10) an optionally substituted C_{1-6} alkoxy group, (11) a group represented by the formula $R^6S(O)_p$ (wherein R^6 represents an optionally substituted C_{1-6} alkyl group, and p represents 0, 1 or 2), (12) an oxo group, (13) a hydroxyimino group, (14) an optionally substituted C_{1-6} alkoxyimino group and (15) an optionally substituted C_{1-4} alkylenedioxy group;

[6] A compound represented by the general formula:




[wherein R^7 represents a cyano group, a nitro group, a halogen atom, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or a C_{1-6} alkyl group substituted with 1 to 5 halogen atoms, R^8 and R^9 are the same or different and each represents (1) a hydrogen atom, (2) a cyano group, (3) a nitro group, (4) a C_{1-6} alkyl group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (5) a C_{1-6} acyl group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (6) a C_{1-6} alkoxy group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group or (7) an optionally esterified or amidated carboxyl group, q represents 0, 1 or 2, Z^1 represents a carbonyl group, a carbon atom substituted with a hydroxyimino group or an optionally substituted C_{1-6} alkoxyimino group, a carbon atom substituted with a C_{1-4} alkylenedioxy group or a group represented

by the formula:




(wherein R^{10} and R^{11} are the same or different and each represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group, (5) a hydroxy group, (6) a C_{1-6} alkyl group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (7) a C_{1-6} acyl group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (8) a C_{1-6} alkoxy group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (9) an amino group optionally substituted with a C_{1-6} alkyl group and/or a C_{1-6} acyl group or (10) an optionally esterified or amidated carboxyl group), and Z^2 represents an oxygen atom, a sulfur atom, SO, SO_2 , a carbonyl group, a carbon atom substituted with a hydroxyimino group or an optionally substituted C_{1-6} alkoxyimino group, an amino group optionally substituted with a C_{1-6} alkyl group or a C_{1-6} acyl group, a carbon atom substituted with a C_{1-4} alkylenedioxy group or a group represented by the formula:




(wherein R^{12} and R^{13} are the same or different and each represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) a nitro group, (5) a hydroxy group, (6) a C_{1-6} alkyl group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (7) a C_{1-6} acyl group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (8) a C_{1-6} alkoxy group optionally substituted with a halogen atom, a hydroxy group or a C_{1-6} alkoxy group, (9) an amino group optionally substituted with a C_{1-6} alkyl group and/or a C_{1-6} acyl group or (10) an optionally esterified or amidated carboxyl group)] or a salt thereof;

[7] a method for preparing the compound according to claim 1 or a salt thereof, comprising subjecting a compound represented by the general formula:



[wherein Ring A^a represents an optionally substituted 5- to 8-membered ring, Ring C^a represents a further optionally substituted benzene ring, X^{1a} represents a carbon atom, X^{2a} represents a carbon atom, an oxygen atom or a group represented by the formula S(O)_k^a (wherein k^a represents 0, 1 or 2), R^{1a} represents an electron-withdrawing group, and M represents a leaving group] or a salt thereof, and a compound represented by the general formula:



10

[wherein Ring B^a represents a further optionally substituted 4- to 10-membered ring, Y^{1a} represents a group represented by the formula CR^{2a}R^{3a} (wherein R^{2a} and R^{3a} are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), and Y^{2a} represents a group represented by the formula CR^{4a}R^{5a} (wherein R^{4a} and R^{5a} are the same or different and each represents a hydrogen atom, a cyano group, a nitro group, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group), a nitrogen atom, an oxygen atom or a group represented by the formula S(O)_m^a (wherein m^a represents 0, 1 or 2), or when Ring B is a further optionally substituted bicyclic ring, CR² in Y¹ or CR⁴ or the nitrogen atom in Y² may constitute a part of Ring B] or a salt thereof to a reaction, and if desired, eliminating the protective group;

[8] A prodrug of the compound as described in the above-mentioned [1] or [6];

[9] A pharmaceutical composition comprising the compound as described in the above-mentioned [1] or [6] or a salt or a prodrug thereof;

[10] The pharmaceutical composition as described in the
5 above-mentioned [9], which is an androgen receptor agonist;

[11] The pharmaceutical composition as described in the above-mentioned [9], which is an agent for preventing and/or treating hypogonadism;

[12] The pharmaceutical composition as described in the
10 above-mentioned [9], which is an agent for preventing and/or treating osteoporosis;

[13] The pharmaceutical composition as described in the above-mentioned [9], which is an agent for preventing and/or treating hormone-resistant cancer;

15 [14] The pharmaceutical composition as described in the above-mentioned [13], wherein the hormone-resistant cancer is LHRH agonist-resistant cancer;

[15] The pharmaceutical composition as described in the above-mentioned [13] or [14], wherein the cancer is prostate
20 cancer;

[16] A method for preventing and/or treating hormone-resistant cancer, comprising administering an effective amount of an androgen receptor agonist to a mammal;

[17] An agent for preventing and/or treating hormone-
25 resistant cancer, comprising an androgen receptor agonist;

[18] The agent as described in the above-mentioned [17], wherein the androgen receptor agonist is a non-steroidal compound.

【0005】

Furthermore, the present invention relates to:

30 [19] A medicine comprising the combination of the compound as described in the above-mentioned [1] or a salt or a prodrug thereof with an anticancer agent;

[20] A medicine comprising the combination of the compound as described in the above-mentioned [1] or a salt or a prodrug
35 thereof with a hormonal therapeutic agent;

[21] The medicine as described in the above-mentioned [20], wherein the hormonal therapeutic agent is a LH-RH modulator;

[22] The medicine as described in the above-mentioned [21], wherein the LH-RH modulator is a LH-RH agonist;

5 [23] The medicine as described in the above-mentioned [22], wherein the LH-RH agonist is leuporelin or a salt thereof;

[24] A method for preventing and/or treating cancer, comprising administering an effective amount of the compound as described in the above-mentioned [1] or a salt or a prodrug
10 thereof to a mammal;

[25] A method for preventing and/or treating cancer, comprising administering to a mammal an effective amount of the compound as described in the above-mentioned [1] or a salt or a prodrug thereof in combination with an effective amount of other
15 anticancer agent;

[26] A method for preventing and/or treating cancer, comprising administering to a mammal an effective amount of the compound as described in the above-mentioned [1] or a salt or a prodrug thereof in combination with an effective amount of a
20 hormonal therapeutic agent;

[27] The method as described in the above-mentioned [26], wherein the hormonal therapeutic agent is a LH-RH modulator;

[28] The method as described in the above-mentioned [27], wherein the LH-RH modulator is a LH-RH agonist;

25 [29] The method as described in the above-mentioned [28], wherein the LH-RH agonist is leuporelin or a salt thereof;

[30] A method for preventing and/or treating cancer, comprising administering an effective amount of the compound as described in the above-mentioned [1] or a salt or a prodrug
30 thereof to a mammal after an administration other anticancer agent;

[31] A method for preventing and/or treating cancer, comprising administering an effective amount of the compound as described in the above-mentioned [1] or a salt or a prodrug
35 thereof to a mammal before an application of surgery,

radiotherapy, gene therapy, thermotherapy, cryotherapy and/or laser cauterization;

[32] A method for preventing and/or treating cancer, comprising administering an effective amount of the compound as
5 described in the above-mentioned [1] or a salt or a prodrug thereof to a mammal after an application of surgery, radiotherapy, gene therapy, thermotherapy, cryotherapy and/or laser cauterization;

[33] Use of the compound as described in the above-mentioned
10 [1] or a salt or a prodrug thereof for the production of an androgen receptor agonist; and

[34] Use of the compound as described in the above-mentioned [1] or a salt or a prodrug thereof for the production of an agent for preventing and/or treating cancer.

15 **[0006]**

Hereinafter, the contents of the present invention will be explained specifically.

First, terms used in the present invention will be explained.

The "hydrocarbon group" in the "optionally substituted
20 hydrocarbon group" represented by R^2 , R^{2a} , R^3 , R^{3a} , R^4 , R^{4a} , R^5 and R^{5a} includes, for example, an "aliphatic linear hydrocarbon group", an "alicyclic hydrocarbon group" and an "aromatic hydrocarbon group".

The "aliphatic linear hydrocarbon group" as an example of
25 the hydrocarbon group includes, for example, a straight or branched aliphatic hydrocarbon group such as an alkyl group, an alkenyl group, an alkynyl group.

The "alkyl group" includes, for example, a C_{1-10} alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
30 sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 3,3-dimethylpropyl, 2-ethylbutyl, n-heptyl, 1-methylheptyl, 1-ethylhexyl, n-octyl, 1-methylheptyl, nonyl, etc., preferably a C_{1-6} alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl,
35 sec-butyl, tert-butyl, etc.), etc.

The "alkenyl group" includes, for example, a C₂₋₁₀ alkenyl group such as vinyl, allyl, isopropenyl, 2-methylallyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, etc., preferably a C₂₋₆ alkenyl group, etc.

The alkynyl group includes, for example, a C₂₋₁₀ alkynyl group such as ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne, 3-butyne, 1-pentyne, 2-pentyne, 3-pentyne, 4-pentyne, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl, preferably, C₂₋₆ alkynyl group, etc.

【0007】

The "alicyclic hydrocarbon group" as an example of the hydrocarbon group includes, for example, a cycloalkyl group, a cycloalkenyl group, cycloalkanedienyl group and a saturated or unsaturated, monocyclic or fused polycyclic alicyclic hydrocarbon group such as a dicyclic or tricyclic fused ring of these groups and a C₆₋₁₄ aryl group (e.g., benzene, etc.), etc.

The "cycloalkyl group" includes, for example, a C₃₋₁₀ cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, etc.

The "cycloalkenyl group" includes, for example, a C₃₋₁₀ cycloalkenyl group such as 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 1-cyclobuten-1-yl, 1-cyclopenten-1-yl, etc.

The "cycloalkanedienyl group" includes, for example, a C₄₋₆ cycloalkanedienyl group such as 2,4-cyclopentadien-1-yl, 2,4-cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl, etc.

The "aromatic hydrocarbon group" as an example of the hydrocarbon group includes monocyclic or fused polycyclic aromatic hydrocarbon group, and is not particularly limited but preferably, a C₆₋₂₂ aromatic hydrocarbon group, more preferably, a C₆₋₁₈ aromatic hydrocarbon group, further preferably, a C₆₋₁₀ aromatic hydrocarbon group, etc. Specifically, for example,

phenyl, o-tolyl, m-tolyl, p-tolyl, 2,3-xylyl, 2,4-xylyl, mesityl, o-cumenyl, m-cumenyl, p-cumenyl, α -methylbenzyl, benzhydryl, o-biphenyl, m-biphenyl, p-biphenyl, 1-naphthyl, 2-naphthyl, 2-indenyl, 2-anthryl, azulenyl, phenantholyl, fluorenyl, etc.,
 5 among these, phenyl, 1-naphthyl, 2-naphthyl, 2-anthryl, etc. are preferable.

【0008】

The "electron-withdrawing group" represented by R^1 and R^{1a} is not particularly limited as long as it has tendency to attract
 10 electrons of others generally on the basis of hydrogen in the molecule, and is used in organic chemistry, but for example, a cyano group, a nitro group, a halogen atom, an optionally substituted acyl group, an optionally esterified or amidated carboxyl group or a C_{1-6} alkyl group substituted with 1 to 5
 15 halogen atoms, etc can be used.

【0009】

The " C_{1-6} alkyl group" in the "optionally substituted C_{1-6} alkyl group" represented by R^6 and the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes those as defined
 20 above.

The " C_{1-6} alkoxy group" in the "optionally substituted C_{1-6} alkoxy group" represented by the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutyloxy, sec-
 25 butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy and 2-ethylbutyloxy, etc., preferably, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, etc.

30 The "halogen atom" represented by R^1 , R^{1a} , R^7 , R^{10} , R^{11} , R^{12} , R^{13} and the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, etc., preferably, a fluorine atom or a chlorine atom, etc.

35 【0010】

The "acyl group" in the "optionally substituted acyl group" represented by R^1 , R^{1a} , R^2 , R^{2a} , R^3 , R^{3a} , R^4 , R^{4a} , R^5 , R^{5a} and R^7 includes, for example, a lower (C_{1-6}) alkanoyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl; a lower (C_{3-7}) alkenoyl group such as acryloyl, methacryloyl, crotonoyl and isocrotonoyl; a C_{4-7} cycloalkanecarbonyl group such as a cyclopropanecarbonyl group, a cyclobutanecarbonyl group, a cyclopentanecarbonyl group and a cyclohexanecarbonyl group; a lower (C_{1-4}) alkanesulfonyl group such as mesyl, ethanesulfonyl and propanesulfonyl; a C_{7-14} aroyl group such as benzoyl, p-toluoyl, 1-naphthoyl and 2-naphthoyl; a C_{6-10} aryl lower (C_{2-4}) alkanoyl group such as phenylacetyl, phenylpropionyl, hydroatropoyl and phenylbutyryl; a C_{6-10} aryl lower (C_{3-5}) alkenoyl group such as cinnamoyl and atropoyl; a C_{6-10} arenesulfonyl group such as benzenesulfonyl and p-toluenesulfonyl group, etc.

The " C_{1-6} acyl group" in the "optionally substituted C_{1-6} acyl group" represented by the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes a lower (C_{1-6}) alkanoyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl; a lower (C_{3-6}) alkenoyl group such as acryloyl, methacryloyl, crotonoyl and isocrotonoyl; a C_{4-6} cycloalkanecarbonyl group such as a cyclopropanecarbonyl group, a cyclobutanecarbonyl group and a cyclopentanecarbonyl group, etc.

25 **[0011]**

The "optionally esterified or amidated carboxyl group" represented by R^1 , R^{1a} , R^2 , R^{2a} , R^3 , R^{3a} , R^4 , R^{4a} , R^5 , R^{5a} , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} and the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes a carboxyl group, alkoxycarbonyl, aryloxy carbonyl, aralkyloxy carbonyl, carbamoyl, N-monosubstituted carbamoyl and N,N-disubstituted carbamoyl, etc.

The "alkoxycarbonyl" as used herein includes, for example, lower (C_{1-6}) alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-

butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl and neopentyloxycarbonyl, etc., among these preferably, C₁₋₃ alkoxy carbonyl such as methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl, etc. The "lower alkoxy carbonyl" may have a
 5 substituent, and the substituent includes a hydroxy group, an optionally substituted amino group [the amino group, for example, may have 1 or 2 substituents such as a lower alkyl group (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc., preferably, methyl,
 10 ethyl, etc.) optionally substituted with 1 to 5 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), an acyl group (e.g., C₁₋₆ alkanoyl such as formyl, acetyl, propionyl and pivaloyl, benzoyl, etc.), a carboxyl group and C₁₋₆ alkoxy carbonyl, etc.], a halogen atom (e.g., fluorine, chlorine, bromine, iodine,
 15 etc.), a nitro group, a cyano group, a lower alkoxy group (e.g., C₁₋₆ alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, etc., preferably, methoxy, ethoxy, etc.) optionally substituted with 1 to 5 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), etc.
 20 Furthermore, these substituents may be the same or different and the number of substituents is preferably 1, 2 or 3 (more preferably 1 or 2).

The "aryloxycarbonyl" as used herein is preferably, for example, C₆₋₁₄ aryloxycarbonyl such as phenoxycarbonyl, 1-
 25 naphthoxycarbonyl, 2-naphthoxycarbonyl, 1-phenanthroxycarbonyl, etc. The "aryloxycarbonyl" may have a substituent, and the substituent includes those such as the above-mentioned substituents in the "alkoxy carbonyl" as the substituent in the same number.

30 The "aralkyloxycarbonyl" as used herein is preferably, for example, C₇₋₁₄ aralkyloxycarbonyl such as benzyloxycarbonyl, phenethyloxycarbonyl, etc. (preferably, C₆₋₁₀ aryl-C₁₋₄ alkoxy carbonyl, etc.). The "aralkyloxycarbonyl" may have a substituent, and the substituent includes those such as the above-mentioned
 35 substituents in the "alkoxy carbonyl" as the substituent in the

same number.

The "N-monosubstituted carbamoyl" as used herein includes, for example, lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.), lower alkenyl (e.g., C₂₋₆ alkenyl such as vinyl, allyl, isopropenyl, propenyl, butenyl, pentenyl, hexenyl, etc.), cycloalkyl (e.g., C₃₋₆ cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, etc.), aryl (e.g., C₆₋₁₀ aryl such as phenyl, 1-naphthyl, 2-naphthyl, etc.), aralkyl (e.g., C₇₋₁₀ aralkyl such as benzyl and phenethyl, preferably, phenyl-C₁₋₄ alkyl, etc.), arylalkenyl (e.g., C₈₋₁₀ arylalkenyl such as cinnamyl, preferably, phenyl-C₂₋₄ alkenyl, etc.), heterocyclic group (e.g., those such as the below-mentioned "heterocyclic group" in the "optionally substituted heterocyclic group" as a substituent, etc.), etc.

The lower alkyl, lower alkenyl, cycloalkyl, aryl, aralkyl, arylalkenyl and the heterocyclic group may have a substituent, and the substituent includes those such as the above-mentioned substituents in the "alkoxycarbonyl" as the substituent in the same number.

The "N,N-disubstituted carbamoyl" as used herein means a carbamoyl group having two substituents on the nitrogen atom. Examples of one of the two substituents include those such as the above-mentioned substituents in the "N-monosubstituted carbamoyl" as the substituent, and examples of the other substituent includes, for example, lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, etc.), C₃₋₇ cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.), C₇₋₁₀ aralkyl (e.g., benzyl and phenethyl, etc., preferably, phenyl-C₁₋₄ alkyl, etc.), etc.

Furthermore, the two substituents may form a cyclic amino together with the nitrogen atom, and in this case, the cyclic aminocarbamoyl includes, for example, a 3- to 8-membered (preferably, a 5- or 6-membered) cyclic aminocarbonyl such as 1-azetidinyldicarbonyl, 1-pyrrolidinylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, 1-piperazinylcarbonyl, and 1-

piperazinylcarbonyl optionally having lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, etc.), aralkyl (e.g., C₇₋₁₀ aralkyl such as benzyl, phenethyl, etc.), aryl (e.g., C₆₋₁₀ aryl such as phenyl, 1-naphthyl, 2-naphthyl, etc.), etc. at the position 4, etc.

[0012]

The "C₁₋₆ alkyl group substituted with 1 to 5 halogen atoms" represented by R¹, R^{1a} and R⁷ includes C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.) optionally having 1 to 5, preferably, 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.) etc., specifically, for example, fluoromethyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, 1-fluoroethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 2-fluoropropyl, 1,2-difluoropropyl, 3,3,3-trifluoropropyl, 1-fluorobutyl, 4,4,4-trifluorobutyl, 1-fluoropentyl, 5,5,5-trifluoropentyl, 1-fluorohexyl, 3,3-difluorohexyl, 6,6,6-trifluorohexyl, etc.

[0013]

The "optionally substituted amino group" represented by the "substituent on Ring A or Ring B except for R², R³, R⁴ and R⁵" includes groups such as the below-defined "optionally substituted amino group" in the "substituent".

The "C₁₋₆ alkoxyimino group" of the "optionally substituted C₁₋₆ alkoxyimino group" in the "carbon atom substituted with optionally substituted C₁₋₆ alkoxyimino group" represented by Z¹ and Z², and the "C₁₋₆ alkoxyimino group" in the "optionally substituted C₁₋₆ alkoxyimino group" represented by the "substituent on Ring A or Ring B except for R², R³, R⁴ and R⁵" include, for example, methoxyimino, ethoxyimino, n-propoxyimino, isopropoxyimino, n-butoxyimino, isobutyloxyimino, sec-butyloxyimino, tert-butyloxyimino, n-pentyloxyimino, isopentyloxyimino, neopentyloxyimino, n-hexyloxyimino, isohexyloxyimino, 1,1-dimethylbutyloxyimino, 2,2-dimethylbutyloxyimino, 3,3-dimethylbutyloxyimino, 2-

ethylbutyloxyimino, etc., preferably, methoxyimino, ethoxyimino, n-propoxyimino, isopropoxyimino, n-butoxyimino, etc.

【0014】

The "C₁₋₄ alkylenedioxy group" in the "carbon atom
5 substituted with a C₁₋₄ alkylenedioxy group" represented by Z¹ and Z², and the "C₁₋₄ alkylenedioxy group" in the "optionally substituted C₁₋₄ alkylenedioxy group" represented by the "substituent on Ring A or Ring B except for R², R³, R⁴ and R⁵" include, for example, a methylenedioxy group, an ethylenedioxy
10 group, a propylenedioxy group, a butylenedioxy group, etc., preferably, a methylenedioxy group, an ethylenedioxy group.

【0015】

The "C₁₋₆ alkyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group" represented by R⁸, R⁹,
15 R¹⁰, R¹¹, R¹² and R¹³ includes those substituted with 0 to 5, preferably 0 to 3 of the above-defined "halogen atom", a hydroxy group and the above-defined "C₁₋₆ alkoxy group" at the substitutable positions of the above-defined "C₁₋₆ alkyl group". It includes, for example, those substituted with 0 to 5,
20 preferably, 0 to 3 of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom; a hydroxy group; a C₁₋₆ alkoxy group such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutyloxy, sec-butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-
25 dimethylbutyloxy, 3,3-dimethylbutyloxy and 2-ethylbutyloxy, at the substitutable positions of a C₁₋₆ alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 3,3-
30 dimethylpropyl, 2-ethylbutyl and n-heptyl. It includes specifically methyl, fluoromethyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, hydroxymethyl, methoxymethyl, ethoxymethyl, pentyloxymethyl, ethyl, 1-fluoroethyl, 2-bromoethyl, 1,2-dichloroethyl, 1,2-dichloro-1-hydroxyethyl, 2,2,2-
35 trifluoroethyl, pentafluoroethyl, 1-hydroxyethyl, 1,2-

dihydroxyethyl, n-propyl, isopropyl, 1-hydroxypropyl, ethoxypropyl, 2-fluoropropyl, 1,2-difluoropropyl, 3,3,3-trifluoropropyl, n-butyl, isobutyl, 1-chlorobutyl, 4,4,4-trifluorobutyl, fluoromethoxybutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1-hydroxy-2-fluoro-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 1-fluoropentyl, 5,5,5-trifluoropentyl, n-hexyl, isohexyl, 1-fluorohexyl, 3,3-difluorohexyl, 6,6,6-trifluorohexyl, etc.

[0016]

10 The "C₁₋₆ acyl group optionally substituted with a halogen atom, a hydroxy group or a C₁₋₆ alkoxy group" represented by R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ includes those substituted with 0 to 5, preferably 0 to 3 of the above-defined "halogen atom", a hydroxy group and the above-defined "C₁₋₆ alkoxy group" at the
15 substitutable positions of the above-defined "C₁₋₆ acyl group". It includes, for example, those substituted with 0 to 5, preferably, 0 to 3 of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom; a hydroxy group; a C₁₋₆ alkoxy group such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutyloxy, 20 sec-butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy and 2-ethylbutyloxy, at the substitutable positions of a C₁₋₆ acyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, 25 pivaloyl, hexanoyl, acryloyl, methacryloyl, crotonoyl, isocrotonoyl, a cyclopropanecarbonyl group, a cyclobutanecarbonyl group and a cyclopentanecarbonyl group.

[0017]

The "C₁₋₆ alkoxy group optionally substituted with a halogen
30 atom, a hydroxy group or a C₁₋₆ alkoxy group" represented by R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ includes those substituted with 0 to 5, preferably 0 to 3 of the above-defined "halogen atom", a hydroxy group and the above-defined "C₁₋₆ alkoxy group" at the substitutable positions of the above-defined "C₁₋₆ alkoxy group".
35 It includes, for example, those substituted with 0 to 5,

preferably, 0 to 3, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom; a hydroxy group; a C₁₋₆ alkoxy group such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutyloxy, sec-butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy and 2-ethylbutyloxy at the substitutable positions of a C₁₋₆ alkoxy group such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutyloxy, sec-butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy and 2-ethylbutyloxy.

[0018]

The "amino group optionally substituted with a C₁₋₆ alkyl group and/or a C₁₋₆ acyl group" represented by R¹⁰, R¹¹, R¹² and R¹³ includes those in which the amino group is substituted with 0 to 2 groups selected from a C₁₋₆ alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl and a C₁₋₆ acyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, acryloyl, methacryloyl, crotonoyl, isocrotonoyl, a cyclopropanecarbonyl group, a cyclobutanecarbonyl group and a cyclopentanecarbonyl group.

[0019]

The "amino group optionally substituted with a C₁₋₆ alkyl group or a C₁₋₆ acyl group" represented by Z² includes those in which the amino group is substituted with 0 to 2 groups selected from a C₁₋₆ alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl and a C₁₋₆ acyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, acryloyl, methacryloyl, crotonoyl, isocrotonoyl, a cyclopropanecarbonyl group, a cyclobutanecarbonyl group and a cyclopentanecarbonyl group.

[0020]

k, m, p, q, k^a and m^a represent 0, 1 or 2. Therefore, when k, m, p, k^a and m^a represent 0 in the formulae S(O)_k, S(O)_m, S(O)_p,

$S(O)_k^a$ and $S(O)_m^a$, the formulae mean S; when k, m, p, k^a and m^a represent 1 in the formulae $S(O)_k$, $S(O)_m$, $S(O)_p$, $S(O)_k^a$ and $S(O)_m^a$, the formulae mean S(O); when k, m, p, k^a and m^a represent 2 in the formulae $S(O)_k$, $S(O)_m$, $S(O)_p$, $S(O)_k^a$ and $S(O)_m^a$, the formulae mean $S(O)_2$. Furthermore, when q represents 0, the formulae mean a chemical bond, when q represents 1, the formulae mean a methylene group, and when q represents 2, the formulae mean an ethylene group.

[0021]

10 The "5- to 8-membered ring" in the "optionally substituted 5- to 8-membered ring" represented by Ring A and Ring A^a includes, for example, "alicyclic hydrocarbon", "aromatic hydrocarbon", a "heterocycle", etc.

15 The "4- to 10-membered ring" in the "further optionally substituted 4- to 10-membered ring" represented by Ring B and Ring B^a includes, for example, a "non-aromatic heterocycle", etc.

[0022]

20 The "alicyclic hydrocarbon" includes, for example, cycloalkane, cycloalkene, cycloalkanediene and a saturated or unsaturated monocyclic or fused polycyclic C₅₋₈ or C₄₋₁₀ alicyclic hydrocarbon such as a bicyclic fused ring of these groups and benzene.

25 The "cycloalkane" includes, for example, C₃₋₁₀ cycloalkane such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, etc.

The "cycloalkene" includes, for example, C₃₋₁₀ cycloalkene such as cyclopentene, cyclohexene, cyclobutene, etc.

30 The "cycloalkanediene" includes, for example, C₄₋₆ cycloalkanediene such as cyclopentadiene, cyclohexadiene, cyclohexanediene, etc.

The "aromatic hydrocarbon" includes monocyclic or fused polycyclic aromatic hydrocarbon, and is not particularly limited but preferably, C₆₋₈ aromatic hydrocarbon, more preferably, C₆ aromatic hydrocarbon, etc., specifically, for example, benzene, 35 toluene, xylene, mesitylene, cumene, styrene, 1,2,3-

trimethylbenzene, pentalene, etc., preferably, benzene, toluene, etc.

【0023】

The "heterocycle" includes, for example, an aromatic
 5 heterocycle, a saturated or unsaturated non-aromatic heterocycle
 (an aliphatic heterocycle), etc., containing at least one
 (preferably, 1 to 4, further preferably, 1 to 2) hetero atoms of
 1 to 3 kinds (preferably, 1 to 2 kinds) selected from an oxygen
 atom, a sulfur atom and a nitrogen atom, etc. as a ring-
 10 constituting atom (a ring atom), and is not particularly limited
 but preferably, 4- to 10-membered or 5- to 8-membered heterocycle,
 etc.

Specific examples of the "aromatic heterocycle" include 5-
 or 6-membered aromatic monocyclic heterocycle (e.g., furan,
 15 thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole,
 imidazole, pyrazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-
 oxadiazole, furazan, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-
 thiadiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine,
 pyridazine, pyrimidine, pyrazine, triazine, etc.), and a 8- to
 20 12-membered aromatic fused heterocycle (e.g., 1*H*-pyrrolo[1,2-
 c]imidazole, pyrrolo[1,2-*a*]imidazol-4-ium, pyrrolo[1,2-
 c]imidazol-4-ium, pyrrolo[2,3-*c*]pyrazole, pyrrolo[3,2-*c*]pyrazole,
 pyrrolo[3,4-*c*]pyrazole, 1*H*-pyrrolo[3,2-*c*]pyrazole, pyrrolo[1,2-
 b]pyrazol-7-ium, 1*H*-furo[2,3-*d*]imidazole, 1*H*-furo[3,4-*d*]imidazole,
 25 1*H*-furo[2,3-*c*]pyrazole, 1*H*-furo[2,3-*d*]imidazole, 1*H*-furo[3,2-
 c]pyrazole, 1*H*-furo[3,4-*c*]pyrazole, 1*H*-thieno[2,3-*d*]imidazole,
 thieno[2,3-*b*]furan, 4*H*-imidazo[4,5-*d*]thiazole, imidazo[2,1-
 b]thiazole, 5*H*-pyrrolo[1,2-*c*]imidazole, etc.).

Specific examples of the "non-aromatic heterocycle" include,
 30 for example, a 4- to 10-membered or 5- to 8-membered saturated or
 unsaturated (preferably, saturated) non-aromatic heterocycle
 (aliphatic heterocycle) such as pyrroline, imidazoline,
 imidazolidine, pyrazoline, pyrazolidine, quinuclidine, aziridine,
 oxirane, azetidine, pyrrolidine, tetrahydrofuran, thiolane,
 35 piperidine, tetrahydropyran, dioxolane, thiazane, morpholine,

thiomorpholine, piperazine, azepane, perhydroindole, perhydropyrrolo[2,3-d]pyridine, perhydropyrrolo[3,2-d]pyridine, and the like.

Herein, when Ring B is a further optionally substituted bicyclic ring, CR² in Y¹ or CR⁴ or the nitrogen atom in Y² may constitute a part of Ring B.

[0024]

The substituent in the present invention such as the substituent in the "optionally substituted hydrocarbon group" represented by R², R^{2a}, R³, R^{3a}, R⁴, R^{4a}, R⁵ and R^{5a}; the substituent in the "optionally substituted 5- to 8-membered ring" represented by Ring A and Ring A^a; the substituent in the "further optionally substituted 4- to 10-membered ring" represented by Ring B and Ring B^a; the substituent in the "further optionally substituted benzene ring" represented by Ring C and Ring C^a; the substituent in the "optionally substituted benzene ring" of Ring A; the substituent in the "optionally substituted pyrrolidine ring", the "optionally substituted piperidine ring", the "optionally substituted piperazine ring", the "optionally substituted morpholine ring", the "optionally substituted thiomorpholine ring" or the "optionally substituted perhydroazepine ring" of Ring B is not particularly limited, but for example, (i) an optionally substituted alkyl group, (ii) an optionally substituted alkenyl group, (iii) an optionally substituted alkynyl group, (iv) an optionally substituted aryl group, (v) an optionally substituted aralkyl group, (vi) an optionally substituted cycloalkyl group, (vii) an optionally substituted cycloalkenyl group, (viii) an optionally substituted heterocyclic group, (ix) an optionally substituted amino group, (x) an optionally substituted imido group (e.g., a group represented by the formula -C(U')=N-U [wherein U and U' represent a hydrogen atom or a substituent (U represents preferably a hydrogen atom), etc.], (xi) an optionally substituted amidino group (e.g., a group represented by the formula -C(NE'E'')=N-E [wherein E, E' and E'' represent a hydrogen atom or a substituent (E represents

preferably a hydrogen atom)], etc.), (xii) an optionally substituted hydroxy group, (xiii) an optionally substituted thiol group, (xiv) an optionally substituted alkylsulfinyl group, (xv) an optionally esterified or amidated carboxyl group, (xvi) an optionally substituted thiocarbamoyl group, (xvii) an optionally substituted sulfamoyl group, (xviii) a halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc., preferably, chlorine, bromine, etc.); (xix) a cyano group, (xx) an isocyano group, (xxi) a cyanate group, (xxii) an isocyanate group, (xxiii) a thiocyanate group, (xxiv) an isothiocyanate group, (xxv) a nitro group, (xxvi) a nitroso group, (xxvii) a sulfonic acid-derived acyl group, (xxviii) a carbonic acid-derived acyl group, (xxix) an oxo group, (xxx) a C₁₋₄ alkylenedioxy group, etc. are used, These optional substituents may exist in the number of 1 to 5 (preferably, 1 to 3) at the substitutable positions.

【0025】

The alkyl group in the "optionally substituted alkyl group" as the above-mentioned substituent includes, for example, C₁₋₆ alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 1-methylpropyl, n-hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 3,3-dimethylpropyl, etc. Herein, the substituent of the alkyl group includes a lower alkoxy group (e.g., C₁₋₆ alkoxy such as methoxy, ethoxy, propoxy, etc.), a halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc.), a lower alkyl group (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, etc.), a lower alkenyl group (e.g., C₂₋₆ alkenyl such as vinyl, allyl, etc.), a lower alkynyl group (e.g., C₂₋₆ alkynyl such as ethynyl, propargyl, etc.), an optionally substituted amino group, an optionally substituted hydroxy group, a cyano group, an optionally substituted amidino group, a carboxy group, a lower alkoxycarbonyl group (e.g., C₁₋₆ alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, etc.), an optionally substituted carbamoyl group (e.g., a carbamoyl group optionally substituted with a C₁₋₆ alkyl group or an acyl group (e.g., formyl, C₂₋₆

alkanoyl, benzoyl, optionally halogenated C₁₋₆ alkoxy carbonyl, optionally halogenated C₁₋₆ alkylsulfonyl, benzenesulfonyl, etc.) optionally substituted with a 5- or 6-membered monocyclic aromatic heterocyclic group (e.g., pyridyl, etc.), 1-
 5 azetidiny carbonyl, 1-pyrrolidinyl carbonyl, piperidinocarbonyl, morpholinocarbonyl, 1-piperazinyl carbonyl, etc.), etc. These optional substituents may exist at the substitutable positions in the number of 1 to 3.

【0026】

10 The "optionally substituted amino group"; the "optionally substituted hydroxy group" and the "optionally substituted amidino group" as the substituent of the above-mentioned "optionally substituted alkyl group" includes those such as the "optionally substituted amino group", the "optionally substituted
 15 hydroxy group" and the "optionally substituted amidino group" as the substituent of the below-described "optionally substituted aromatic ring", etc.

【0027】

The alkenyl group in the "optionally substituted alkenyl
 20 group" as the above-mentioned substituent includes, for example, C₂₋₆ alkenyl such as vinyl, allyl, isopropenyl, 2-methylallyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl,
 25 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, etc. Herein, the substituent of the alkenyl includes those such as the above-mentioned substituent in the "optionally substituted alkyl group" as the substituent in the same number.

【0028】

30 The alkynyl group in the "optionally substituted alkynyl group" as the above-mentioned substituent includes, for example, C₂₋₆ alkynyl such as ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-
 35 hexynyl. Herein, the substituent of the alkynyl group includes

those such as the above-mentioned substituent in the "optionally substituted alkyl group" as the substituent in the same number.

【0029】

The aryl group in the "optionally substituted aryl group" as
5 the above-mentioned substituent includes, for example, C₆₋₁₄ aryl
such as phenyl, naphthyl, anthryl, phenantholyl, acenaphthylenyl,
etc. Herein, the substituent of the aryl group includes those
such as the above-mentioned substituent in the "optionally
substituted alkyl group" as the substituent in the same number.

10 **【0030】**

The aralkyl group in the "optionally substituted aralkyl
group" as the above-mentioned substituent includes, for example,
C₇₋₁₁ aralkyl such as benzyl, phenethyl, naphthylmethyl, etc.
Herein, the substituent of the aralkyl group includes those such
15 as the above-mentioned substituent in the "optionally substituted
alkyl group" as the substituent in the same number.

【0031】

The cycloalkyl group in the "optionally substituted
cycloalkyl group" as the above-mentioned substituent includes,
20 for example, C₃₋₇ cycloalkyl such as cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, etc. Herein, the
substituent of the cycloalkyl group includes those such as the
above-mentioned substituent in the "optionally substituted alkyl
group" as the substituent in the same number.

25 **【0032】**

The cycloalkenyl group in the "optionally substituted
cycloalkenyl group" as the above-mentioned substituent includes,
for example, C₃₋₇ cycloalkenyl such as cyclopropenyl, cyclobutenyl,
cyclopentenyl, cyclohexenyl, etc. Herein, the substituent of the
30 optionally substituted cycloalkenyl group includes those such as
the above-mentioned substituent in the "optionally substituted
alkyl group" as the substituent in the same number.

【0033】

The heterocyclic group in the "optionally substituted
35 heterocyclic group" as the above-mentioned substituent includes,

for example, an aromatic heterocyclic group, a saturated or unsaturated non-aromatic heterocyclic group (an aliphatic heterocyclic group), etc., containing at least one (preferably, 1 to 4, further preferably, 1 to 2) hetero atoms of 1 to 3 kinds (preferably, 1 to 2 kinds) selected from an oxygen atom, a sulfur atom and a nitrogen atom, etc. as a ring-constituting atom (a ring atom).

Herein, the "aromatic heterocyclic group" includes, for example, a 5- or 6-membered monocyclic aromatic heterocyclic group such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, and, for example, a 8 to 12-membered fused polycyclic aromatic heterocyclic group such as benzofuranyl, isobenzofuranyl, benzo[b]thienyl, indolyl, isoindolyl, 1H-indazolyl, benzindazolyl, benzoxazolyl, 1,2-benzoisoxazolyl, benzothiazolyl, benzopyranyl, 1,2-benzoisothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl, purinyl, pteridinyl, carbazolyl, α -carbolinyl, β -carbolinyl, γ -carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, phenanthridinyl, phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl, 1,2,4-triazolo[4,3-a]pyridyl, 1,2,4-triazolo[4,3-b]pyridazinyl, etc.

30 【0034】

Herein, the "non-aromatic heterocyclic group" includes, for example, a 3- to 8-membered (preferably, 5- or 6-membered) saturated or unsaturated (preferably, saturated) non-aromatic heterocyclic group (aliphatic heterocyclic group) such as oxiranyl, azetidiny, oxetanyl, thietanyl, pyrrolidinyl,

tetrahydrofuryl, thiolanyl, piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl, etc., or non-aromatic heterocyclic group in which the double bonds of the above-mentioned monocyclic aromatic heterocyclic group or the fused
 5 polycyclic aromatic heterocyclic group are saturated partially or completely such as 1,2,3,4-tetrahydroquinolyl and 1,2,3,4-tetrahydroisoquinolyl, etc.

The substituent which the "optionally substituted heterocyclic group" as the substituent may have, includes a lower
 10 alkyl group (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, etc.), a lower alkenyl group (e.g., C₂₋₆ alkenyl such as vinyl, allyl, etc.), a lower alkynyl group (e.g., C₂₋₆ alkynyl such as ethynyl, propargyl, etc.), an acyl group (e.g., C₁₋₆ alkanoyl such as formyl, acetyl, propionyl, pivaloyl, benzoyl, etc.), an
 15 optionally substituted amino group, an optionally substituted hydroxy group, a halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc., preferably, chlorine, bromine, etc.), an optionally substituted imido group, an optionally substituted amidino group, etc. These optional substituents may exist in the number
 20 of 1 to 5 (preferably, 1 to 3) at the substitutable positions.

The "optionally substituted amino group", the "optionally substituted hydroxy group", the "optionally substituted imido group" and the "optionally substituted amidino group", which the "optionally substituted heterocyclic group" as the substituent
 25 may have, include those such as the "optionally substituted amino group", the "optionally substituted hydroxy group", the "optionally substituted imido group" and the "optionally substituted amidino group" as the below-described substituent of the "optionally substituted aromatic ring", etc.

30 **[0035]**

The substituent in the "optionally substituted amino group", the "optionally substituted imido group", the "optionally substituted amidino group", the "optionally substituted hydroxy group" or the "optionally substituted thiol group" as the above-
 35 mentioned substituent, includes, for example, a lower alkyl group

(e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.) optionally substituted with a substituent selected from optionally halogenated C₁₋₆ alkoxy (e.g., methoxy, ethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, trichloromethoxy, 2,2,2-trichloroethoxy, etc.) and a C₇₋₁₁ alkylaryl group (e.g., o-tolyl, m-tolyl, p-tolyl, xylyl, mesityl, etc., preferably, C₁₋₅alkyl-phenyl, etc.), an acyl group (C₁₋₆ alkanoyl (e.g., formyl, acetyl, propionyl and pivaloyl, etc.), benzoyl, a C₁₋₆ alkylsulfonyl (e.g., methanesulfonyl, etc.), benzenesulfonyl, etc.), an optionally halogenated C₁₋₆ alkoxycarbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl, trifluoromethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, trichloromethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, etc.), a C₁₋₆ alkoxycarbonyl group optionally substituted with a phenyl group (e.g., benzyloxycarbonyl, etc.), aryl (e.g., C₆₋₁₀ aryl such as phenyl, 1-naphthyl, 2-naphthyl, etc.), aralkyl (e.g., C₇₋₁₀ aralkyl such as benzyl and phenethyl, preferably, phenyl-C₁₋₄ alkyl, etc.), arylalkenyl (e.g., C₈₋₁₀ arylalkenyl such as cinnamyl, preferably, phenyl-C₂₋₄ alkenyl, etc.), a heterocyclic group (those such as the "heterocyclic group" in the "optionally substituted heterocyclic group" as the above-mentioned substituent, preferably, pyridyl, further preferably, 4-pyridyl, etc.), etc. These optional substituents may exist at the substitutable positions in the number of 1 to 3.

25 **【0036】**

Furthermore, the "amino group" in the "optionally substituted amino group" as the above-mentioned substituent may be substituted with an optionally substituted imidoyl group (e.g., a C₁₋₆ alkylimidoyl (e.g., formylimidoyl, acetylimidoyl, etc.), a C₁₋₆ alkoxyimidoyl, a C₁₋₆ alkylthioimidoyl, amidino, etc.), an amino group optionally substituted with 1 or 2 C₁₋₆ alkyl groups, etc. These optional substituents may exist at the substitutable positions in the number of 1 or 2. Furthermore, the two substituents may form a cyclic amino group together with the nitrogen atom, and in such case, the cyclic amino group includes,

for example, 3- to 8-membered (preferably, 5- or 6-membered) cyclic amino such as 1-azetidiny, 1-pyrrolidinyl, piperidino, thiomorpholino, morpholino, 1-piperazinyl and 1-piperazinyl optionally having lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl and hexyl, etc.), aralkyl (e.g., C₇₋₁₀ aralkyl such as benzyl, phenethyl, etc.), aryl (e.g., C₆₋₁₀ aryl such as phenyl, 1-naphthyl, 2-naphthyl, etc.), etc. at the position 4, 1-pyrrolyl, 1-imidazolyl, etc.

【0037】

10 The alkylsulfinyl group in the "optionally substituted alkylsulfinyl group" as the above-mentioned substituent includes C₁₋₆ alkylsulfinyl such as methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl, 15 pentylsulfinyl and hexylsulfinyl. Herein, the substituent of the alkylsulfinyl includes those such as the above-mentioned substituent in the "optionally substituted alkyl" as the substituent in the same number.

【0038】

20 The "optionally esterified or amidated carboxyl group" as the above-mentioned substituent includes a carboxyl group, alkoxy-carbonyl, aryloxy-carbonyl, aralkyloxy-carbonyl, carbamoyl, N-monosubstituted carbamoyl and N,N-disubstituted carbamoyl.

Herein, the "alkoxy-carbonyl" includes, for example, C₁₋₆ alkoxy-carbonyl (lower alkoxy-carbonyl) such as methoxy-carbonyl, 25 ethoxy-carbonyl, propoxy-carbonyl, isopropoxy-carbonyl, butoxy-carbonyl, isobutoxy-carbonyl, sec-butoxy-carbonyl, tert-butoxy-carbonyl, pentyloxy-carbonyl, isopentyloxy-carbonyl, neopentyloxy-carbonyl, etc., among these preferably, C₁₋₃ alkoxy-carbonyl such as methoxy-carbonyl, ethoxy-carbonyl and 30 propoxy-carbonyl, etc. The "lower alkoxy-carbonyl" may have a substituent, and the substituent includes a hydroxy group, an optionally substituted amino group [for example, the amino group may have 1 or 2 substituents, such as a lower alkyl group (e.g., 35 C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl,

isobutyl, tert-butyl, pentyl, hexyl, etc., preferably, methyl, ethyl, etc.) optionally substituted with 1 to 5 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), an acyl group (e.g., C₁₋₆ alkanoyl such as formyl, acetyl, propionyl and
 5 pivaloyl, benzoyl, etc.), a carboxyl group and a C₁₋₆ alkoxy-carbonyl], a halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc.), a nitro group, a cyano group, a lower alkoxy group (e.g., C₁₋₆ alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, etc.,
 10 preferably, methoxy, ethoxy, etc.) optionally substituted with 1 to 5 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), etc. Furthermore, these substituents may be the same or different and the number of the substituent is preferably 1, 2 or 3 (more preferably 1 or 2).

15 **【0039】**

Herein, the "aryloxycarbonyl" is preferably, for example, C₆₋₁₄ aryloxycarbonyl such as phenoxycarbonyl, 1-naphthoxycarbonyl, 2-naphthoxycarbonyl, 1-phenanthroxycarbonyl, etc. The "aryloxycarbonyl" may have a substituent, and the substituent
 20 includes those such as the above-mentioned substituents in the "alkoxycarbonyl" as the substituent in the same number.

Herein, the "aralkyloxycarbonyl" is preferably, for example, C₇₋₁₄ aralkyloxycarbonyl such as benzyloxycarbonyl, phenethyloxycarbonyl, etc. (preferably, C₆₋₁₀ aryl-C₁₋₄ alkoxy-carbonyl, etc.). The "aralkyloxycarbonyl" may have a substituent,
 25 and the substituent includes those such as the above-mentioned substituents in the "alkoxycarbonyl" as the substituent in the same number.

Herein, the "N-monosubstituted carbamoyl" includes, for
 30 example, lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.), lower alkenyl (e.g., C₂₋₆ alkenyl such as vinyl, allyl, isopropenyl, propenyl, butenyl, pentenyl, hexenyl, etc.), cycloalkyl (e.g., C₃₋₆ cycloalkyl such as cyclopropyl, cyclobutyl,
 35 cyclopentyl and cyclohexyl, etc.), aryl (e.g., C₆₋₁₀ aryl such as

phenyl, 1-naphthyl, 2-naphthyl, etc.), aralkyl (e.g., C₇₋₁₀ aralkyl such as benzyl and phenethyl, preferably, phenyl-C₁₋₄ alkyl, etc.), arylalkenyl (e.g., C₈₋₁₀ arylalkenyl such as cinnamyl, preferably, phenyl-C₂₋₄ alkenyl, etc.), a heterocyclic group (e.g., those such
 5 as the "heterocyclic group" in the "optionally substituted heterocyclic group" as the above-mentioned substituent, etc.), etc. The lower alkyl, the lower alkenyl, the cycloalkyl, the aryl, the aralkyl, the arylalkenyl and the heterocyclic group may have a substituent, and the substituent includes those such as
 10 the above-mentioned substituents in the "alkoxycarbonyl" as the substituent in the same number.

【0040】

Herein, the "N,N-disubstituted carbamoyl" means a carbamoyl group having two substituents on the nitrogen atom. Examples of
 15 one of the two substituents include those such as the above-mentioned substituent in the "N-monosubstituted carbamoyl" as the substituent, and examples of the other substituent include, for example, lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, etc.), C₃₋₇
 20 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.), C₇₋₁₀ aralkyl (e.g., benzyl and phenethyl, etc., preferably, phenyl-C₁₋₄ alkyl, etc.), etc. Furthermore, the two substituents may form a cyclic amino together with the nitrogen atom, and in such case, the cyclic aminocarbamoyl includes, for
 25 example, a 3- to 8-membered (preferably, a 5- or 6-membered) cyclic aminocarbonyl such as 1-azetidinyldicarbonyl, 1-pyrrolidinylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, 1-piperazinylcarbonyl, and 1-piperazinylcarbonyl optionally having
 30 lower alkyl (e.g., C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, etc.), aralkyl (e.g., C₇₋₁₀ aralkyl such as benzyl, phenethyl, etc.), aryl (e.g., C₆₋₁₀ aryl such as phenyl, 1-naphthyl, 2-naphthyl, etc.), etc. at the position 4, etc.

【0041】

35 The substituent of the "optionally substituted thiocarbamoyl

group" and the "optionally substituted sulfamoyl group" as the above-mentioned substituent includes those such as the substituent of the "N-monosubstituted carbamoyl" or the "N,N-disubstituted carbamoyl" in the "optionally esterified or
5 amidated carboxyl group" as the above-mentioned substituent.

【0042】

The "sulfonic acid-derived acyl" as the above-mentioned substituent includes, for example, those in which the one substituent on the nitrogen atom of the above-mentioned "N-
10 monosubstituted carbamoyl" is bonded to sulfonyl, etc., preferably, acyl such as C₁₋₆ alkylsulfonyl such as methanesulfonyl and ethanesulfonyl.

【0043】

The "carboxylic acid-derived acyl" as the substituent
15 includes a hydrogen atom or those in which the one substituent on the nitrogen atom of the above-mentioned "N-monosubstituted carbamoyl" is bonded to carbonyl, preferably, acyl such as C₁₋₆ alkanoyl such as formyl, acetyl, propionyl and pivaloyl, and benzoyl.

20 【0044】

The "C₁₋₄ alkylenedioxy group" as the substituent includes a methylenedioxy group, an ethylenedioxy group, a propylenedioxy group, a butylenedioxy group, etc., which may be substituted on the same carbon or different carbons.

25 【0045】

The substituent in the "optionally substituted C₁₋₆ alkyl group" represented by R⁶ and the "substituent on Ring A or Ring B except for R², R³, R⁴ and R⁵" includes those such as the substituent used in the "optionally substituted alkyl group" as
30 the above-mentioned substituent in the same number.

The substituent in the "optionally substituted C₁₋₆ alkoxy group" represented by the "substituent on Ring A or Ring B except for R², R³, R⁴ and R⁵" includes those such as the substituent used in the "optionally substituted alkyl group" as the above-
35 mentioned substituent in the same number.

The substituent in the "optionally substituted acyl group" represented by R^1 , R^{1a} , R^2 , R^{2a} , R^3 , R^{3a} , R^4 , R^{4a} , R^5 , R^{5a} and R^7 includes those such as the substituent used in the "optionally substituted alkyl group" as the above-mentioned substituent in
 5 the same number.

The substituent in the "optionally substituted C_{1-6} acyl group" represented by the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes those such as substituent used in the "optionally substituted alkyl group" as the above-mentioned
 10 substituent in the same number.

The substituent in the "optionally substituted C_{1-6} alkoxyimino group" in the "carbon atom substituted with an optionally substituted C_{1-6} alkoxyimino group" represented by Z^1 and Z^2 and the "optionally substituted C_{1-6} alkoxyimino group" represented by the "substituent on Ring A or Ring B except for R^2 ,
 15 R^3 , R^4 and R^5 " includes those such as substituent used in the "optionally substituted alkyl group" as the above-mentioned substituent in the same number.

The substituent in the "optionally substituted C_{1-4} alkylenedioxy group" represented by the "substituent on Ring A or Ring B except for R^2 , R^3 , R^4 and R^5 " includes those such as substituent used in the "optionally substituted alkyl group" as the above-mentioned substituent in the same number.

【0046】

25 The "leaving group" represented by M includes, for example, halogen such as fluorine, chlorine, bromine and iodine, trifluoromethanesulfonate, p-toluenesulfonate, methanesulfonyl, etc.

【0047】

30 Ring A and ring Aa are optionally substituted, and when X^1 and/or X^2 , or X^{1a} and/or X^{2a} are(is) carbon atom(s), the carbon atom are(is) optionally substituted. The substituent includes those such as substituent used in the above-mentioned "optionally substituted hydrocarbon group" represented by R^2 , R^{2a} , R^3 , R^{3a} , R^4 ,
 35 R^{4a} , R^5 and R^{5a} in the same number.

Ring B and ring Ba are optionally substituted, and when Y² or Y^{2a} is a nitrogen atom, the nitrogen atom is optionally substituted. The substituent includes those such as substituent used in the above-mentioned "optionally substituted amino group" in the same number.

【0048】

Ring A or Ring A^a includes, especially preferably, an optionally substituted benzene ring, an optionally substituted furan ring, an optionally substituted dihydrofuran ring, an optionally substituted cyclopentene ring, an optionally substituted cyclohexene ring, an optionally substituted dihydropyran ring, an optionally substituted pyran ring, an optionally substituted thiophene ring, an optionally substituted pyrrole ring, an optionally substituted pyridine ring, an optionally substituted pyrroline ring, an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring, etc.

Ring B or Ring B^a includes, especially preferably, an optionally substituted pyrroline ring, an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring, an optionally substituted piperazine ring, an optionally substituted morpholine ring, an optionally substituted thiomorpholine ring or an optionally substituted perhydroazepine ring, etc.

R¹, R^{1a} and R⁷ include, especially preferably a cyano group, a nitro group, a halogen atom, a trifluoromethyl group, etc.


Substituents other than R², R³, R⁴ and R⁵ on Ring B are especially preferably a hydrogen atom, a halogen atom, a cyano group, a nitro group, a hydroxy group, an optionally substituted C₁₋₆ alkyl group, etc.

【0049】


[General preparation]

The compound of the present invention may be prepared by general organic synthesis methods, for example, by the following methods.


Compound (I) of the present invention can be synthesized by the following method.



Compound (I) of the present invention can be prepared by, for example, subjecting a compound represented by the formula (III):



[wherein each symbol is as defined above] or a salt thereof, and a compound represented by the formula (IV):



[wherein each symbol is as defined above] or a salt thereof to a reaction, and if it has protective group, eliminating the protective group. The "leaving group" includes represented by M, for example, halogen such as fluorine, chlorine, bromine and iodine, trifluoromethanesulfonate, p-toluenesulfonate, methanesulfonyl, etc.


Compound (IV) or a salt thereof is used usually in an amount of 1 to 3 moles per 1 mole of Compound (III). The reaction can be facilitated, if necessary, by adding a base such as potassium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium t-butoxide, potassium t-butoxide, triethylamine, diisopropylamine (DIEA), pyridine, 4-(dimethylamino)pyridine (DMAP), 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), 1,5-diazabicyclo[4,3,0]non-5-ene (DBN). Further, transition metal catalyst (e.g., J.O.C., 1997, 62, pp1264-1267) is suitably used as a catalyst.

For example, the reaction can be carried out in an inert


solvent, for example, methanol, ethanol, propanol, isopropanol, n-butanol, tetrahydrofuran, diethyl ether, acetonitrile, acetone, ethyl acetate, 1,2-dimethoxyethane, 1,4-dioxane, toluene, benzene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, DMF, dimethylsulfoxide (DMSO), etc., or a mixed solvent thereof. The reaction is carried out at the temperature range of about 0°C to 180°C. The reaction time is not particularly limited, usually 0.1 hour to 100 hours, preferably, 0.5 hours to 72 hours.

【0050】

Furthermore, Compound (I) can be prepared by, for example, subjecting a compound represented by the formula (V):



[wherein each symbol is as defined above] or a salt thereof and a compound represented formula (VI):



[wherein B^b represents a chain moiety to be Ring B^a after cyclization with the amino group of the above-mentioned formula (V), and L¹ and L² are the same or different and each represents a leaving group. Other symbols are as defined above.] to a reaction, and if it has protective group, eliminating the protective group. The "leaving group" represented by L¹ and L² may be the same or different and includes, for example, halogen such as fluorine, chlorine, bromine and iodine, and a sulfonyl group such as trifluoromethanesulfonyl, p-toluenesulfonyl, methanesulfonyl.

Compound (VI) is used in an amount of usually 1 to 3 moles per 1 mole of Compound (V) or a salt thereof. The reaction can be facilitated, if necessary, by adding a base such as potassium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium hydroxide, triethylamine, diisopropylamine

(DIEA), pyridine, 4-(dimethylamino)pyridine (DMAP), 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU) and 1,5-diazabicyclo[4,3,0]non-5-ene (DBN), and sodium iodide, etc.

For example, the reaction can be carried out in an inert
5 solvent, for example, methanol, ethanol, propanol, isopropanol, n-butanol, tetrahydrofuran, diethyl ether, acetonitrile, acetone, ethyl acetate, 1,2-dimethoxyethane, 1,4-dioxane, toluene, benzene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, DMF, dimethylsulfoxide (DMSO), etc., or mixed solvent thereof. The
10 reaction is carried out at the temperature range of about 0°C to 180°C. The reaction time is not particularly limited, usually 0.1 hour to 100 hours, preferably, 0.5 hours to 24 hours.

Further, one or more substituents on Ring B in Compound (I) can be converted to other substituents. For example, a carbonyl
15 group can be reduced to produce alcohol, and the alcohol can be dehydrated to produce olefin, or the alcohol can be alkylated to produce ether according to a known method per se.

Compound (III), (IV), (V) and (VI) which are used as starting materials can be synthesized by a known method or
20 modifications thereof, for example, by the methods described in the following Reference Examples.

Furthermore, the above-mentioned Compound (II) can also be synthesized by the above-mentioned method or known method or modifications thereof.

25 Herein, the group in the above-mentioned formulae may be protected with a protective group which is generally used in an organic synthesis, and after reaction, if desired, the protective group can be eliminated by a known method.

【0051】

30 The thus obtained Compound (I) or (II) can be isolated and purified by known separation and purification methods such as concentration, concentration under reduced pressure, solvent extraction, pH adjustment, salting out, crystallization, recrystallization, re-dissolution, chromatography, etc.

35 When Compound (I) or (II) is obtained as a free form, it can

be converted into a salt according to a conventional method or modifications thereof, and conversely when Compound (I), etc. is obtained as a salt, it can be converted into a free form or another salt according to a conventional method modifications thereof.

Compound (I) or (II) may be hydrated or non-hydrated.

When Compound (I) or (II) is obtained as a mixture of optically active substances, it can be separated into (S)-isomer or (R)-isomer with a known optical resolution per se.

Compound (I) or (II) may be labeled with an isotope (e.g., ^3H , ^{14}C , etc.), etc.

【0052】

The compounds represented by the formulas (I), (II), (III), (IV), (V) and (VI) in the present invention may form salts.

Salts of the compounds are not particularly limited as long as they do not interfere with the reaction, and include, for example, a salt with an inorganic base, an ammonium salt, a salt with an organic base a salt with an inorganic acid, a salt with an organic acid, a salt with an amino acid, etc. Preferable examples of the salt with an inorganic base include an alkali metal salt such as sodium salt, potassium salt, etc.; an alkaline earth metal salt such as calcium salt, magnesium salt, etc.; aluminum salt; ammonium salt; etc. Preferable examples of the salt with an organic base include a salt with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc. Preferable examples of the salt with an inorganic acid include a salt with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc. Preferable examples of the salt with an organic acid include a salt with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. Preferable examples of the salt with

a basic amino acid include a salt with arginine, lysine, ornithine, etc. Preferable examples of the salt with an acidic amino acid include a salt with aspartic acid, glutamic acid, etc.

【0053】

5 The prodrug of Compound (I) or (II) or a salt thereof (hereinafter, abbreviated to Compound (I)) means a compound which is converted to Compound (I) with a reaction using an enzyme, a gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to Compound
10 (I) with oxidation, reduction, hydrolysis, etc. according to an enzyme and a compound which is converted to Compound (I) with hydrolysis by gastric acid, etc. Examples of the prodrug of Compound (I) include a compound wherein an amino group of Compound (I) is substituted with acyl, alkyl, phosphoric acid,
15 etc. (e.g., a compound wherein an amino group of Compound (I) is substituted with eicosanyl, alanyl, pentylaminocarbonyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonyl, tetrahydrofuranyl, pyrrolidylmethyl, pivaloyloxymethyl, tert-butyl, etc.); a compound wherein a hydroxy group of Compound (I) is substituted
20 with acyl, alkyl, phosphoric acid, boric acid, etc. (e.g., a compound wherein a hydroxy group of Compound (I) is substituted with acetyl, palmitoyl, propanoyl, pivaloyl, succinyl, fumaryl, alanyl, dimethylaminomethylcarbonyl, etc.); a compound wherein a carboxyl group of Compound (I) is substituted with ester, amide,
25 etc. (e.g., a compound wherein a carboxyl group of Compound (I) is substituted with ethyl ester, phenyl ester, carboxymethyl ester, dimethylaminomethyl ester, pivaloyloxymethyl ester, ethoxycarbonyloxyethyl ester, phthalidyl ester, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester, cyclohexyloxycarbonyl ethyl ester,
30 methyl amide, etc.); etc. These prodrugs can be manufactured by the known method per se from Compound (I).

In addition, the prodrug of Compound (I) may be a compound which is converted into Compound (I) under the physiological conditions as described in "Pharmaceutical Research and
35 Development", Vol.7 (Molecular Design), pages 163-198 published

in 1990 by Hirokawa Publishing Co.

【0054】

Compound (I) or (II) or a salt thereof of the present invention or a prodrug thereof (hereinafter, it may be abbreviated to a compound of the present invention) has androgen receptor modulator actions, especially an androgen receptor agonist actions, and can be used for preventing or treating diseases for which administration of an androgen receptor agonist is effective in a mammal. The diseases for which administration of an androgen receptor agonist is effective, include hypogonadism, osteoporosis, hormone-resistant cancer (especially LHRH agonist-resistant cancer), climacteric disturbance, anemia, atherosclerosis, Alzheimer's disease, erection failure, depression or wasting diseases, etc.

The compound of the present invention is useful as an agent of preventing or treating breast cancer, prostate cancer, cancer of the uterine body, cancer of the uterine cervix, ovary cancer, bladder cancer, thyroid cancer, bone tumor, penis cancer, especially, prostate cancer, which has acquired hormone-resistance, among various cancers.

The hormone-resistant cancer includes, for example, LHRH derivative-resistant cancer, preferably, LHRH agonist-resistant cancer.

The compound of the present invention has low toxicity, and can be used as a medicine as itself, or as a pharmaceutical composition for a mammal (e.g., human, horse, bovine, dog, cat, rat, mouse, rabbit, pig, monkey, etc.) by mixing with pharmaceutically acceptable carriers according to a known method per se.

The pharmaceutical composition may contain other active ingredients, for example, following drugs for hormone therapy, anticancer agents (e.g., chemotherapeutic agents, immunotherapeutic agents, or cell growth factor and inhibitors for the receptor actions, etc.), in combination with the compound of the present invention etc.

【0055】

As a medicine for mammals such as humans, the compound of the present invention can be administered orally in the form of, for example, tablets, capsules (including soft capsules and
5 microcapsules), powders, and granules, or parenterally in the form of injections, suppositories, and pellets. Examples of the "parenteral administration route" include intravenous, intramuscular, subcutaneous, intra-tissue, intranasal, intradermal, instillation, intracerebral, intrarectal,
10 intravaginal, intraperitoneal, intratumoral, juxtaposition of tumor and administration directly to the lesion.

The dose of the compound of the present invention varies depending on route for administration, symptoms, etc. For example, in case of oral administration for patient (40 to 80 kg
15 body weight) with breast cancer or prostate cancer as an anticancer agent, the daily dose is 0.1 mg to 200 mg/kg body weight, preferably 1 to 100 mg/kg body weight, more preferably 1 to 50 mg/kg body weight, and it can be administered once or twice or three times per day.

20 【0056】

The compound of the present invention may be administered orally or parenterally as solid formulation such as tablet, capsule, granule, powder, etc.; or liquid formulation such as syrup, injection, etc. as admixture with a pharmaceutically
25 acceptable carrier.

Examples of the pharmaceutically acceptable carrier include various organic or inorganic carriers which are generally used in this field. For example, an excipient, a lubricant, a binder, a disintegrating agent, etc. are used in solid formulations, and a
30 solvent, a solubilizer, a suspending agent, an isotonizing agent, a buffer, a soothing agent, etc. are used in liquid formulations. In addition, if desired, an appropriate additive such as an antiseptic, antioxidant, a colorant, a sweetener, etc. may be used.

35 Suitable examples of the excipient include lactose, sucrose,

D-mannitol, starch, crystalline cellulose, light silicic acid anhydride, etc.

Suitable examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica, etc.

5 Suitable examples of the binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, etc.

 Suitable examples of the disintegrating agent include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium,
10 croscarmellose sodium, sodium carboxymethyl starch, etc.

 Suitable examples of the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, etc.

 Suitable examples of the solubilizer include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol,
15 trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.

 Suitable examples of the suspending agent include surfactants such as stearyl triethanolamine, sodium laurylsulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride,
20 benzethonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose hydroxyethyl cellulose, hydroxypropyl cellulose, etc.

 Suitable examples of the isotonizing agent include sodium
25 chloride, glycerin, D-mannitol, etc.

 Suitable examples of the buffer include a buffer solution of phosphate, acetate, carbonate, citrate, etc. Suitable examples of the soothing agent include benzyl alcohol, etc.

 Suitable examples of the antiseptic include paraoxybenzoates,
30 chlorobutanol, benzyl alcohol phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.

 Suitable examples of the antioxidant include sulfites, ascorbic acid, etc.

【0057】

35 A pharmaceutical composition can be manufactured by a

conventional method by containing the compound of the present invention in a ratio of normally 0.1 to 95% (w/w) to the total amount of the preparation, although the ratio varies depending on dosage form, method of administration, carrier, etc.

5 A combination of (1) administering an effective amount of a compound of the present invention and (2) 1 to 3 selected from the group consisting of (i) administering an effective amount of other anti-cancer agents, (ii) administering an effective amount of hormonal therapeutic agents and (iii) non-drug therapy can
10 prevent and/or treat cancer more effectively. The non-drug therapy includes, for example, surgery, radiotherapy, gene therapy, thermotherapy, cryotherapy, laser cauterization, etc., and two or more of these may be combined.

For example, the compound of the present invention can be
15 administered to the same subject simultaneously with hormonal therapeutic agents, anticancer agents (e.g., chemotherapeutic agents, immunotherapeutic agents, or drugs that inhibit the activity of growth factors or growth factor receptors), antiemetic agents (hereinafter, these are abbreviated to as a
20 combination drug).

Although the compound of the present invention exhibits excellent anticancer action even when used as a simple agent, its effect or QOL of patients can be enhanced by using it in combination with one or more of the combination drug(s) mentioned
25 above (multi-agent co-administration).

【0058】

The "hormonal therapeutic agents" include fosfestrol, diethylstilbestrol, chlorotrianiserin, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, cyproterone
30 acetate, danazol, allylestrenol, gestrinone, mepartricin, raloxifene, ormeloxifene, levormeloxifene, anti-estrogens (e.g., tamoxifen citrate, toremifene citrate, etc.), pill preparations, mepitiostane, testrolactone, aminoglutethimide, LH-RH agonists (e.g., goserelin acetate, buserelin, leuprorelin, etc.),
35 droloxifene, epitiostanol, ethinylestradiol sulfonate, aromatase

inhibitors (e.g., fadrozole hydrochloride, anastrozole, retrozole, exemestane, vorozole, formestane, etc.), anti-androgens (e.g., flutamide, bicartamide, nilutamide), 5 α -reductase inhibitors (e.g., finasteride, epristeride, etc.), adrenocorticohormone
 5 drugs (e.g., dexamethasone, prednisolone, betamethasone, triamcinolone, etc.), androgen synthesis inhibitors (e.g., abiraterone etc.), retinoid and drugs that retard retinoid metabolism (e.g., liarozole, etc.), etc. and LH-RH derivatives are preferable.

10 The "chemotherapeutic agents" include alkylating agents, antimetabolites, anticancer antibiotics, plant-derived anticancer agents, etc.

The "alkylating agents" include nitrogen mustard, nitrogen mustard N-oxide hydrochloride, chlorambucil, cyclophosphamide,
 15 ifosfamide, thiotepa, carboquone, improsulfan tosylate, busulfan, nimustine hydrochloride, mitobronitol, melphalan, dacarbazine, ranimustine, sodium estramustine phosphate, triethylenemelamine, carmustine, lomustine, streptozocin, pipobroman, etoglucid, carboplatin, cisplatin, miboplatin, nedaplatin, oxaliplatin,
 20 altretamine, ambamustine, dibrospidium hydrochloride, fotemustine, prednimustine, pumitepa, ribomustin, temozolomide, treosulphan, trophosphamide, zinostatin stimalamer, carboquone, adozelesin, systemustine, bizelesin etc.

The "antimetabolites" include mercaptopurine, 6-
 25 mercaptopurine riboside, thioinosine, methotrexate, enocitabine, cytarabine, cytarabine ocfosfate, ancitabine hydrochloride, 5-FU drugs (e.g., fluorouracil, tegafur, UFT, doxifluridine, carmofur, gallocitabine, emitefur, etc.), aminopterin, leucovorin calcium, tabloid, butocine, folinate calcium, levofolinate calcium,
 30 cladribine, emitefur, fludarabine, gemcitabine, hydroxycarbamide, pentostatin, piritrexim, idoxuridine, mitoguazone, thiazophrine, and ambamustine, etc.

The "anticancer antibiotics" include actinomycin-D, actinomycin-C, mitomycin-C, chromomycin-A3, bleomycin
 35 hydrochloride, bleomycin sulfate, peplomycin sulfate,

daunorubicin hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, pirarubicin hydrochloride, epirubicin hydrochloride, neocarzinostatin, mithramycin, sarcomycin, carzinophilin, mitotane, zorubicin hydrochloride, mitoxantrone
5 hydrochloride, idarubicin hydrochloride, etc.

The "plant-derived anticancer agents" include etoposide, etoposide phosphate, vinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, paclitaxel, docetaxel, DJ-927, vinorelbine, etc.

10 The "immunotherapeutic agents (BRM)" include picibanil, krestin, sizofiran, lentinan, ubenimex, interferons, interleukins, macrophage colony-stimulating factor, granulocyte colony-stimulating factor, erythropoietin, lymphotoxin, BCG vaccine, Corynebacterium parvum, levamisole, polysaccharide K, procodazole,
15 etc.

The "growth factor" in the "drugs that inhibit the activity of growth factors or growth factor receptors" includes any substances that promote cell proliferation, which are normally peptides having a molecular weight of not more than 20,000 that
20 are capable of exhibiting their activity at low concentrations by binding to a receptor, including (1) EGF (epidermal growth factor) or substances possessing substantially the same activity as it [e.g., EGF, heregulin (HER2 ligand), etc.], (2) insulin or substances possessing substantially the same activity as it [e.g.,
25 insulin, IGF (insulin-like growth factor)-1, IGF-2, etc.], (3) FGF (fibroblast growth factor) or substances possessing substantially the same activity as it [e.g., acidic FGF, basic FGF, KGF (keratinocyte growth factor), FGF-10, etc.], (4) other cell growth factors [e.g., CSF (colony stimulating factor), EPO
30 (erythropoietin), IL-2 (interleukin-2), NGF (nerve growth factor), PDGF (platelet-derived growth factor), TGF β (transforming growth factor β), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), etc.], etc.

The "growth factor receptors" include any receptors capable
35 of binding to the aforementioned growth factors, including EGF

receptor, heregulin receptor (HER2), insulin receptor, IGF receptor, FGF receptor-1 or FGF receptor-2, etc.

The "drugs that inhibit the activity of cell growth factor" include various kinase inhibitors, trastuzumab (Herceptin
5 (trademark): (HER2 antibody)), imatinib mesilate, ZD1839, cetuximab, etc.

In addition to the aforementioned drugs, L-asparaginase, aceglatone, procarbazine hydrochloride, protoporphyrin-cobalt complex salt, mercuric hematoporphyrin-sodium, topoisomerase I
10 inhibitors (e.g., irinotecan, nogitecan, exatecan (DX-8951f, DE-310, rubitecan, T-0128, etc.), topoisomerase II inhibitors (e.g., sobuzoxane, etc.), differentiation inducers (e.g., retinoid, vitamin D, etc.), angiogenesis inhibitors, α -blockers (e.g., tamsulosin hydrochloride), TZT-1027, etc., may be used.

15 The "antiemetic agents" includes 5-HT₃ antagonist such as ondansetron, tropisetron hydrochloride, azasetron, ramosetron, granisetron, dorasetron mesilate and palonosetron, a gastrointestinal tract motility promoter such as 5-HT₄ antagonist such as domperidone, mosapride and metoclopramide; a
20 gastrointestinal tract motility regulator such as trimebutine; phenothiazine drugs such as prochlorperazine maleate, promethazine and tiethylperazine; anxiolytics such as haloperidole, phenol phthalate chlorpromazine, diazepam and droperidole; steroids such as dexamethasone, prednisolone,
25 betamethasone and triamcinolone; other drugs such as dimethylhydric acid, diphenhydramine, hyoscin, hyoscin bromide and tetrabenazine, etc.

【0059】

The LH-RH derivative includes an LH-RH derivative or salt
30 thereof which is effective against hormone-dependent diseases, especially sex hormone-dependent diseases such as sex hormone-dependent cancers (e.g., prostate cancer, uterine cancer, breast cancer, hypophyseal tumor, hepatic cancer, etc.), prostatic hypertrophy, endometriosis, uterine myoma, precocious puberty,
35 dysmenorrhea, amenorrhea, premenstrual syndrome, multilocular

ovary syndrome, etc., and contraception (or infertility when rebound effect after drug withdrawal is applied). Further it includes an LH-RH derivative or salt thereof which is effective against benign tumor or malignant tumor which is sex hormone-
 5 independent and LH-RH sensitive.

Specific examples of the LH-RH derivatives or salt thereof include peptides described in "Treatment with GnRH analogs: Controversies and perspectives" issued in 1996 by The Parthenon Publishing Group Ltd., PCT Japanese Translation Patent
 10 Publication No. 91-503165, JP-A 91-101695, JP-A 95-97334 and JP-A 96-259460, etc.

【0060】


The LH-RH derivative includes LH-RH agonists and LH-RH antagonists. The LH-RH antagonist includes, for example, a
 15 physiologically active peptide represented by the formula:



[wherein X is N(4H₂-furoyl)Gly or NAc, A is a residue selected from NMeTyr, Tyr, Aph(Atz) and NMeAph(Atz), B is a residue selected from DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur),
 20 DhArg(Et₂), DAph(Atz) and DhCi, and C is Lys(Nisp), Arg or hArg(Et₂)] or a salt thereof, etc., especially preferably, abarelix, ganirelix, cetrorelix, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidin-2,4(1H,3H)-
 25 dione, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-ethylureido)phenyl]-3-phenylthieno[2,3-d]pyrimidin-2,4(1H,3H)-dione, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-ethylureido)phenyl]-3-phenylthieno[2,3-d]pyrimidin-2,4(1H,3H)-dione hydrochloride, etc.

30 【0061】

The LH-RH agonist includes, for example, a physiologically active peptide represented by the formula:



[wherein Y is a residue selected from DLeu, DAla, DTrp, DSer(tBu),
 35 D2Nal and DHis(ImBzl) and Z is NH-C₂H₅ or Gly-NH₂] or a salt

thereof, etc, especially, for example, goserelin acetate, buserelin, etc., suitably, a peptide wherein Y is DLeu, and Z is NH-C₂H₅ (that is, Peptide A represented by 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C₂H₅; leuprorelin) or a salt thereof
 5 (e.g., acetate).

The abbreviations for an amino acid, a peptide, a protecting group etc. in polypeptides described herein are based on abbreviations according to IUPAC-IUB Commission on Biochemical Nomenclature or conventional abbreviations in the art. In
 10 addition, when the amino acids have optical isomers, they represent L-form unless otherwise indicated.

Examples of abbreviations are shown below:

Abu: Aminobutyric acid
 Aibu: 2-Aminobutyric acid
 15 Ala: Alanine
 Arg: Arginine
 Gly: Glycine
 His: Histidine
 Ile: Isoleucine
 20 Leu: Leucine
 Met: Methionine
 Nle: Norleucine
 Nval: Norvaline
 Phe: Phenylalanine
 25 Phg: Phenylglycine
 Pro: Proline
 (Pyr)Glu: Pyroglutamic acid
 Ser: Serine
 Thr: Threonine
 30 Trp: Tryptophan
 Tyr: Tyrosine
 Val: Valine
 D2Nal: D-3-(2-naphthyl)alanine residue
 DSer(tBu): O-tert-butyl-D-serine
 35 DHis(ImBzl): N^{im}-benzyl-D-histidine

PAM: Phenylacetamidomethyl
 Boc: t-Butyloxycarbonyl
 Fmoc: 9-fluorenylmethyloxycarbonyl
 Cl-Z: 2-Chloro-benzyloxycarbonyl
 5 Br-Z: 2-Bromo-benzyloxycarbonyl
 Bzl: Benzyl
 Cl₂-Bzl: 2,6-Dichlorobenzyl
 Tos: p-Toluenesulfonyl
 HONb: N-hydroxy-5-norbornene-2,3-dicarboxyimide
 10 HOBt: 1-Hydroxybenzotriazole
 HOOBt: 3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine
 MeBzl: 4-Methylbenzyl
 Bom: Benzyloxymethyl
 Bum: t-Butoxymethyl
 15 Trt: Trityl
 DNP: Dinitrophenyl
 DCC: N,N'-dicyclohexylcarbodiimide

【0062】

Among the above-mentioned these especially, the combination
 20 drug is preferably a LH-RH agonist (e.g., goserelin acetate,
 buserelin, leuprorelin, etc.), etc.

【0063】

In combinations of the compound of the present invention and
 the combination drug, the administration time of the compound of
 25 the present invention and the combination drug is not restricted,
 and the compound of the present invention or the combination drug
 can be administered to the administration subject simultaneously,
 or may be administered at different times. The dosage of the
 combination drug may be determined according to the
 30 administration amount clinically used, and can be appropriately
 selected depending on the administration subject, administration
 route, disease, combination etc.

The administration mode of the compound of the present
 invention and the combination drug is not particularly limited,
 35 and it is sufficient that the compound of the present invention

and the combination drug are combined in administration. Examples of such administration mode include the following methods: (1) The compound of the present invention and the combination drug are simultaneously produced to give a single preparation which is administered. (2) The compound of the present invention and the combination drug are separately produced to give two kinds of preparations which are administered simultaneously by the same administration route. (3) The compound of the present invention and the combination drug are separately produced to give two kinds of preparations which are administered by the same administration route only at the different times. (4) The compound of the present invention and the combination drug are separately produced to give two kinds of preparations which are administered simultaneously by different administration routes. (5) The compound of the present invention and the combination drug are separately produced to give two kinds of preparations which are administered by different administration routes at different times (for example, the compound of the present invention and the combination drug are administered in this order, or in the reverse order). Hereafter, these administration modes are referred to as the combination preparation of the present invention.

【0064】

The combination preparation of the present invention has low toxicity, and for example, the compound of the present invention or (and) the above-mentioned combination drug can be mixed, according to a per se known method, with a pharmaceutically acceptable carrier to give pharmaceutical compositions, for example, tablets (including a sugar-coated tablet, film-coated tablet), powders, granules, capsules (including a soft capsule), solutions, injections, suppositories, sustained release agents etc. which can be safely administered orally or parenterally (e.g., local, rectum, vein, etc.). The injection can be administered by intravenous, intramuscular, subcutaneous, intra-tissue, intranasal, intradermal, instillation, intracerebral,

intrarectal, intravaginal, intraperitoneal, intratumoral, juxtaposition of tumor and administration directly to the lesion.

The pharmaceutically acceptable carrier which may be used in production of the combination preparation includes those used for
5 the above mentioned pharmaceutical composition of the present invention.

【0065】

The compounding ratio of the compound of the present invention to the combination drug in the combination preparation
10 of the present invention can be appropriately selected depending on the administration subject, administration route, diseases etc.

For example, the content of the compound of the present invention in the combination preparation differs depending on the form of preparation, and is usually from about 0.01% by weight to
15 100% by weight, preferably from about 0.1% by weight to 50% by weight, more preferably from about 0.5% by weight to 20% by weight, to the total of the preparation.

The content of the combination drug in the combination preparation of the present invention differs depending on the
20 form of preparation, and is usually from about 0.01% by weight to 100% by weight, preferably from about 0.1% by weight to 50% by weight, more preferably from about 0.5% by weight to 20% by weight, to the total of the preparation.

The content of additives such as a carrier etc. in the
25 combination preparation of the present invention differs depending on the form of preparation, and is usually from about 1% by weight to 99.99% by weight, preferably from about 10% by weight to 90% by weight, to the total of the preparation.

When the compound of the present invention and the
30 combination drug are formulated separately, the same contents may be adopted.

【0066】

These preparations can be manufactured by a per se known method commonly used in the pharmaceutical manufacturing process.

35 For example, the compound of the present invention and the

combination drug can be made as an injection such as an aqueous injection together with a dispersing agent (e.g., Tween 80 (manufactured by Atlas Powder, US), HCO 60 (manufactured by Nikko Chemicals Co., Ltd.), polyethylene glycol, carboxymethyl cellulose, sodium alginate, hydroxypropylmethyl cellulose, dextrin etc.), a stabilizer (e.g., ascorbic acid, sodium pyrosulfite, etc.), a surfactant (e.g., Polysorbate 80, macrogol etc.), a solubilizer (e.g., glycerin, ethanol etc.), a buffer (e.g., phosphoric acid and alkali metal salt thereof, citric acid and alkali metal salt thereof, etc.), an isotonizing agent (e.g., sodium chloride, potassium chloride, mannitol, sorbitol, glucose etc.), a pH regulator (e.g., hydrochloric acid, sodium hydroxide etc.), an antiseptic (e.g., ethyl p-oxybenzoate, benzoic acid, methylparaben, propylparaben, benzyl alcohol etc.), a dissolving agent (e.g., cone. glycerin, meglumine etc.), a dissolution aid (e.g., propylene glycol, sucrose etc.), a soothing agent (e.g., glucose, benzyl alcohol etc.), etc., or an oily injection by dissolving, suspending or emulsifying them in a vegetable oil such as olive oil, sesame oil, cotton seed oil, corn oil etc. or a dissolution aid such as propylene glycol, and molding them.

【0067】

In the case of a preparation for oral administration, the compound of the present invention and the combination drug can be made as a preparation for oral administration by adding an excipient (e.g., lactose, sucrose, starch etc.), a disintegrating agent (e.g., starch, calcium carbonate etc.), a binder (e.g., starch, arabic gum, carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl cellulose etc.), a lubricant (e.g., talc, magnesium stearate, polyethylene glycol 6000 etc.) etc., to the compound of the present invention or the combination drug, according to a per se known method, and compressing and molding the mixture, then if desired, coating the molded product by a per se known method for the purpose of masking of taste, enteric property or sustained release. The film forming agent includes, for example, hydroxypropylmethyl cellulose, ethyl cellulose, hydroxymethyl

cellulose, hydroxypropyl cellulose, polyoxyethylene glycol, Tween 80, Pluronic F68, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxymethyl cellulose acetate succinate, Eudragit (methacrylic acid/acrylic acid copolymer, manufactured by Rohm, DE), pigment (e.g., iron oxide red, titanium dioxide, etc.) etc. The preparation for oral administration may be either a rapid release preparation or a sustained release preparation.

【0068】

For example, in the case of a suppository, the compound of the present invention and the combination drug can be made into an oily or aqueous solid, semisolid or liquid suppository according to a per se known method. The oily substrate used in the above-mentioned composition includes, for example, glycerides of higher fatty acids [e.g., cacao butter, Witepsols (manufactured by Dynamite Nobel, DE), etc.], intermediate grade fatty acids [e.g., Miglyols (manufactured by Dynamite Nobel, DE), etc.], or vegetable oils (e.g., sesame oil, soy bean oil, cotton seed oil etc.), etc. Further, the aqueous base includes, for example, polyethylene glycols and propylene glycol, and the aqueous gel base includes, for example, natural gums, cellulose derivatives, vinyl polymers, acrylic acid polymers, etc.

The above-mentioned sustained release agent includes sustained release microcapsules, etc.

For obtaining a sustained release microcapsule, a per se known method can be adopted. For example, it is preferable to mold into a sustained release preparation shown in [2] below.

A compound of the present invention is preferably molded into an oral administration preparation such as a solid preparation (e.g., powder, granule, tablet, capsule, etc.) etc., or molded into a rectal administration preparation such as a suppository. Particularly, an oral administration preparation is preferable.

The combination drug can be made into the above-mentioned drug form depending on the kind of the drug.

【0069】

In the following, there will be shown specifically [1] an injection of the compound of the present invention or the combination drug and preparation thereof, [2] a rapid release preparation or sustained release preparation of the compound of the present invention or the combination drug and preparation thereof and [3] a sublingual tablet, a buccal or an intraoral quick integrating agent of the compound of the present invention or the combination drug or preparation thereof.

10 [1] Injection and preparation thereof

It is preferred that an injection is prepared by dissolving the compound of the present invention or the combination drug in water. This injection may be allowed to contain a benzoate and/or a salicylate.

15 The injection is obtained by dissolving the compound of the present invention or the combination drug, and if desired, a benzoate and/or a salicylate, into water.

The above-mentioned salts of benzoic acid and salicylic acid include, for example, salts of alkali metals such as sodium, potassium etc., salts of alkaline earth metals such as calcium, magnesium etc., ammonium salts, meglumine salts, organic acid salts such as tromethamol, etc.

The concentration of the compound of the present invention or the combination drug in the injection is from 0.5 w/v% to 50 w/v%, preferably from about 3 w/v% to about 20 w/v%. The concentration of a salt of benzoic acid or/and a salt of salicylic acid is from 0.5 w/v% to 50 w/v%, preferably from 3 w/v% to 20 w/v%.

【0070】

30 Conventional additives to be used in an injection may be appropriately added in a preparation of the present invention. Examples of the additives include a stabilizer (e.g., ascorbic acid, sodium pyrosulfite, etc.), a surfactant (e.g., Polysorbate 80, macrogol etc.), a solubilizer (e.g., glycerin, ethanol etc.), a buffer (e.g., phosphoric acid and alkali metal salt thereof,

35

citric acid and alkali metal salt thereof, etc.), an isotonizing agent (e.g., sodium chloride, potassium chloride, etc.), a dispersing agent (e.g., hydroxypropylmethyl cellulose, dextrin), a pH regulator (e.g., hydrochloric acid, sodium hydroxide etc.),
5 an antiseptic (e.g., ethyl p-oxybenzoate, benzoic acid etc.), a dissolving agent (e.g., conc. glycerin, meglumine etc.), a dissolution aid (e.g., propylene glycol, sucrose etc.), a soothing agent (e.g., glucose, benzyl alcohol etc.), etc. These additives are blended in a usual proportion generally employed in
10 an injection.

It is advantageous that the pH of the injection is controlled from 2 to 12, preferably from 2.5 to 8.0 by addition of a pH regulator.

An injection is obtained by dissolving the compound of the
15 present invention or the combination drug and if desired, a salt of benzoic acid and/or a salt of salicylic acid, and if necessary, the above-mentioned additives into water. These may be dissolved in any order, and can be appropriately dissolved in the same manner as in a conventional method of producing an injection.

20 An aqueous solution for injection may be advantageously heated, alternatively, for example, filter sterilization, high pressure heat sterilization, etc. can be conducted in the same manner as those for a usual injection, to provide an injection.

It may be advantageous that an aqueous solution for
25 injection is subjected to high pressure heat sterilization at 100°C to 121°C for 5 minutes to 30 minutes.

Further, a preparation endowed with the antibacterial property of a solution may also be produced so that it can be used as a preparation which is divided and administered multiple-
30 times.

【0071】

[2] Sustained release preparation or rapid release preparation, and preparation thereof

Preferred is a sustained release preparation which is
35 obtained, by coating a core containing the compound of the

present invention or the combination drug with a film forming agent such as a water-insoluble substance, swellable polymer, etc., if desired. For example, a sustained release preparation for oral once-a-day administration is preferable.

5 The water insoluble substance used in a film forming agent includes, for example, a cellulose ether such as ethyl cellulose, butyl cellulose, etc.; a cellulose ester such as cellulose acetate, cellulose propionate, etc.; a polyvinyl ester such as polyvinyl acetate, polyvinyl butyrate, etc.; an acrylic acid
10 polymer such as acrylic acid/methacrylic acid copolymer, methylmethacrylate copolymer, ethoxyethyl methacrylate/cinnamoethylmethacrylate/aminoalkyl methacrylate copolymer, polyacrylic acid, polymethacrylic acid, methacrylic acid alkyl amide copolymer, poly(methyl methacrylate),
15 polymethacrylate, polymethacryl amide, amino alkyl methacrylate copolymer, poly(methacrylic acid anhydride), glycidyl methacrylate copolymer, specially an Eudragit (manufactured by Rohm Pharma) such as Eudragit RS-100, RL-100, RS-30D, RL-30D, RL-PO, RS-PO (copolymer of ethyl acrylate/methyl
20 methacrylate/trimethyl chloride methacrylate/ammonium ethyl), Eudragit NE-30D (copolymer of methyl methacrylate/ethyl acrylate), etc., a hydrogenated oil such as hardened castor oil (e.g., Lovely wax (Freund Corporation), etc.), etc.; a wax such as carnauba wax, fatty acid glycerin ester, paraffin, etc.;
25 polyglycerin fatty acid ester, etc.

【0072】

The swellable polymer is preferably a polymer having acidic dissociating group and pH-dependent swelling property, and a polymer having acidic dissociating group which swells little in
30 an area such as stomach and swells in a neutral area such as the small intestine or the large intestine.

The polymer having acidic dissociating group and pH-dependent swelling property includes, for example, crosslinkable polyacrylic polymer such as Carbomer 934P, 940, 941, 974P, 980,
35 1342 etc., polycarbophil, calcium polycarbophil (all are

manufactured by BF Goodrich.), Hibiswako 103, 104, 105, 304 (all are manufactured by Wako Pure Chemical Industries, Ltd.), etc.

【0073】

The film forming agent used in a sustained release
5 preparation may further contain a hydrophilic substance.

The hydrophilic substance includes, for example, a polysaccharide optionally having sulfuric acid group such as pullulans, dextrin, arginic acid alkali metal salt, etc.; a polysaccharide having a hydroxyalkyl group or a carboxyalkyl
10 group such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, etc.; methyl cellulose; polyvinyl pyrrolidone; polyvinyl alcohol; polyethylene glycol; etc.

The content of water-insoluble substance in the film forming
15 agent of sustained release preparation is about 30% (w/w) to about 90% (w/w), preferably about 35% (w/w) to about 80% (w/w), and more preferably about 40% (w/w) to about 75% (w/w). The content of swellable polymer is about 3% (w/w) to about 30% (w/w), preferably about 3% (w/w) to about 15% (w/w). The film forming
20 agent may further contain a hydrophilic substance, in this case, the content of the hydrophilic substance in the film forming agent is about 50% (w/w) or less, preferably about 5% (w/w) to about 40% (w/w), and more preferably about 5% (w/w) to about 35% (w/w). This % (w/w) indicates % by weight based on a film
25 forming agent composition which is obtained by removing a solvent (e.g., water, lower alcohols such as methanol, ethanol etc.) from a film forming agent liquid.

【0074】

The sustained release preparation is manufactured by
30 preparing a core containing drug as exemplified below, then, coating the resultant core with a film forming agent liquid prepared by heating and dissolving a water-insoluble substance, swellable polymer, etc. or by dissolving or dispersing it in a solvent.

35 I. Preparation of core containing a drug

The form of a core containing a drug to be coated with a film forming agent (hereinafter, sometimes simply referred to as the core) is not particularly limited, and preferably, the core is formed into particles such as granules or fine particles.

5 When the core is composed of granules or fine particles, the average particle size thereof is preferably from about 150 to about 2,000 μm , further preferably, from about 500 μm to about 1,400 μm .

Preparation of the core can be conducted by a usual
10 preparation. For example, it can be prepared by mixing a suitable excipient, binding agent, disintegrating agent, lubricant, stabilizer, etc. with a drug, and subjecting the mixture to wet-extrusion granulating method or fluidized bed granulating method, etc.

15 The content of drugs in a core is from about 0.5% (w/w) to about 95% (w/w), preferably from about 5.0% (w/w) to about 80% (w/w), further preferably from about 30% (w/w) to about 70% (w/w).

【0075】

The excipient contained in the core includes, for example,
20 saccharides such as sucrose, lactose, mannitol, glucose etc., starch, crystalline cellulose, calcium phosphate, corn starch etc. Among them, crystalline cellulose, corn starch are preferable.

The binders include, for example, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, polyvinyl
25 pyrrolidone, Pluronic F68, arabic gum, gelatin, starch, etc. The disintegrators include, for example, carboxymethyl cellulose calcium (ECG505), croscarmellose sodium (Ac-Di-Sol), crosslinkable polyvinyl pyrrolidone (crospovidone), low-substituted hydroxypropyl cellulose (L-HPC), etc. Among these,
30 hydroxypropyl cellulose, polyvinyl pyrrolidone and low-substituted hydroxypropyl cellulose are preferable. The lubricants or the aggregation inhibitor includes, for example, talc, magnesium stearate and an inorganic salt thereof. The lubricant includes a polyethylene glycol, etc. The stabilizing
35 agent includes an acid such as tartaric acid, citric acid,

succinic acid, fumaric acid, maleic acid, etc.

【0076】

In addition to the above-mentioned, the core can also be prepared by, for example, a rolling granulation method in which a drug or a mixture of the drug with an excipient, lubricant, etc. is added portionwise onto an inert carrier particle which is the core of the core while spraying a binder dissolved in a suitable solvent such as water, lower alcohol (e.g., methanol, ethanol, etc.) etc., a pan coating method, a fluidized bed coating method or a melt granulating method. The inert carrier particle includes, for example, those made of sucrose, lactose, starch, crystalline cellulose or waxes, and the average particle size thereof is preferably from about 100 μm to about 1,500 μm .

For the purpose of separating the drug contained in the core from the film forming agent, the surface of the core may be coated with a protective agent. The protective agent includes, for example, the above-mentioned hydrophilic substances, water-insoluble substances etc. The protective agent includes, preferably polyethylene glycol, and polysaccharides having a hydroxyalkyl group or carboxyalkyl group, more preferably, hydroxypropylmethyl cellulose and hydroxypropyl cellulose. The protective agent may contain a stabilizer such as acids such as tartaric acid, citric acid, succinic acid, fumaric acid, maleic acid etc., and a lubricant such as talc etc. When the protective agent is used, the coating amount is from about 1% (w/w) to about 15% (w/w), preferably from about 1% (w/w) to about 10% (w/w), further preferably from about 2% (w/w) to about 8% (w/w), based on the core.

The coating of the protective agent can be carried out by a usual coating method, and specifically, the coating can be carried out by spraying the protective agent by a fluidized bed coating method, pan coating method etc.

【0077】

II. Coating of core with a film forming agent

A core obtained in the above-mentioned step I is coated with

a film forming agent liquid obtained by heating and dissolving the above-mentioned water-insoluble substance and pH-dependent swellable polymer, and a hydrophilic substance, or by dissolving or dispersing them in a solvent, to give a sustained release
5 preparation.

The method for coating a core with a film forming agent liquid includes, for example, a spray coating method etc.

The composition ratio of a water-insoluble substance, swellable polymer and hydrophilic substance in a film forming
10 agent liquid is appropriately selected so that the contents of these components in a coated film are the above-mentioned contents.

The coating amount of a film forming agent is from about 1% (w/w) to about 90% (w/w), preferably from about 5% (w/w) to about
15 50% (w/w), further preferably from about 5% (w/w) to 35% (w/w), based on a core (exclusive of the coating amount of the protective agent)

【0078】

The solvent in the film forming agent liquid includes water
20 or an organic solvent, alone or in admixture thereof. In the case of use in admixture, the mixing ratio of water to an organic solvent (water/organic solvent: weight ratio) can be varied in the range from 1 to 100%, and preferably from % to about 30%. The organic solvent is not particularly limited as long as it
25 dissolves a water-insoluble substance, and for example, it includes lower alcohols such as methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, etc., lower alkanones such as acetone, etc., acetonitrile, chloroform, methylene chloride, etc. Among them, lower alcohols are preferable, and ethyl alcohol and
30 isopropyl alcohol are particularly preferable. Water, and a mixture of water with an organic solvent are preferably used as a solvent for a film forming agent. In this case, if necessary, an acid such as tartaric acid, citric acid, succinic acid, fumaric acid, maleic acid, etc. may also be added into a film forming
35 agent liquid for stabilizing the film forming agent liquid.

An operation of coating by spray coating can be conducted by a usual coating method, and specifically, it can be conducted by spray-coating a film forming agent liquid onto a core, for example, by a fluidized bed coating method, pan coating method
5 etc. In this case, if necessary, talc, titanium oxide, magnesium stearate, calcium stearate, light anhydrous silicic acid etc. may also be added as a lubricant, and glycerin fatty ester, hydrogenated castor oil, triethyl citrate, cetyl alcohol, stearyl alcohol etc. may also be added as a plasticizer.

10 After coating with a film forming agent, if necessary, an antistatic agent such as talc etc. may be mixed.

【0079】

The rapid release preparation may be liquid (solution, suspension, emulsion etc.) or solid (particle, pill, tablet etc.).
15 It may be oral agents or parenteral agents such as an injection, etc., and preferably, oral agents.

The rapid release preparation, usually, may contain, in addition to an active component drug, also carriers, additives and excipients conventionally used in the field of formulation
20 (hereinafter, sometimes abbreviated as the excipient). The preparation excipient used is not particularly limited as long as it is an excipient ordinarily used as a preparation excipient. For example, the excipient for an oral solid preparation includes lactose, starch, corn starch, crystalline cellulose (Avicel PH101,
25 manufactured by Asahi Kasei Corporation, etc.), powder sugar, granulated sugar, mannitol, light anhydrous silicic acid, magnesium carbonate, calcium carbonate, L-cysteine, etc., and preferably, corn starch and mannitol, etc. These excipients can be used alone or in combination of two or more. The content of
30 the excipient is, for example, from about 4.5 w/w% to about 99.4 w/w%, preferably from about 20 w/w% to about 98.5 w/w%, further preferably from about 30 w/w% to about 97 w/w%, based on the total amount of the rapid release preparation.

The content of a drug in the rapid release preparation can
35 be appropriately selected in the range from about 0.5% to about

95%, preferably from about 1% to about 60% based on the total amount of the rapid release preparation.

【0080】

When the rapid release preparation is an oral solid
5 preparation, it usually contains a disintegrating agent in
addition to the above-mentioned components. The disintegrating
agent includes, for example, carboxymethyl cellulose calcium
(ECG-505, manufactured by GOTOKU CHEMICAL COMPANY LTD.),
croscarmellose sodium (for example, acjizol, manufactured by
10 Asahi Kasei Corporation), crospovidone (for example, colidone CL,
manufactured by BASF), low-substituted hydroxypropyl cellulose
(manufactured by Shin-Etsu Chemical Co., Ltd.),
carboxymethylstarch (manufactured by Matsutani Chemical Industry
Co., Ltd.), carboxymethylstarch sodium (Exprotab, manufactured by
15 Kimura Sangyo), partially α -starch (PCS, manufactured by Asahi
Kasei Corporation), etc., and for example, includes those which
disintegrate a granule by absorbing water in contact with water,
causing swelling, or making a channel between an effective
ingredient constituting the core and an excipient. These
20 disintegrating agents can be used alone or in combinations of two
or more. The amount of the disintegrating agent used is
appropriately selected depending on the kind and blending amount
of a drug used, formulation design for release property, etc.,
and for example, from about 0.05 w/w% to about 30 w/w%,
25 preferably from about 0.5 w/w% to about 15 w/w%, based on the
total amount of the rapid release preparation.

【0081】

When the rapid release preparation is an oral solid
preparation, it may further contain if desired, additives
30 conventional in solid preparations in addition to the above-
mentioned composition. Such an additive includes, for example, a
binder (e.g., sucrose, gelatin, arabic gum powder, methyl
cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose,
carboxymethyl cellulose, polyvinylpyrrolidone, pullulans,
35 dextrin, etc.), a lubricant (e.g., polyethylene glycol, magnesium

stearate, talc, light anhydrous silicic acid (for example, aerosil (Nippon Aerosil)), a surfactant (e.g., anionic surfactants such as sodium alkylsulfate, etc., nonionic surfactants such as polyoxyethylene fatty acid ester and
5 polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil derivatives, etc.), a coloring agent (e.g., tar coloring matter, caramel, iron oxide red, titanium oxide, riboflavins), if necessary, a corrigent (e.g., sweetening agent, flavor, etc.), an adsorbent, an antiseptic, a wetting agent, an antistatic agent,
10 etc. Further, a stabilizer such as an organic acid such as tartaric acid, citric acid, succinic acid, fumaric acid, etc. may also be added.

The above-mentioned binder includes preferably hydroxypropyl cellulose, polyethylene glycol and polyvinylpyrrolidone, etc.

15 The rapid release preparation can be prepared by mixing the above-mentioned components, and if necessary, further kneading the mixture, and molding it based on a usual technology of producing preparations. The above-mentioned mixing is conducted by generally used methods, for example, mixing, kneading, etc.
20 Specifically, when a rapid release preparation is formed, for example, into a particle, it can be prepared, according to the same means as in the above-mentioned method for preparing a core of a sustained release preparation, by mixing the components using a vertical granulator, universal kneader (manufactured by
25 Hata Iron Works Co., Ltd.), fluidized bed granulator FD-5S (manufactured by Powrex Corporation), etc., then, subjecting the mixture to a wet extrusion granulation method, fluidized bed granulation method, etc.

Thus obtained quick releasing preparation and sustained
30 releasing preparation may be themselves made into products or made into products appropriately together with preparation excipients etc., separately, by an ordinary method, then, may be administered simultaneously or may be administered in combination at any administration interval, or they may be themselves made
35 into one oral preparation (e.g., granule, fine particle, tablet,

capsule etc.) or made into one oral preparation together with preparation excipients etc. It may also be permissible that they are made into granules or fine particles, and filled in the same capsule to be used as a preparation for oral administration.

5 **【0082】**

 [3] Sublingual, buccal or intraoral quick disintegrating agent and preparation thereof

 Sublingual, buccal or intraoral quick disintegrating agents may be a solid preparation such as tablet etc., or may be an oral
10 mucosa membrane patch (film).

 The sublingual, buccal or intraoral quick disintegrating agent is preferably a preparation containing the compound of the present invention or the combination drug and an excipient. It may contain also auxiliary agents such as a lubricant,
15 isotonizing agent, hydrophilic carrier, water-dispersible polymer, stabilizer etc. Further, for easy absorption and increased bioavailability, β -cyclodextrin or β -cyclodextrin derivatives (e.g., hydroxypropyl- β -cyclodextrin etc.), etc. may also be contained.

20 The above-mentioned excipient includes lactose, sucrose, D-mannitol, starch, crystalline cellulose, light anhydrous silicic acid, etc. The lubricant includes magnesium stearate, calcium stearate, talc, colloidal silica, etc., and particularly preferably, magnesium stearate and colloidal silica. The
25 isotonizing agent includes sodium chloride, glucose, fructose, mannitol, sorbitol, lactose, saccharose, glycerin, urea, etc., and particularly preferably, mannitol. The hydrophilic carrier includes swellable hydrophilic carriers such as crystalline cellulose, ethyl cellulose, crosslinkable polyvinylpyrrolidone,
30 light anhydrous silicic acid, silicic acid, dicalcium phosphate, calcium carbonate etc., and particularly preferably, crystalline cellulose (e.g., fine crystalline cellulose, etc.). The water-dispersible polymer includes gums (e.g., gum tragacanth, acacia gum, cyamopsis gum), alginates (e.g., sodium alginate),
35 cellulose derivatives (e.g., methyl cellulose, carboxymethyl

cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose), gelatin, water-soluble starch, polyacrylic acids (e.g., Carbomer), polymethacrylic acid, polyvinyl alcohol, polyethylene glycol, polyvinylpyrrolidone, 5 polycarbophil, ascorbate, palmitates, etc., and preferably, hydroxypropylmethyl cellulose, polyacrylic acid, alginate, gelatin, carboxymethyl cellulose, polyvinylpyrrolidone, polyethylene glycol, etc., particularly preferably, hydroxypropylmethyl cellulose. The stabilizer includes cysteine, 10 thiosorbitol, tartaric acid, citric acid, sodium carbonate, ascorbic acid, glycine, sodium sulfite, etc., and particularly preferably, citric acid and ascorbic acid.

【0083】

The sublingual, buccal or intraoral quick disintegrating 15 agent can be manufactured by mixing the compound of the present invention or the combination drug and an excipient by a per se known method. Further, if desired, auxiliary agents such as a lubricant, isotonizing agent, hydrophilic carrier, water-dispersible polymer, stabilizer, coloring agent, sweetening agent, 20 antiseptic etc. may be mixed. The sublingual, buccal or intraoral quick disintegrating agent is obtained by mixing the above-mentioned components simultaneously or at a time interval, then subjecting the mixture to tablet-making molding under pressure. For obtaining suitable hardness, it may also be 25 permissible that the materials are moistened by using a solvent such as water, alcohol etc. if desired before and after the tablet making process, and after the molding, the materials are dried, to obtain a product.

【0084】

30 In the case of molding into a mucosa membrane patch (film), the compound of the present invention or the combination drug and the above-mentioned water-dispersible polymer (preferably, hydroxypropyl cellulose, hydroxypropylmethyl cellulose), excipient etc. are dissolved in a solvent such as water etc., and 35 the resulted solution is cast to give a film. Further, additives

such as a plasticizer, a stabilizer, an antioxidant, an antiseptic, a coloring agent, a buffer, a sweetening agent etc. may also be added. For imparting suitable elasticity to the film, glycols such as polyethylene glycol, propylene glycol, etc. may
5 be contained, or for enhancing adhesion of the film to an intraoral mucosa membrane lining, a bio-adhesive polymer (e.g., polycarbophil, carbopol) may also be contained. In the casting, a solution is poured on the non-adhesive surface, spread to uniform thickness (preferably, about 10 micron to about 1,000
10 micron) by an application tool such as a doctor blade etc., then, the solution is dried to form a film. It may be advantageous that thus formed film is dried at room temperature or under heat, and cut into given area.

【0085】

15 The intraoral quick disintegrating preparation is preferably solid quick diffuse preparation composed of a network body comprising the compound of the present invention or the combination drug, and a water-soluble or water-diffusible carrier which is inert to the compound of the present invention or the
20 combination drug. This network body is obtained by sublimating a solvent from the solid composition constituted of a solution prepared by dissolving the compound of the present invention or the combination drug in a suitable solvent.

The composition of an intraoral quick disintegrating agent
25 preferably contains a matrix forming agent and a secondary component in addition to the compound of the present invention or the combination drug.

The matrix forming agent includes animal proteins or vegetable proteins such as gelatins, dextrans, soybean, wheat and
30 psyllium seed protein etc.; rubber substances such as arabic gum, guar gum, agar, xanthane gum, etc.; polysaccharides; alginic acids; carboxymethyl celluloses; carrageenans; dextrans; pectins; synthetic polymers such as polyvinylpyrrolidone, etc.; substances derived from a gelatin-arabic gum complex, etc. Further, it
35 includes saccharides such as mannitol, dextrose, lactose,

galactose, trehalose, etc.; cyclic saccharides such as cyclodextrin etc.; inorganic salts such as sodium phosphate, sodium chloride and aluminum silicate, etc.; amino acids having 2 to 12 carbon atoms such as glycine, L-alanine, L-aspartic acid, 5 L-glutamic acid, L-hydroxyproline, L-isoleucine, L-leucine, L-phenylalanine, etc.

One or more of the matrix forming agent(s) can be introduced in a solution or suspension before solidification. Such matrix forming agent may be present in addition to a surfactant, or may 10 be present with the surfactant excluded. The matrix forming agents may help to keep the compound of the present invention or the combination drug diffused in the solution or suspension, in addition to formation of the matrix.

【0086】

15 The composition may contain secondary components such as a preservative, an antioxidant, a surfactant, a thickening agent, a coloring agent, a pH controlling agent, a flavoring agent, a sweetening agent, a food taste masking agent, etc. The coloring agent includes red, black and yellow iron oxides, and FD & C dyes 20 such as FD & C Blue 2, FD & C Red 40, etc. manufactured by Elis and Eberald. Examples of the suitable flavoring agent include mint, raspberry, licorice, orange, lemon, grape fruit, caramel, vanilla, cherry, grape flavor and combinations thereof. Examples of the suitable pH controlling agent include citric acid, 25 tartaric acid, phosphoric acid, hydrochloric acid and maleic acid. Examples of the suitable sweetening agent include aspartame, acesulfame K and thaumatine, etc. Examples of the suitable food taste masking agent include sodium bicarbonate, ion exchange resin, cyclodextrin-inclusion compounds, adsorbent substances and 30 microcapsulated apomorphine.

The preparation contains the compound of the present invention or the combination drug in an amount usually from about 0.1% by weight to about 50% by weight, preferably from about 0.1% by weight to about 30% by weight, and is preferably a preparation 35 (such as the above-mentioned sublingual agent, buccal etc.) which

can dissolve 90% or more the compound of the present invention or the combination drug (into water) within the time range of about 1 minute to about 60 minutes, preferably of about 1 minute to 15 minutes, more preferably of about 2 minutes to about 5 minutes, and intraoral quick disintegrating preparations which are disintegrated within the range of 1 second to 60 seconds, preferably of 1 to 30 seconds, further preferably of 1 to 10 seconds after being placed in the oral cavity.

【0087】

10 The content of the above-mentioned excipient in the whole preparation is from about 10% by weight to about 99% by weight, preferably from about 30% by weight to about 90% by weight. The content of β -cyclodextrin or β -cyclodextrin derivative in the whole preparation is from 0 to about 30% by weight. The content
15 of the lubricant in the whole preparation is from about 0.01% by weight to about 10% by weight, preferably from about 1% by weight to about 5% by weight. The content of the isotonizing agent in the whole preparation is from about 0.1% by weight to about 90% by weight, preferably, from about 10% by weight to about 70% by
20 weight. The content of the hydrophilic carrier agent in the whole preparation is from about 0.1% by weight to about 50% by weight, preferably, from about 10% by weight to about 30% by weight. The content of the water-dispersible polymer in the whole preparation is from about 0.1 to about 30% by weight,
25 preferably, from about 10% by weight to about 25% by weight. The content of the stabilizer in the whole preparation is from about 0.1% by weight to about 10% by weight, preferably, from about 1% by weight to about 5% by weight. The above-mentioned preparation may further contain additives such as a coloring agent, a
30 sweetening agent, an antiseptic, etc., if necessary.

【0088】

The dose of a combination preparation of the present invention differs depending on the kind of the compound (I) of the present invention, age, body weight, condition, drug form,
35 administration method, administration period etc., and for

example, for a prostate cancer patient (adult, body weight: about 60 kg), the combination preparation is administered intravenously, at a dose of about 0.01 to about 1,000 mg/kg/day, preferably about 0.01 to about 100 mg/kg/day, more preferably about 0.1 to
5 about 100 mg/kg/day, particularly about 0.1 to about 50 mg/kg/day, especially about 1.5 to about 30 mg/kg/day, in terms of the compound of the present invention or the combination drug, once or several times a day in divided portions. Of course, since the dose as described above varies depending on various conditions,
10 it may be sometimes sufficient to administer smaller amounts than the above-mentioned dosage, and further, it may be sometimes necessary to administer greater amounts than that.

The amount of the combination drug can be set at any value unless side effects are problematical. The daily dosage in terms
15 of the combination drug differs depending on the severity of symptoms, age, sex, body weight, sensitivity difference of the subject, administration time and interval, property, prescription, and kind of the pharmaceutical preparation, kind of effective ingredient, etc., and not particularly limited; for example, in
20 the case of oral administration, the dose of the drug is usually from about 0.001 mg to 2,000 mg, preferably from about 0.01 mg to 500 mg, further preferably from about 0.1 mg to 100 mg, per 1 kg body weight of a mammal, which is usually administered once to four times a day in divided portions.

25 【0089】

In administration of the combination preparation, the compound of the present invention may be administered after administration of the combination drug or the combination drug may be administered after administration of the compound of the
30 present invention, though they may be administered simultaneously. When administered at a time interval, the interval differs depending on the effective ingredient, drug form and administration method. For example, when the combination drug is administered first, the compound of the present invention is
35 administered within time range of from 1 minute to 3 days,

preferably from 10 minutes to 1 day, more preferably from 15 minutes to 1 hour after administration of the combined drug. When the compound of the present invention is administered first, the combined drug is administered within time range of from 1
5 minute to 1 day, preferably from 10 minutes to 6 hours, more preferably from 15 minutes to 1 hour after administration of the compound of the present invention.

In a preferable administration method, for example, the combination drug formulated into an oral administration
10 preparation is administered orally at a daily dose of about 0.001 mg/kg to 200 mg/kg, and 15 minutes later, the compound of the present invention formulated into an oral administration preparation is administered orally at a daily dose of about 0.005 mg/kg to 100 mg/kg.

15 **【0090】**

In addition, the pharmaceutical composition of the present invention or the combination preparation of the present invention can be combined with a non-drug therapy such as (1) surgery, (2) hypertensive chemotherapy using angiotensin II etc., (3) gene
20 therapy, (4) thermotherapy, (5) cryotherapy, (6) laser cauterization, (7) radiotherapy, etc.

For example, the pharmaceutical composition of the present invention or the combination preparation of the present invention exhibits effects of inhibiting an expression of resistance,
25 extending disease-free survival, suppressing cancer metastasis or recurrence, prolonging survival, etc. when used before or after surgery, etc., or a combination treatment comprising 2 or 3 of these therapies.

Also, treatment with the pharmaceutical composition of the
30 present invention or the combination preparation of the present invention can be combined with supportive therapies [e.g., (i) administration of antibiotics (e.g., β -lactams such as pamporin, etc., macrolides such as clarithromycin, etc.) to a combined expression of various infectious diseases, (ii) administration of
35 intravenous hyperalimentation, amino acid preparations and

general vitamin preparations for improvement of malnutrition,
(iii) morphine administration for pain mitigation, (iv)
administration of drugs which mitigate adverse reactions such as
nausea, vomiting, anorexia, diarrhea, leukopenia,
5 thrombocytopenia, hemoglobin concentration reduction, hair loss,
hepatopathy, renopathy, DIC, fever, etc., (v) administration of
drugs for inhibition of multiple drug resistance in cancer, etc.].

Preferably, the pharmaceutical composition of the present
invention or the combination preparation of the present invention
10 is administered orally (including sustained-release preparations),
intravenously (including boluses, infusions and clathrates),
subcutaneously and intramuscularly (including boluses, infusions
and sustained-release preparations), transdermally,
intratumorally or proximally before or after conducting the
15 above-described treatment.

As a period for administering the pharmaceutical composition
of the present invention or the combination preparation of the
present invention before surgery, etc., for example, it can be
administrated once about 30 minutes to 24 hours before surgery,
20 etc., or in 1 to 3 cycles about 3 months to 6 months before
surgery, etc. In this way, surgery, etc. can be conducted easily
because, for example, cancer tissue would be reduced by
administering the pharmaceutical composition of the present
invention or the combination preparation of the present invention
25 before surgery, etc.

For administering time of the pharmaceutical composition of
the present invention or the combination preparation of the
present invention after surgery, etc., for example, it can be
administrated repeatedly in a unit of a few weeks to 3 months,
30 about 30 minutes to 24 hours after surgery, etc. In this way, it
increases the effect of the surgery, etc. by administering the
pharmaceutical composition of the present invention or the
combination preparation of the present invention after the
surgery, etc.

The present inventors have found unexpectedly that an androgen receptor agonist suppresses growth of a hormone-resistant cancer, and further that an androgen receptor agonist having non-steroidal backbone such as the compound of the present invention is useful for preventing and/or treating the hormone-resistant cancer.

Further object of the present invention is to provide a method for preventing and/or treating hormone-resistant cancer comprising administering an androgen receptor agonist, and an agent for preventing and/or treating hormone-resistant cancer comprising an androgen receptor agonist.

The androgen receptor agonist includes a steroidal androgen receptor agonist and a non-steroidal androgen receptor agonist.

The steroidal androgen receptor agonist includes endogenous androgens such as dehydroepiandrosterone, testosterone, dihydrotestosterone (DHT) and androstendione, synthetic androgens (anabolic steroid) such as mestanolone, oxymesterone, methandrostenolone, fluoxymesterone, chlorotestosterone acetate, methenolone acetate, oxymetholone, stanozolol, furazabol, oxandrolone, 19-nortestosterone, norethandrolone and ethylestrenol, norbolethone, etc.

The non-steroidal androgen receptor agonist includes LGD-2226, etc. in addition to the compound of the present invention (I).

The androgen receptor agonist includes the above-mentioned compounds, alone or in combination of two or more, especially preferably, a non-steroidal androgen receptor agonist.

【0092】

The cancer includes prostate cancer, etc.

The hormone-resistant cancer includes, for example, LHRH derivative-resistant cancer, etc., preferably, LHRH derivative-resistant prostate cancer, more preferably, LHRH agonist-resistant cancer, further preferably, LHRH agonist-resistant prostate cancer.

Herein, the LHRH derivative and the LHRH agonist are as the

compounds defined above.

【0093】

The method of preventing and/or treating hormone-resistant cancer comprising administering an androgen receptor agonist
5 includes,

(a) administering an effective amount of an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) or a salt thereof, etc. to a mammal having hormone-resistant prostate cancer cells,

10 (b) administering an effective amount of a LHRH derivative or a salt thereof, etc. to a mammal having prostate cancer cells, and after prostate cancer cells become hormone-resistant, administering an effective amount of an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) or a salt
15 thereof,

(c) administering a combination of an effective amount of a LHRH derivative or a salt thereof and an effective amount of an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) or a salt thereof to a mammal having prostate
20 cancer cells,

(d) administering a combination of an effective amount of a LHRH derivative or a salt thereof and an effective amount of an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) or a salt thereof to a mammal having prostate
25 cancer cells to reduce prostate cancer, followed by conducting surgical operation or radiotherapy,

(e) 1) administering an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) or a salt thereof for a prescribed period to hormone-resistant prostate
30 cancer cells, 2) then if the cancer cells become hormone-dependent, administering an effective amount of one or more compounds selected from a LHRH derivative, a lyase inhibitor, an aromatase inhibitor and an antiandrogen or a salt thereof, or if the cancer cell become hormone-resistant, administering an
35 effective amount of an androgen receptor agonist (especially a

non-steroidal androgen receptor agonist) or a salt thereof, and
3) if necessary, repeating the process of 2) until the object of
the cancer treatment is achieved,

(f) administering alternatively an effective amount of 1) an
5 androgen receptor agonist (especially a non-steroidal androgen
receptor agonist) or a salt thereof and 2) one or more compounds
selected from a LHRH derivative, a lyase inhibitor, an aromatase
inhibitor and an antiandrogen or a salt thereof (e.g., during the
period of 3 months to 5 years), etc.

10 【0094】

By administering an effective amount of a LHRH derivative, a
lyase inhibitor, an aromatase inhibitor or antiandrogens or a
salt thereof for the prescribed period (e.g., 3 months to 5
years), hormone-resistance of prostate cancer cells may be
15 increased. Then, by administering an effective amount of an
androgen receptor agonist (especially a non-steroidal androgen
receptor agonist) or a salt thereof, growth of prostate cancer
cells may be suppressed or the cancer may be reduced. By
continuing administration of an androgen receptor agonist
20 (especially a non-steroidal androgen receptor agonist), hormone-
resistance of the prostate cancer cells may return again to the
level of normal cells. Alternatively, if the prostate cancer
growth is initiated (tumor accumulation, etc. is increased), it
is converted to administration of one or more compounds selected
25 from a LHRH derivative, a lyase inhibitor, an aromatase inhibitor
and an antiandrogen or a salt thereof. Then, depending on level
of the hormone-resistance of the cancer, it is converted
selectively to (i) administration of one or two compounds
selected from a LHRH derivative, a lyase inhibitor, an aromatase
30 inhibitor and an antiandrogen or a salt thereof (when the
hormone-resistance of the cancer is in the same level as normal
cells [for example, LNCaP 104-Scell (Cancer Res, 54, p1566-1573),
LNCaP-FGC cell, etc.]), or (ii) administration of an androgen
receptor agonist (especially a non-steroidal androgen receptor
35 agonist) or a salt thereof (when the hormone-resistance of the

cancer is elevated than normal cells [for example, LNCaP 104-R2cell (Cancer Res, 54, p1566-1573), LNCaP-hr cell, etc.]), which allows to carry out optimal therapy for the prostate cancer.

The conversion timing for such administrations may be suitably set for every therapy, but for example, it is in the range of 3 months to 5 years, preferably, 6 months year to 4 years, more preferably, 1 year to 3 years, further preferably, 1 year to 2 years.

Therefore, if MAB (Maximum androgen blockade) therapy, etc. is conducted by administering a LHRH derivative (e.g., LHRH agonist, etc.), a lyase inhibitor, an aromatase inhibitor or antiandrogens, etc. for the prescribed period, the chance increases that the prostate cancer become more hormone-resistant, and then the therapy by combination of an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) or a salt thereof of the present invention may exert the effects. In this case, an androgen receptor agonist (especially a non-steroidal androgen receptor agonist) may be administered with continuing the administration of the LHRH derivative, or it may be converted to administration of the androgen receptor agonist (especially the non-steroidal androgen receptor agonist) with discontinuing administration of the LHRH derivative, both of which are included in the present invention.

Hormone-resistance of cancer can be measured by a method of examining reactivity of cancer cells to an androgen, or can be estimated by a tumor marker or a physiological index under administration of a prescribed drug, or increase or decrease of tumor accumulation.

【0095】

【Mode of Embodiment of the Invention】

The present invention is hereinafter described in detail by means of the following Reference Examples, Examples, Formulation Examples and Experimental Examples, but is not limited thereto.

In the reference examples and examples, elution of column chromatography was conducted under observation by TLC (thin layer

chromatography). In TLC observation, the TLC plate used was the Merck Kieselgel 60F₂₅₄ plate, the developing solvent used was the solvent used as the eluent for column chromatography, and the means of detection used was a UV detector. The silica gel for
5 the column chromatography was also Merck Kieselgel 60F₂₅₄ (70 to 230 mesh). NMR spectrum was proton-NMR, and was measured with tetramethylsilane as the internal standard, by using the Varian Gemini-200 (200 MHz type spectrometer), Varian Mercury-300 (300 MHz) or the JMTCO400/54 (400 MHz) type spectrometer manufactured
10 by JEOL; δ values are expressed in ppm.

Infrared spectrum (IR) was measured using Paragon 1000 manufactured by PerkinElmer.

The abbreviations used in the reference examples and examples are defined as follows:

15 s: Singlet
br: Broad
d: Doublet
t: Triplet
q: Quartet
20 dd: Double doublet
ddd: Double double doublet
dt: Double triplet
m: Multiplet
J: Coupling constant
25 Hz: Hertz

【0096】

【Examples】

Reference Example 1

To a mixture of copper sulfate (11.4 g) and water (80 ml)
30 was added sodium iodide (13.9 g) at room temperature, and the mixture was stirred at 0°C for 10 minutes. Sulfuric acid (3.0 ml) and nitric acid (3.0 ml) were added thereto, and after 5 minutes, 4-nitro-1-naphthylamine (5.00 g) was added thereto. After 5 minutes, a mixture of sodium nitrite (2.57 g) and water
35 (5.0 ml) was added thereto at 0°C for 1 hour. The mixture was

extracted with ethyl acetate, and the extracts were washed with sodium thiosulfate solution and brine, dried, and concentrated. The obtained residue was purified by silica gel column chromatography to give 1-iodo-4-nitronaphthalene (1.70 g).

5 ¹H-NMR (300 MHz, CDCl₃) δ: 7.69-7.80 (2H, m), 7.87 (1H, d, *J*=8.1 Hz), 8.22 (1H, d, *J*=8.1 Hz), 8.25-8.28 (1H, m), 8.46-8.49 (1H, m).

【0097】

Reference Example 2

A mixture of 1-iodo-4-nitronaphthalene (1.70 g), sodium
10 trifluoroacetate (3.07 g), copper iodide (I) (2.10 g) and 1-methyl-2-pyrrolidone (40 ml) was stirred at 160°C for 5 hours under argon atmosphere. After cooling to room temperature, brine and ethyl acetate were added thereto, and the insolubles were filtered off using celite. The mother liquor was distributed,
15 and the organic layer was washed with brine, dried, and concentrated. The obtained residue was purified by silica gel column chromatography to give 1-nitro-4-(trifluoromethyl)naphthalene (897 mg).

¹H-NMR (300 MHz, CDCl₃) δ: 7.74-7.83 (2H, m), 7.96 (1H, d, *J*=7.8
20 Hz), 8.09 (1H, d, *J*=7.8 Hz), 8.28-8.32 (1H, m), 8.39-8.45 (1H, m).

【0098】

Reference Example 3

A mixture of 1-nitro-4-(trifluoromethyl)naphthalene (813 mg), 10% palladium carbon (50% water content, 717 mg), methanol (16
25 ml) was stirred at room temperature for 1.5 hours under hydrogen atmosphere. The palladium carbon was filtered off using celite. The mother liquor was concentrated and the obtained residue was purified by silica gel column chromatography to give 4-(trifluoromethyl)-1-naphthylamine (634 mg).

30 ¹H-NMR (300 MHz, CDCl₃) δ: 4.46 (2H, br.s), 6.71 (1H, d, *J*=8.1 Hz), 7.49-7.62 (2H, m), 7.66 (1H, d, *J*=8.1 Hz), 7.82-7.85 (1H, m), 8.12-8.16 (1H, m).

【0099】

Reference Example 4

35 To a mixture of 4-amino-1-naphthonitrile (250 mg) and

dichloromethane (10 ml) was added bromine (75 μ L) at room temperature. After stirring for 2.5 hours, sodium hydrogen carbonate solution was added thereto, and the mixture was extracted with ethyl acetate. The extracts were washed with
 5 sodium thiosulfate solution, and brine, dried, and concentrated. The obtained residue was purified by silica gel column chromatography to give 4-amino-3-bromo-1-naphthonitrile (301 mg).
 $^1\text{H-NMR}$ (CDCl_3) δ : 5.23 (2H, br.s), 7.59 (1H, ddd, $J=8.4$, 6.8 and 1.4 Hz), 7.68 (1H, ddd, $J=8.4$, 6.8 and 1.4 Hz), 7.93 (1H, s),
 10 8.14-8.18 (1H, m).

IR (KBr) 3366, 2215, 1632 cm^{-1}

【0100】

Reference Example 5

To a mixture of (S)-ethyl nipecotate (1.15 g) and
 15 tetrahydrofuran (16 ml) was added lithium aluminum hydride (278 mg) at 0°C . The mixture was stirred for 3 hours with elevating the temperature to room temperature. Water (0.28 ml), 25% potassium hydroxide solution (0.28 ml) and water (0.84 ml) were added thereto in this order, and the mixture was stirred for 15
 20 hours. The insolubles were filtered off using celite and the mother liquor was concentrated, to give (S)-3-(hydroxymethyl)piperidine (797 mg).

$[\alpha]_D = -11.3^\circ$ ($c = 0.730$, MeOH).

$^1\text{H-NMR}$ (300 Hz, CDCl_3) δ : 1.07-1.20 (1H, m), 1.40-1.54 (1H, m),
 25 1.61-1.82 (3H, m), 2.39 (1H, dd, $J=12.0$ and 9.9 Hz), 2.54-2.62 (3H, m), 2.95-3.01 (1H, m), 3.13-3.18 (1H, m), 3.40-3.54 (2H, m).

【0101】

Reference Example 6

To a mixture of (R)-ethyl nipecotate (1.15 g) and
 30 tetrahydrofuran (16 ml) was added lithium aluminum hydride (278 mg) at 0°C . The mixture was stirred for 3 hours with elevating the temperature to room temperature. Water (0.28 ml), 25% potassium hydroxide solution (0.28 ml) and brine (0.84 ml) were added thereto in this order, and the mixture was stirred for 15
 35 hours. The insolubles were filtered off using celite and the

mother liquor was concentrated, to give (R)-3-(hydroxymethyl)piperidine (852 mg).

$[\alpha]_D = +11.7^\circ$ ($c = 0.730$, MeOH).

$^1\text{H-NMR}$ (300 Hz, CDCl_3) δ : 1.07-1.20 (1H, m), 1.40-1.54 (1H, m),
5 1.61-1.82 (3H, m), 2.39 (1H, dd, $J=12.0$ and 9.9 Hz), 2.54-2.62 (3H, m), 2.95-3.01 (1H, m), 3.13-3.18 (1H, m), 3.40-3.54 (2H, m).

【0102】

Reference Example 7

To a mixture of 4-amino-1-nitronaphthalene (5.00 g) and
10 dichloromethane (120 ml) was added a mixture of bromine (4.25 g) and dichloromethane (10 ml) at room temperature. After stirring for 3 hours, sodium sulfite solution was added thereto, and the mixture was extracted with ethyl acetate. The extracts were washed with sodium carbonate solution, and brine, dried, and
15 concentrated. The obtained residue was purified by silica gel column chromatography to give 4-amino-3-bromo-1-nitronaphthalene (1.33 g).

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6) δ : 7.55 (2H, br.s), 7.61 (1H, ddd, $J=8.4$, 6.9 and 1.5 Hz), 7.79 (1H, ddd, $J=8.4$, 6.9 and 1.5 Hz), 8.45-8.48
20 (1H, m), 8.56 (1H, s), 8.78-8.81 (1H, m).

【0103】

Reference Example 8

To a mixture of sodium nitrite (336 mg) and sulfuric acid (1.7 ml) was added a mixture of 4-amino-3-bromo-1-
25 nitronaphthalene (500 mg) and acetic acid (3.5 ml) at 0°C . After 30 minutes of stirring, diethyl ether was added thereto. The produced precipitate was taken by filtration, and washed with 95% ethanol at 0°C . The obtained solid was added to water at 0°C , and the mixture was immediately added to a mixture of potassium
30 cyanide (792 mg), copper chloride (I) (463 mg) and water (25 ml). After 30 minutes of stirring, and the mixture was extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated, and the obtained residue was purified by silica gel column chromatography to give 2-bromo-4-nitro-1-naphthonitrile
35 (141 mg).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.84-7.92 (2H, m), 8.32 (1H, s), 8.36-8.47 (2H, m).

IR (KBr) 2236, 1532 cm^{-1}

【0104】

5 Reference Example 9

A mixture of 2-bromo-4-nitro-1-naphthonitrile (141 mg), iron (134 mg), ammonium chloride (12 mg), ethanol (5.0 ml) and water (1.5 ml) was stirred at 90°C for 30 minutes. The reaction solution was cooled to room temperature, and poured into brine.

10 The mixture was extracted with ethyl acetate, and the extracts were washed with brine, dried, and concentrated. The obtained residue was purified by silica gel column chromatography to give 4-amino-2-bromo-1-naphthonitrile (81 mg).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 4.79 (2H, br.s), 6.93 (1H, s), 7.56 (1H, ddd, $J=8.4$, 6.9 and 1.2 Hz), 7.68 (1H, ddd, $J=8.4$, 6.9 and 1.2 Hz), 7.77 (1H, d, $J=8.4$ Hz), 8.15 (1H, d, $J=8.4$ Hz).

IR (KBr) 2215, 1572, 1514 cm^{-1}

【0105】

Reference Example 10

20 To a mixture of 2-(hydroxymethyl)piperidine (10.0 g), 1 M potassium carbonate solution (250 ml) and tetrahydrofuran (150 ml) was added benzyloxycarbonyl chloride (16.3 g) at 0°C. The temperature was elevated to room temperature, and the mixture was stirred for 24 hours. The mixture was acidified with 2 N
25 hydrochloric acid, and extracted with ethyl acetate. The extracts were washed with brine, dried, and concentrated. The obtained residue was purified by silica gel column chromatography to give benzyl 2-(hydroxymethyl)-1-piperidinecarboxylate (15.2 g).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.40-1.70 (6H, m), 2.91-2.99 (1H, m),
30 3.63 (1H, dt, $J=11.1$ and 6.0 Hz), 3.84 (1H, ddd, $J=11.1$, 9.0 and 6.0 Hz), 4.01-4.05 (1H, m), 4.32-4.39 (2H, m), 5.13 (2H, ABq, $J=12.3$ Hz), 7.27-7.38 (5H, m).

【0106】

Reference Example 11

35 To a mixture of benzyl 2-(hydroxymethyl)-1-

piperidinecarboxylate (3.00 g), diisopropylethylamine (6.3 mL) and dichloromethane (30 mL) was added chloromethylmethyl ether (80%, 2.42 g) at 0°C. The temperature was elevated to room temperature, and the mixture was stirred for 14 hours. The
5 reaction solution was washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain benzyl 2-(methoxymethoxymethyl)-1-piperidinecarboxylate (3.43 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.41-1.78 (6H, m), 2.83-2.92 (1H, m),
10 3.31 (3H, s), 3.59 (1H, dd, J=9.9 and 7.2 Hz), 3.67 (1H, dd, J=9.9 and 7.2 Hz), 4.06-4.11 (1H, m), 4.46-4.52 (1H, m), 5.13 (2H, ABq, J=12.3 Hz), 7.27-7.37 (5H, m).

【0107】

Reference Example 12

15 A mixture of benzyl 2-(methoxymethoxymethyl)-1-piperidinecarboxylate (3.23 g), 10% palladium - carbon (50% water content, 1.17 g) and methanol (50 mL) was stirred at room temperature for 5 hours under hydrogen atmosphere. The catalyst was filtered off using celite and the mother liquor was
20 concentrated to obtain 2-(methoxymethoxymethyl)piperidine (1.27 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.04-1.83 (6H, m), 2.23 (1H, br.s), 2.58-2.81 (2H, m), 3.06-3.12 (1H, m), 3.30-3.39 (1H, m), 3.36 (3H, s), 3.50 (1H, dd, J=9.2 and 5.2 Hz), 4.63 (2H, s).

25 【0108】

Reference Example 13

Sodium hydride (60% in oil, 5.28 g) was washed with hexane and suspended in tetrahydrofuran (150 mL). 5-hydroxy-2-nitrobenzaldehyde (14.7 g) was added at room temperature and the
30 mixture was stirred for 20 minutes. Chloromethylmethyl ether (80%, 15.9 g) was added and the mixture was stirred for 1 hour. The reaction solution was poured into water and extracted with diethyl ether. The extracts were washed with a 1 N aqueous sodium hydroxide solution and brine, dried, and concentrated.
35 The obtained residue was purified by silica gel column

chromatography to obtain 5-methoxymethoxy-2-nitrobenzaldehyde (16.5 g).

¹H-NMR (300 MHz, CDCl₃) δ: 3.49 (3H, s), 5.29 (2H, s), 7.29 (1H, dd, J=9.0 and 3.0 Hz), 7.47 (1H, d, J=3.0 Hz), 8.15 (1H, d, J=9.0 Hz), 10.46 (1H, s).

【0109】

Reference Example 14

To a mixture of 5-methoxymethoxy-2-nitrobenzaldehyde (17.0 g) and methanol (150 mL) was added sodium borohydride (910 mg) at room temperature. After stirring for 20 minutes, the mixture was concentrated and the residue was distributed between ethyl acetate and water. The organic layer was washed with brine, dried, and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 5-methoxymethoxy-2-nitrobenzyl alcohol (15.6 g).

¹H-NMR (300 MHz, CDCl₃) δ: 2.73 (1H, t, J=6.6 Hz), 3.49 (3H, s), 4.98 (2H, d, J=6.6 Hz), 5.28 (2H, s), 7.05 (1H, dd, J=8.8 and 3.0 Hz), 7.36 (1H, d, J=3.0 Hz), 8.17 (1H, d, J=8.8 Hz).

【0110】

Reference Example 15

To a mixture of 5-methoxymethoxy-2-nitrobenzyl alcohol (8.65 g), triethylamine (8.48 mL) and tetrahydrofuran (130 mL) was added methanesulfonyl chloride (3.77 mL) at 0°C. After stirring for 30 minutes, the mixture was concentrated. To the obtained residue was added acetone (150 mL) and sodium iodide (21.2 g). After stirring at room temperature for 1 hour, the mixture was concentrated and the residue was distributed between ethyl acetate and water. The organic layer was washed with brine, dried, and concentrated. The obtained residue was processed with silica gel column chromatography to obtain a pale yellow solid matter (10.8 g). To a mixture of diethyl malonate (8.00 g) and dimethylsulfoxide (80 mL) was added sodium hydride (60% in oil, 2.00 g) at room temperature and the mixture was stirred for 20 minutes. The above-described pale yellow solid matter (10.8 g) was added thereto, and the mixture was stirred for 5 minutes.

The reactant was poured into water and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain diethyl 2-[5-(methoxymethoxy)-2-nitrobenzyl] malonate (10.4 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.22 (6H, t, J=7.2 Hz), 3.47 (3H, s), 3.53 (2H, d, J=7.8 Hz), 3.88 (1H, t, J=7.8 Hz), 4.18 (4H, q, J=7.2 Hz), 5.22 (2H, s), 6.98 (1H, d, J=2.4 Hz), 7.01 (1H, dd, J=9.0 and 2.4 Hz), 8.10 (1H, d, J=9.0 Hz).

10 **【0111】**

Reference Example 16

A mixture of diethyl 2-[5-(methoxymethoxy)-2-nitrobenzyl] malonate (8.68 g), trifluoroacetic acid (30 mL) and dichloromethane (30 mL) was stirred at room temperature for 4 hours. The reaction solution was concentrated, and the obtained residue was processed with silica gel column chromatography to obtain a pale yellow oily matter (7.44 g). Under argon atmosphere, a mixture of the obtained matter (7.28 g), methyl iodide (3.65 g), potassium carbonate (3.88 g) and N,N-dimethylformamide (80 mL) was stirred at room temperature for 1 hour. The reaction solution was poured into water and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain diethyl 2-(5-methoxy-2-nitrobenzyl) malonate (6.30 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.22 (6H, t, J=7.2 Hz), 3.53 (2H, d, J=7.8 Hz), 3.86 (3H, s), 3.88 (1H, t, J=7.8 Hz), 4.16 (2H, q, J=7.2 Hz), 4.17 (2H, q, J=7.2 Hz), 6.83-6.87 (2H, m), 8.10-8.13 (1H, m).

30 **【0112】**

Reference Example 17

To a mixture of diethyl 2-(5-methoxy-2-nitrobenzyl) malonate (6.04 g) and hydrochloric acid (80 mL) was stirred at 105°C for 21 hours. After cooling to room temperature, the mixture was extracted with ethyl acetate. The extracts were washed with

brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 3-(5-methoxy-2-nitrophenyl) propionic acid (3.30 g).

¹H-NMR (300 MHz, CDCl₃) δ: 2.80 (2H, t, J=7.8 Hz), 3.27 (2H, t, J=7.8 Hz), 3.88 (3H, s), 6.82-6.85 (2H, m), 8.07-8.10 (1H, m).

【0113】

Reference Example 18

3-(5-Methoxy-2-nitrophenyl) propionic acid (3.23 g) was added to polyphosphoric acid (32 g) at 80°C and the mixture was stirred for 20 minutes. After cooling to room temperature, the mixture was iced water and extracted with ethyl acetate. Produced insolubles were filtered off using celite, and then the organic layer was washed with brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 7-methoxy-4-nitro-1-indanone (1.60 g).

¹H-NMR (300 MHz, CDCl₃) δ: 2.74-2.78 (2H, m), 3.56-3.60 (2H, m), 4.08 (3H, s), 6.96 (1H, d, J=9.0 Hz), 8.47 (1H, d, J=9.0 Hz).

【0114】

Reference Example 19

A mixture of 7-methoxy-4-nitro-1-indanone (1.60 g) and dichloromethane (50 mL) was cooled to -78°C, and a 1M boron tribromide - dichloromethane solution (10.7 mL) was added thereto for 30 minutes. After stirring for 30 minutes, the temperature was elevated to room temperature, and the mixture was stirred for 1.5 hours. The reaction solution was poured into iced water and insolubles were filtered off using celite. The organic layer was washed with brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 7-hydroxy-4-nitro-1-indanone (1.26 g).

¹H-NMR (300 MHz, DMSO-d₆) δ: 2.83-2.87 (2H, m), 3.63-3.67 (2H, m), 6.94 (1H, d, J=9.0 Hz), 8.42 (1H, d, J=9.0 Hz), 10.03 (1H, s).

【0115】

Reference Example 20

Diisopropylamine (2.83g) was dissolved in anhydrous ether (40 mL) and a 1.6 M n - butyllithium solution (15 mL) was added

dropwise with stirring under cooling to -60°C . 1-Benzyl-5-methylpyrrolidin-2-one (3.78g) was dissolved in anhydrous ether (15 mL). The resulting solution was kept and added dropwise at -60°C , and then returned to 5°C and stirred for 2 hours. The cooling bath was removed, dry carbon disulfide was introduced for 30 minutes. To the mixture was added iced water, the aqueous layer was separated. The organic layer was twice extracted with 2 N sodium hydroxide. The aqueous layers were combined, washed with ether, and then made acidic with concentrated hydrochloric acid under cooling. The aqueous layer was twice extracted with ethyl acetate, the extract was washed with water, dried and concentrated to obtain 1-benzyl-5-methyl-2-oxopyrrolidine-3-carboxylic acid (3.45 g) as a pale yellow oily matter.

^1H -NMR (200 MHz, CDCl_3) δ : 1.21(1.5H, d, $J=6.6\text{Hz}$), 1.27(1.5H, d, $J=5.2\text{Hz}$), 1.80-2.20(1 H, m), 2.39-2.70(1H, m), 3.40-3.76(2H, m), 4.00-4.20(1H, m), 4.98(1H, dd, $J=4.0$ and 15.0Hz), 7.10-7.50(5H, m).

【0116】

Reference Example 21

1-Benzyl-5-methyl-2-oxopyrrolidine-3-carboxylic acid (3.45 g) dissolved in anhydrous tetrahydrofuran (40 mL) was added dropwise to lithium aluminum hydride (1.2 g) in anhydrous tetrahydrofuran (80 mL) under stirring. The reaction solution was heated under reflux for 5 hours, and then water (2 mL) under ice-cooling, 4 N - sodium hydroxide (1.5 mL) and water (5.0 mL) was sequentially added dropwise thereto. The produced precipitate was taken by filtration and washed with tetrahydrofuran. After concentrating and drying the filtrate, the residue was purified by basic silica gel column chromatography to obtain cis-(1-benzyl-5-methylpyrrolidin-3-yl)methanol (0.8 g) and trans-(1-benzyl-5-methylpyrrolidin-3-yl)methanol (0.75 g) as colorless oily matters.

cis-isomer ^1H -NMR (200 MHz, CDCl_3) δ : 1.24(3H, d, $J=5.8\text{Hz}$), 1.36-1.52(1H, m), 2.10-2.60(4H, m), 2.80(1H, d, $J=10.0\text{Hz}$), 3.01(1H, d, $J=12.8\text{Hz}$), 7.16-7.42(5H, m).

trans-isomer ^1H -NMR (200 MHz, CDCl_3) δ : 1.16(3H, d, $J=6.2\text{Hz}$), 1.50-1.82(2H, m), 1.95(1H, dd, $J=8.0$ and 8.2Hz), 2.20-2.40(2H, m), 3.03(1H, dd, $J=7.2$ and 7.4Hz), 3.15(1H, d, $J=12.8\text{Hz}$), 3.40-3.64(2H, m), 4.00(1H, d, $J=12.8\text{Hz}$), 7.12-7.40(5H, m).

5 **【0117】**

Reference Example 22

A mixture of cis-(1-benzyl-5-methylpyrrolidin-3-yl)methanol (350 mg), methyl alcohol (10 mL), 1 N - hydrochloric acid (1.5 mL) and 10% palladium carbon (water content 300 mg) was stirred
10 for 15 hours under hydrogen atmosphere. The catalyst was filtered off and the filtrate was concentrated and dried to obtain cis-(5-methylpyrrolidin-3-yl)methanol hydrochloride (220 mg).

^1H -NMR (200 MHz, CD_3OD) δ : 1.30-1.55(1H, m) 1.42(3H, d, $J=6.6\text{Hz}$),
15 2.20-2.40(1H, m), 2.48-2.72(1H, m), 3.10-3.22(1H, 3.30-3.48(1H, m), 3.48-3.80(3H, m).

【0118】

Reference Example 23

A mixture of trans-(1-benzyl-5-methylpyrrolidin-3-yl)methanol (350 mg), methyl alcohol (10 mL), 1 N - hydrochloric acid (1.5 mL) and 10% palladium carbon (water content 300 mg) was stirred for 15 hours under hydrogen atmosphere. The catalyst was filtered off and the filtrate was concentrated and dried to obtain trans-(5-methylpyrrolidin-3-yl)methanol hydrochloride (220
25 mg).

^1H -NMR (200 MHz, CD_3OD) δ : 1.39(3H, d, $J=6.6\text{Hz}$), 1.70-1.90(1H, m), 1.98-2.16(1H, m), 2.54-2.80(1H, m), 3.02-3.20(1H, m).

【0119】

Reference Example 24

To a mixture of nipecotic acid (10.0 g) and a 1 N sodium hydroxide solution (77 mL) was added at 0°C benzyloxycarbonyl chloride (13.2 g) and a 1 N sodium hydroxide solution (77 mL). The temperature was elevated to room temperature and the mixture was stirred for 14 hours. The reaction solution was washed with
35 diethyl ether and acidified with 1 N hydrochloric acid. The

mixture was extracted with ethyl acetate, the extract was washed with water, dried and concentrated to obtain 1-

[(benzyloxy)carbonyl]-3-piperidinecarboxylic acid (20.1 g).

¹H-NMR (CDCl₃) δ: 1.42-1.76 (3H, m), 2.05-2.11 (1H, m), 2.48-2.53
5 (1H, m), 2.89-3.44 (2H, m), 3.94-4.00 (1H, m), 4.05-4.64 (1H, m),
5.14 (2H, ABq, J=12.6 Hz), 7.27-7.37 (5H, m).

【0120】

Reference Example 25

A mixture of 1-[(benzyloxy)carbonyl]-3-piperidinecarboxylic
10 acid (20.0 g), iodoethane (14.2 g), potassium carbonate (15.7 g),
and N,N-dimethylformamide (150 mL) was stirred at room
temperature for 5 hours. The reaction solution was poured into
water and extracted with ethyl acetate. The extracts were washed
with water, dried and concentrated. The obtained residue was
15 purified by silica gel column chromatography to obtain ethyl 1-
[(benzyloxy)carbonyl]-3-piperidinecarboxylate (20.0 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.24 (3H, t, J=7.5 Hz), 1.45-1.74 (3H,
m), 2.02-2.08 (1H, m), 2.42-2.48 (1H, m), 2.85-3.13 (2H, m),
3.95-4.02 (1H, m), 4.12 (2H, q, J=7.5 Hz), 4.18-4.30 (1H, m),
20 5.12 (2H, s), 7.27-7.36 (5H, m).

【0121】

Reference Example 26

To a solution of 15% potassium hexamethyldisilazide -
toluene (31 mL) was added tetrahydrofuran (5.0 mL) under argon
25 atmosphere, and the mixture was cooled to -78°C. A mixture of
ethyl 1-[(benzyloxy)carbonyl]-3-piperidinecarboxylate (4.00 g)
and tetrahydrofuran (3.0 mL) was added and the mixture was
stirred for 20 minutes. A mixture of iodomethane (1.3 mL) and
tetrahydrofuran (2.0 mL) was added and the temperature was
30 elevated to room temperature. After stirring for 12 hours, the
reaction solution was poured into water and extracted with ethyl
acetate. The extracts were washed with brine, dried and
concentrated. The obtained residue was purified by silica gel
column chromatography to obtain ethyl 1-[(benzyloxy)carbonyl]-3-
35 methyl-3-piperidinecarboxylate (3.76 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.16-1.26 (6H, m), 1.40-1.49 (1H, m), 1.52-1.65 (2H, m), 2.03-2.10 (1H, m), 3.11-3.30 (2H, m), 3.52-3.64 (1H, m), 3.98-4.13 (3H, m), 5.12 (2H, s), 7.27-7.37 (5H, m).

【0122】

5 Reference Example 27

A mixture of ethyl 1-[(benzyloxy)carbonyl]-3-methyl-3-piperidinecarboxylate (3.57 g), 10% palladium - carbon (50% water content, 1.24 g) and methanol (50 mL) was stirred at room temperature for 2.5 hours under hydrogen atmosphere. The
10 catalyst was filtered off using celite, and mother liquor was concentrated to obtain ethyl 3-methyl-3-piperidinecarboxylate (1.86 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.09 (3H, s), 1.27 (3H, t, J=7.2 Hz), 1.33-1.82 (3H, m), 2.14-2.22 (1H, m), 2.40 (1H, d, J=12.9 Hz),
15 2.53-2.62 (1H, m), 2.89-2.95 (1H, m), 3.31 (1H, dd, J=12.9 and 1.5 Hz), 4.09-4.24 (2H, m).

【0123】

Reference Example 28

To a mixture of ethyl 3-methyl-3-piperidinecarboxylate (1.68
20 g) and tetrahydrofuran (21 mL) was added at 0°C lithium aluminum hydride (372 mg). The mixture was stirred for 3 hours with elevating the temperature to room temperature. Water (0.37 ml), a 25% potassium hydroxide solution (0.37 ml) and water (1.10 ml) were sequentially added thereto, and the mixture was stirred for
25 15 hours. The insolubles were filtered off using celite and then the mother liquor was concentrated to obtain 3-(hydroxymethyl)-3-methylpiperidine (1.01 g).

¹H-NMR (300 MHz, CDCl₃) δ: 0.81 (3H, s), 1.28-1.37 (1H, m), 1.49-1.68 (2H, m), 1.80-1.93 (1H, m), 2.54 (1H, d, J=11.7 Hz), 2.60-
30 2.69 (1H, m), 2.85-3.11 (3H, m), 3.58 (2H, s).

【0124】

Reference Example 29

A mixture of 5,6,7,8-tetrahydro-1-naphthol (4.96 g), benzylbromide (4.3 mL), potassium carbonate (6.94 g), and N,N-
35 dimethylformamide (70 mL) was stirred at room temperature for 21

hours. The reactant was poured into water and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 5-(benzyloxy)-1,2,3,4-

5 tetrahydronaphthalene (7.85 g).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.72-1.84 (4H, m), 2.72-2.78 (4H, m), 5.05 (2H, s), 6.68-6.72 (2H, m), 7.04 (1H, d, $J=7.8$ Hz), 7.27-7.45 (5H, m).

【0125】

10 Reference Example 30

To a mixture of 5-(benzyloxy)-1,2,3,4-tetrahydronaphthalene (6.30 g), dichloromethylmethyl ether (4.8 mL), and dichloromethane (50 mL) was added dropwise at 0°C for 30 minutes a mixture of titanium tetrachloride (7.3 mL) and dichloromethane
15 (5.0 mL). After stirring for 15 minutes, the reactant was poured into iced water and stirred vigorously for 30 minutes. The organic layer was washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(benzyloxy)-5,6,7,8-tetrahydro-1-
20 naphthalenecarboxaldehyde (4.86 g).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.77-1.81 (4H, m), 2.74-2.77 (2H, m), 3.18-3.22 (2H, m), 5.15 (2H, s), 6.86 (1H, d, $J=8.4$ Hz), 7.32-7.45 (5H, m), 7.63 (1H, d, $J=8.4$ Hz), 10.09 (1H, s).

【0126】

25 Reference Example 31

To a mixture of 4-(benzyloxy)-5,6,7,8-tetrahydro-1-naphthalenecarboxaldehyde (4.64 g) and dichloromethane (50 mL) was added dropwise a 0.5 M boron tribromide - dichloromethane solution (40 mL) at -78°C for 30 minutes. After stirring for 40
30 minutes, the temperature was elevated to room temperature. The reactant was poured into water and extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-hydroxy-5,6,7,8-tetrahydro-1-
35 naphthalenecarboxaldehyde (2.73 g).

^1H -NMR (300 MHz, CDCl_3) δ : 1.77–1.87 (4H, m), 2.65–2.68 (2H, m), 3.19–3.22 (2H, m), 5.93 (1H, s), 6.76 (1H, d, $J=8.1$ Hz), 7.58 (1H, d, $J=8.1$ Hz), 10.08 (1H, s).

【0127】

5 Reference Example 32

A mixture of 4-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarboxaldehyde (2.72 g), hydroxylamine hydrochloride (1.29 g), sodium acetate (1.90 g), ethanol (60 mL), and water (30 mL) was stirred at room temperature for 1 hour. The reactant was
10 concentrated and the residue was distributed between ethyl acetate and water. The organic layer was washed with brine, dried and concentrated to obtain a yellowish-brown solid matter. A mixture of the obtained solid and anhydride acetic acid (50 mL) was stirred at 150°C for 12 hours. The reactant was concentrated,
15 and the obtained residue was processed with a silica gel column to obtain a colorless solid matter. A mixture of the obtained solid, a 1 N sodium hydroxide solution (28 mL), and tetrahydrofuran (50 mL) was stirred at room temperature for 1.5 hours. The mixture was neutralized with 1N hydrochloric acid and
20 extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated to obtain 4-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarbonitrile (2.24 g).

^1H -NMR (300 MHz, CDCl_3) δ : 1.79–1.88 (4H, m), 2.60–2.64 (2H, m), 2.90–2.94 (2H, m), 5.65 (1H, s), 6.66 (1H, d, $J=8.4$ Hz), 7.35 (1H, d, $J=8.4$ Hz). IR (KBr) 3256, 2938, 2228, 1584 cm^{-1}
25

【0128】

Reference Example 33

To a mixture of 4-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarbonitrile (300 mg), triethylamine (0.72 mL), and
30 dichloromethane (3.0 mL) was added dropwise at -40°C a mixture of trifluoromethanesulfonic anhydride (0.44 mL) and dichloromethane (1.0 mL). After stirring for 15 minutes, the temperature was elevated to room temperature, and the mixture was concentrated. The obtained residue was purified by silica gel column
35 chromatography to obtain 4-cyano-5,6,7,8-tetrahydro-1-

naphthalenyltrifluoromethanesulfonate (500 mg).

¹H-NMR (300 MHz, CDCl₃) δ: 1.81-1.93 (4H, m), 2.81 (2H, t, J=5.4 Hz), 3.01 (2H, t, J=5.4 Hz), 7.18 (1H, d, J=8.4 Hz), 7.54 (1H, d, J=8.4 Hz).

5 **【0129】**

Reference Example 34

To a mixture of 1-methoxy-3-(methoxymethoxy)benzene (5.00 g), N,N,N',N',-tetramethylethylenediamine (5.20 mL), and tetrahydrofuran (250 mL) was added a 1.6 Mn - butyllithium -
 10 hexane solution (21.4 mL) at 0°C for 20 minutes. The temperature was elevated to room temperature, the mixture was stirred for 2 hours, and then cooled to -78°C. Copper (I) iodide (6.82 g) was added thereto and the mixture was stirred for 2 hours with elevating the temperature to -40°C. After cooling to -78°C, a
 15 mixture of metallyl bromide (3.81 mL) and tetrahydrofuran (20 mL) was added for 30 minutes. The temperature was elevated to room temperature, and the mixture was stirred for 12 hours. The reaction solution was poured into water and extracted with ethyl acetate. The extracts were washed with a sodium hydrogen
 20 carbonate solution and brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 1-methoxy-3-(methoxymethoxy)-2-(2-methyl-2-propenyl)benzene (4.77 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.79 (3H, d, J=0.6 Hz), 3.37 (2H, s),
 25 3.45 (3H, s), 3.79 (3H, s), 4.44-4.45 (1H, m), 4.65-4.67 (1H, m), 5.15 (2H, s), 6.58 (1H, dd, J=8.4 and 0.6 Hz), 6.73 (1H, dd, J=8.4 and 0.6 Hz), 7.12 (1H, t, J=8.4 Hz).

【0130】

Reference Example 35

30 To a mixture of 1-methoxy-3-(methoxymethoxy)-2-(2-methyl-2-propenyl)benzene (4.50 g), N,N,N',N',-tetramethylethylenediamine (3.36 mL), and hexane (250 mL) was added at 0°C for 15 minutes a 1.6 Mn - butyllithium - hexane solution (13.9 mL). The temperature was elevated to room temperature, the mixture was
 35 stirred for 3 hours and then cooled to -78°C. N,N-

dimethylformamide (3.92 mL) was added, and the mixture was stirred for 1 hour. The temperature was elevated to room temperature and the mixture was stirred for 13 hours. The reaction solution was washed with water, dried and concentrated.

5 The obtained residue was purified by silica gel column chromatography to obtain 4-methoxy-2-(methoxymethoxy)-3-(2-methyl-2-propenyl)benzaldehyde (3.20 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.82 (3H, s), 3.38 (2H, s), 3.58 (3H, s), 3.89 (3H, s), 4.37 (1H, br.s), 4.71-4.74 (1H, m), 5.05 (2H, s), 6.81 (1H, d, J=8.7 Hz), 7.81 (1H, d, J=8.7 Hz), 10.19 (1H, s).

【0131】

Reference Example 36

A mixture of 4-methoxy-2-(methoxymethoxy)-3-(2-methyl-2-propenyl)benzaldehyde (3.20 g), 4 N hydrochloric acid (50 mL),
15 and 2-propanol (50 mL) was stirred at room temperature for 18 hours. The reaction solution was concentrated, the residue was saturated with saline and then extracted with ethyl acetate. After the extract was washed with a sodium hydrogen carbonate solution and brine, the extract was dried and concentrated. The
20 obtained residue was processed with a silica gel column to obtain a yellow material. A mixture of the obtained material, Amberlyst 15 (3.00 g), and toluene (30 mL) was stirred vigorously at room temperature for 3 days. The mixture was filtrated using celite and the residue was washed with toluene. Mother liquor and
25 washing liquid were combined and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-methoxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxaldehyde (1.72 g).

¹H-NMR (300 MHz, CDCl₃) δ: 1.53 (6H, s), 2.92 (2H, s), 3.88 (3H, s), 6.47 (1H, d, J=8.4 Hz), 7.63 (1H, d, J=8.4 Hz), 10.05 (1H, s).

【0132】

Reference Example 37

To a mixture of tert-hexadecanethiol (2.16 g) and hexamethylphosphoric triamide (HMPA) (9.0 mL) was added at 0°C a
35 1.6 Mn - butyllithium - hexane solution (5.7 mL). After stirring

for 20 minutes, the mixture was added at the same temperature to a mixture of 4-methoxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxaldehyde (860 mg) and HMPA (20 mL). The temperature was elevated to room temperature, and the mixture was stirred for 13
5 hours. The reaction solution was poured into a 1 N sodium hydroxide solution and washed with diethyl ether. The aqueous layer was acidified with 1 N hydrochloric acid and extracted with diethyl ether. The extracts were washed with brine, dried and concentrated. The obtained residue was purified by silica gel
10 column chromatography to obtain 4-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxaldehyde (860 mg).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.55 (6H, s), 2.96 (2H, s), 6.39 (1H, d, $J=8.4$ Hz), 7.53 (1H, d, $J=8.4$ Hz), 10.01 (1H, s).

【0133】

15 Reference Example 38

A mixture of 4-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxaldehyde (500 mg), hydroxylamine hydrochloride (217 mg), sodium acetate (320 mg), ethanol (10 mL), and water (5.0 mL) was stirred at room temperature for 1 hour. The
20 reactant was concentrated and the residue was distributed between ethyl acetate and water. The organic layer was washed with brine, dried and concentrated, to obtain a brown oily matter. A mixture of the obtained matter and acetic acid anhydride (7.5 mL) was stirred at 150°C for 12 hours. The reactant was concentrated,
25 and the obtained residue was processed with a silica gel column, to obtain a pale yellow oily matter. A mixture of the obtained matter and a 1 N sodium hydroxide solution (4.7 mL), and tetrahydrofuran (9.0 mL) was stirred at room temperature for 2.5 hours. The mixture was neutralized with 1 N hydrochloric acid
30 and extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated to obtain 4-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carbonitrile (431 mg).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.54 (6H, s), 2.98 (2H, s), 5.57 (1H, br.s), 6.34 (1H, d, $J=8.7$ Hz), 7.22 (1H, d, $J=8.7$ Hz).

35 IR (KBr) 2230, 1609, 1453 cm^{-1}

【0134】

Reference Example 39

To a mixture of 4-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carbonitrile (250 mg), triethylamine (552 μ L), and
 5 dichloromethane (5.0 mL) was added dropwise at -40°C a mixture of
 trifluoromethanesulfonic anhydride (333 μ L) and dichloromethane
 (2.0 mL). After stirring for 15 minutes, the temperature was
 elevated to room temperature and the mixture was concentrated.
 The obtained residue was purified by silica gel column
 10 chromatography to obtain 7-cyano-2,2-dimethyl-2,3-dihydro-1-
 benzofuran-4-yl trifluoromethanesulfonate (405 mg).
 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.58 (6H, s), 3.17 (2H, s), 6.80 (1H, d,
 $J=8.7$ Hz), 7.42 (1H, d, $J=8.7$ Hz).

【0135】

15 Example 1 (Preparation of Compound 1)

To a mixture of 4-amino-1-naphthonitrile (1.75 g) and N,N-
 dimethylformamide (20 mL) was added sodium hydride (60% in oil,
 1.25 g) at room temperature, and the mixture was stirred for 20
 minutes. After adding 1,4-dibromobutane (2.24 g), the mixture
 20 was stirred at 50°C for 15 hours. The reactant was poured into
 water and extracted with ethyl acetate. The extracts were washed
 with water, dried and concentrated. The obtained residue was
 purified by silica gel column chromatography to obtain 4-(1-
 pyrrolidinyl)-1-naphthonitrile (1.76 g) (Compound 1).

25 mp $109 - 110^{\circ}\text{C}$

$^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 2.01-2.08 (4H, m), 3.59-3.66 (4H, m),
 6.69 (1H, d, $J=8.4$ Hz), 7.39-7.48 (1H, m), 7.55-7.62 (1H, m),
 7.72 (1H, d, $J=8.0$ Hz), 8.13-8.17 (1H, m), 8.26 (1H, d, $J=8.2$ Hz).
 IR (KBr) 2203, 1563, 1518 cm^{-1}

30 Anal. Calcd. for $\text{C}_{15}\text{H}_{14}\text{N}_2$: C, 81.05; H, 6.35; N, 12.60.

Found: C, 80.99; H, 6.33; N, 12.47.

【0136】

Example 2 (Preparation of Compound 2)

A mixture of 4-(1-pyrrolidinyl)-1-naphthonitrile (1.76 g), a
 35 2 N potassium hydroxide solution (2.7 mL), and ethanol (2.7 mL).

was stirred at 100°C for 2 days. Insolubles were filtered off and the filtrate was washed with water. Washing liquid and mother liquor were combined, and acidified with 1 N hydrochloric acid and extracted with ethyl acetate. The extracts were washed
5 with brine, dried and concentrated to obtain 4-(1-pyrrolidinyl)-1-naphthoic acid (17 mg) (Compound 2).

mp 194°C (dec).

¹H-NMR (200 MHz, DMSO-d₆) δ: 1.94-2.00 (4H, m), 3.48-3.54 (4H, m), 6.82 (1H, d, J=8.4 Hz), 7.38-7.47 (1H, m), 7.50-7.58 (1H, m),
10 8.09 (1H, d, J=8.4 Hz), 8.22-8.26 (1H, m), 9.05-9.09 (1H, m), 12.27 (1H, br.s).

【0137】

Example 3 (Preparation of Compound 3)

To a mixture of 4-amino-1-naphthonitrile (500 mg) and N,N-dimethylformamide (5.5 mL) was added sodium hydride (60% in oil,
15 346 mg) at room temperature, and the mixture was stirred for 20 minutes. After adding 1,5-dibromopentane (663 mg), the mixture was stirred at 50°C for 15 hours. The reactant was poured into water and extracted with ethyl acetate. The extracts were washed
20 with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(1-piperidinyl)-1-naphthonitrile (597 mg) (Compound 3).

¹H-NMR (300 MHz, CDCl₃) δ: 1.66-1.73 (2H, m), 1.82-1.90 (4H, m), 3.11-3.14 (4H, m), 6.98 (1H, d, J=8.1 Hz), 7.52-7.58 (1H, m),
25 7.60-7.66 (1H, m), 7.80 (1H, d, J=8.1 Hz), 8.14-8.19 (2H, m).

IR (KBr) 2938, 2215, 1572 cm⁻¹

【0138】

Example 4 (Preparation of Compound 4)

To 4-(1-piperidinyl)-1-naphthonitrile (130 mg) was added 4N
30 hydrogen chloride - ethyl acetate (1.5 mL), and the mixture was stirred at room temperature for 1 hour. The precipitated compound was filtered off and the filtrate was washed with diethyl ether, to obtain 4-(1-piperidinyl)-1-naphthonitrile hydrochloride (120 mg) (Compound 4).

35 ¹H-NMR (300 MHz, DMSO-d₆) δ: 1.62-1.67 (2H, m), 1.76-1.84 (4H, m),

3.08-3.11 (2H, m), 7.14 (1H, d, J=7.8 Hz), 7.67 (1H, ddd, J=8.4, 6.6 and 1.2 Hz), 7.75 (1H, ddd, J=8.4, 6.6 and 1.2 Hz), 8.02-8.06 (2H, m), 8.13-8.16 (1H, m).

【0139】

5 Example 5 (Preparation of Compound 5)

To a mixture of 4-bromo-1-naphthylamine (500 mg) and N,N-dimethylformamide (6.0 mL) was added sodium hydride (60% in oil, 262 mg) at room temperature, and the mixture was stirred for 20 minutes. After adding 1,5-dibromopentane (502 mg), the mixture
10 was stirred at 50°C for 15 hours. The reactant was poured into water and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 1-(4-bromo-1-naphthyl)piperidine (120 mg) (Compound 5).

15 ¹H-NMR (200 MHz, CDCl₃) δ: 1.68 (2H, br.s), 1.84 (4H, qui, J=5.4 Hz), 3.03 (4H, br.s), 6.91 (1H, d, J=8.2 Hz), 7.48-7.68 (3H, m), 8.17-8.24 (2H, m).

【0140】

Example 6 (Preparation of Compound 6)

20 A mixture of 4-(trifluoromethyl)-1-naphthylamine (200 mg), 1,5-dibromopentane (544 mg), potassium carbonate (654 mg), sodium iodide (710 mg), and N,N-dimethylformamide (3.0 mL) was stirred at 90°C for 13 hours. After cooling to room temperature, the reactant was poured into water and extracted with ethyl acetate.
25 The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 1-[4-(trifluoromethyl)-1-naphthyl]piperidine (108 mg) (Compound 6).

¹H-NMR (300 MHz, CDCl₃) δ: 1.68 (2H, br.s), 1.85 (4H, qui, J=5.4 Hz), 3.08 (4H, br.s), 6.99 (1H, d, J=8.1 Hz), 7.50-7.60 (2H, m), 7.75 (1H, dd, J=8.1 and 0.9 Hz), 8.10-8.15 (1H, m), 8.22-8.25 (1H, m).

IR (KBr) 2938, 1582, 1516 cm⁻¹

【0141】

35 Example 7 (Preparation of Compound 7)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), morpholine (0.10 mL), potassium carbonate (162 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(4-morpholinyl)-1-naphthonitrile (113 mg) (Compound 7).
mp 128 - 129°C.

¹H-NMR (300 MHz, CDCl₃) δ: 3.17-3.20 (4H, m), 3.99-4.02 (4H, m), 7.05 (1H, d, J=7.8 Hz), 7.57-7.70 (2H, m), 7.86 (1H, d, J=7.8 Hz), 8.19-8.24 (2H, m).

IR (KBr) 2216, 1574 cm⁻¹

Anal. Calcd. for C₁₅H₁₄N₂O: C, 75.61; H, 5.92; N, 11.76.

Found: C, 75.69; H, 6.15; N, 11.65.

【0142】

Example 8 (Preparation of Compound 8)

A mixture 4-fluoro-1-naphthonitrile (500 mg), thiomorpholine (0.57 mL), potassium carbonate (808 mg), and dimethylsulfoxide (5.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(4-thiomorpholinyl)-1-naphthonitrile (560 mg) (Compound 8).
mp 130 - 131°C.

¹H-NMR (300 MHz, CDCl₃) δ : 2.94-2.97 (4H, m), 3.41-3.45 (4H, m), 7.06 (1H, d, J=8.1 Hz), 7.60 (1H, ddd, J=8.4, 6.6 and 1.2 Hz), 7.68 (1H, ddd, J=8.4, 6.6 and 1.2 Hz), 7.85 (1H, d, J=8.1 Hz), 8.13-8.17 (1H, m), 8.20-8.23 (1H, m).

IR (KBr) 2216, 1574 cm⁻¹

Anal. Calcd. for C₁₅H₁₄N₂S: C, 70.83; H, 5.55; N, 11.01.

Found: C, 70.84; H, 5.60; N, 10.87.

【0143】

Example 9 (Preparation of Compound 9)

To a mixture of 4-(4-thiomorpholinyl)-1-naphthonitrile (500 mg) and dichloromethane (3.0 mL) was added at -78°C a mixture of m-chloroperbenzoic acid (70%, 242 mg) and dichloromethane (3.0 mL), and the mixture was stirred for 1 hour. After adding a sodium sulfite solution, the temperature was elevated to room temperature, and the resulting mixture was extracted with ethyl acetate. The extracts were washed with sodium carbonate solution, brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(1-oxide-4-thiomorpholinyl)-1-naphthonitrile (239 mg) (Compound 9).
mp 183 - 184°C.

¹H-NMR (300 MHz, CDCl₃) δ: 3.11-3.14 (4H, m), 3.34-3.40 (2H, m), 3.85-3.93 (2H, m), 7.18 (1H, d, J=8.1 Hz), 7.62 (1H, ddd, J=8.1, 6.6 and 1.2 Hz), 7.70 (1H, ddd, J=8.1, 6.6 and 1.2 Hz), 7.87 (1H, d, J=8.1 Hz), 8.10-8.13 (1H, m), 8.22-8.25 (1H, m).

IR (KBr) 2218, 1574 cm⁻¹

Anal. Calcd. for C₁₅H₁₄N₂OS: C, 66.64; H, 5.22; N, 10.36.

Found: C, 66.63; H, 4.98; N, 10.21.

【0144】

Example 10 (Preparation of Compound 10)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), azepane (116 mg), potassium carbonate (161 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(1-azepaneyl)-1-naphthonitrile (116 mg) (Compound 10).

¹H-NMR (300 MHz, CDCl₃) δ: 1.77-1.92 (8H, m), 3.40-3.44 (4H, m), 7.02 (1H, d, J=8.1 Hz), 7.52 (1H, ddd, J=8.4, 6.9 and 1.2 Hz), 7.62 (1H, ddd, J=8.4, 6.9 and 1.2 Hz), 7.77 (1H, d, J=8.1 Hz), 8.15-8.18 (1H, m), 8.19-8.23 (1H, m).

IR (KBr) 2930, 2213, 1568 cm⁻¹

【0145】

Example 11 (Preparation of Compound 11)

A mixture of 4-fluoro-1-naphthonitrile (300 mg), 4-hydroxypiperidine (355 mg), potassium carbonate (485 mg), and dimethylsulfoxide (3.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into
 5 water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(4-hydroxy-1-piperidinyl)-1-naphthonitrile (380 mg) (Compound 11). mp 126 - 127°C.

10 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.85-1.96 (2H, m), 2.05-2.20 (2H, m), 2.94-3.02 (2H, m), 3.40-3.47 (2H, m), 3.95-4.03 (1H, m), 7.02 (1H, d, $J=7.8$ Hz), 7.58 (1H, ddd, $J=8.1$, 6.6 and 1.5 Hz), 7.65 (1H, ddd, $J=8.1$, 6.6 and 1.5 Hz), 7.81 (1H, d, $J=7.8$ Hz), 8.13-8.21 (2H, m).

15 IR (KBr) 2216, 1574 cm^{-1}

Anal. Calcd. for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}$: C, 76.16; H, 6.39; N, 11.10.

Found: C, 76.01; H, 6.29; N, 10.92.

【0146】

Example 12 (Preparation of Compound 12)

20 To a mixture of 4-(4-thiomorpholinyl)-1-naphthonitrile (150 mg) and dichloromethane (2.0 mL) was added at -78°C a mixture of m-chloroperbenzoic acid (70%, 291 mg) and dichloromethane (2.0 mL), and the mixture was stirred for 5 hours with elevating to 0°C. After adding a sodium sulfite solution, the mixture was
 25 extracted with ethyl acetate. The extracts were washed with a sodium carbonate solution and brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(1,1-dioxide-4-thiomorpholinyl)-1-naphthonitrile (112 mg) (Compound 12).

30 mp 265°C(dec).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 3.36-3.39 (4H, m), 3.68-3.71 (4H, m), 7.17 (1H, d, $J=7.8$ Hz), 7.65-7.77 (2H, m), 7.89 (1H, d, $J=7.8$ Hz), 8.11-8.14 (1H, m), 8.25-8.29 (1H, m).

IR (KBr) 2218, 1574 cm^{-1}

35 Anal. Calcd. for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_2\text{S}$: C, 62.92; H, 4.93; N, 9.78.

Found: C, 62.83; H, 5.05; N, 9.71.

【0147】

Example 13 (Preparation of Compound 13)

A mixture of 4-fluoro-1-naphthonitrile (1.00 g), 1,4-dioxane-8-azaspiro[4,5]decane (1.67 g), potassium carbonate (1.62 g), and dimethylsulfoxide (10 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(1,4-dioxane-8-azaspiro[4,5]deca-8-yl)-1-naphthonitrile (1.42 g) (Compound 13).

mp 142 - 143°C.

¹H-NMR (300 MHz, CDCl₃) δ: 2.02 (4H, t, J=5.7 Hz), 3.26-3.29 (4H, m), 4.04 (4H, s), 7.05 (1H, d, J=7.8 Hz), 7.59 (1H, ddd, J=8.4, 6.9 and 1.5 Hz), 7.65 (1H, ddd, J=8.4, 6.9 and 1.5 Hz), 7.83 (1H, d, J=7.8 Hz), 8.16-8.22 (2H, m).

IR (KBr) 2216, 1574 cm⁻¹

Anal. Calcd. for C₁₈H₁₈N₂O₂: C, 73.45; H, 6.16; N, 9.52.

Found: C, 73.34; H, 6.19; N, 9.40.

【0148】

Example 14 (Preparation of Compound 14)

A mixture of 4-(1,4-dioxane-8-azaspiro[4,5]deca-8-yl)-1-naphthonitrile (423 mg), p-toluenesulfonic acid monohydrate (410 mg), acetone (17 mL), and water (2.5 mL) was stirred at 75°C for 3.5 hours. The reaction solution was concentrated and a sodium carbonate solution was added thereto, which was extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(4-oxo-1-piperidinyl)-1-naphthonitrile (105 mg) (Compound 14).

mp 143 - 144°C.

¹H-NMR (300 MHz, CDCl₃) δ: 2.77 (4H, t, J=6.0 Hz), 3.49 (4H, t, J=6.0 Hz), 7.09 (1H, d, J=7.8 Hz), 7.62-7.73 (2H, m), 7.85 (1H, d, J=7.8 Hz), 8.22-8.26 (2H, m).

IR (KBr) 2216, 1717, 1574 cm^{-1}

Anal. Calcd. for $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}$: C, 76.78; H, 5.64; N, 11.19.

Found: C, 76.63; H, 5.87; N, 10.98.

【0149】

5 Example 15 (Preparation of Compound 15)

A mixture of 4-fluoro-1-naphthonitrile (500 mg),
isonipecotamide (749 mg), potassium carbonate (808 mg), and
dimethylsulfoxide (5.0 mL) was stirred at 100°C for 3 hours.
After cooling to room temperature, the reactant was poured into
10 water, and then extracted with ethyl acetate. The extracts were
washed with water, dried and concentrated. The obtained residue
was purified by silica gel column chromatography to obtain 1-(4-
cyano-1-naphthyl)-4-piperidine carboxamide (651 mg) (Compound 15).
mp 249 - 250°C.

15 ^1H -NMR (300 MHz, DMSO-d_6) δ : 1.88-1.94 (4H, m), 2.29-2.40 (1H, m),
2.78-2.87 (2H, m), 3.45-3.49 (2H, m), 6.85 (1H, br.s), 7.16 (1H,
d, $J=7.8$ Hz), 7.35 (1H, br.s), 7.68 (1H, ddd, $J=8.4$, 6.9 and 1.2
Hz), 7.76 (1H, ddd, $J=8.4$, 6.9 and 1.2 Hz), 8.02-8.06 (2H, m),
8.13-8.16 (1H, m).

20 IR (KBr) 2211, 1663 cm^{-1}

Anal. Calcd. for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}$: C, 73.10; H, 6.13; N, 15.04.

Found: C, 72.92; H, 6.22; N, 14.87.

【0150】

Example 16 (Preparation of Compound 16)

25 To a mixture of 4-amino-3-bromo-1-naphthonitrile (250 mg)
and N,N-dimethylformamide (3.0 mL) was added sodium hydride (60%
in oil, 121 mg) at room temperature, and the mixture was stirred
for 20 minutes. After adding 1,5-dibromopentane (233 mg), the
resulting mixture was stirred at 50°C for 15 hours. The reactant
30 was poured into water, and extracted with ethyl acetate. The
extracts were washed with water, dried and concentrated. The
obtained residue was purified by silica gel column chromatography
to obtain 3-bromo-4-(1-piperidinyl)-1-naphthonitrile (198 mg)
(Compound 16).

35 ^1H -NMR (300 MHz, CDCl_3) δ : 1.48-1.90 (6H, m), 3.14 (2H, br), 3.49

(2H, br), 7.59-7.70 (2H, m), 7.80 (1H, s), 8.14-8.17 (1H, m), 8.38-8.43 (1H, m).

IR (KBr) 2934, 2222, 1551 cm^{-1}

【0151】

5 Example 17 (Preparation of Compound 17)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), 1-methylpiperazine (117 mg), potassium carbonate (161 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into
10 water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(4-methyl-1-piperazinyl)-1-naphthonitrile (100 mg) (Compound 17).
mp 128 - 129°C.

15 ^1H -NMR (300 MHz, CDCl_3) δ : 2.43 (3H, s), 2.73 (4H, br.s), 3.22 (4H, br.s), 7.03 (1H, d, $J=7.8$ Hz), 7.56 (1H, ddd, $J=8.4$, 6.6 and 1.2 Hz), 7.65 (1H, ddd, $J=8.4$, 6.6 and 1.2 Hz), 7.83 (1H, d, $J=7.8$ Hz), 8.16-8.21 (2H, m).

IR (KBr) 2795, 2215, 1574 cm^{-1}

20 Anal. Calcd. for $\text{C}_{16}\text{H}_{17}\text{N}_3$: C, 76.46; H, 6.82; N, 16.72.

Found: C, 76.29; H, 6.62; N, 16.48

【0152】

Example 18 (Preparation of Compound 18)

A mixture of 4-fluoro-1-naphthonitrile (400 mg), 3-hydroxypyrrolidine (467 mg), potassium carbonate (646 mg), and
25 dimethylsulfoxide (4.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue
30 was purified by silica gel column chromatography to obtain 4-(3-hydroxy-1-pyrrolidinyl)-1-naphthonitrile (447 mg) (Compound 18).
mp 138 - 139°C.

^1H -NMR (300 MHz, CDCl_3) δ : 1.93 (1H, d, $J=6.6$ Hz), 2.08-2.29 (2H, m), 3.49-3.56 (2H, m), 3.84-3.98 (2H, m), 4.62-4.68 (1H, m), 6.73
35 (1H, d, $J=8.1$ Hz), 7.46 (1H, ddd, $J=8.4$, 6.9 and 1.2 Hz), 7.60

(1H, ddd, J=8.4, 6.9 and 1.2 Hz), 7.72 (1H, d, J=8.1 Hz), 8.13-8.16 (1H, m), 8.22-8.25 (1H, m).

IR (KBr) 3434, 2205, 1561 cm^{-1}

Anal. Calcd. for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}$: C, 75.61; H, 5.92; N, 11.76.

5 Found: C, 75.37; H, 5.90; N, 11.57.

【0153】

Example 19 (Preparation of Compound 19)

A mixture of 4-fluoro-1-naphthonitrile (400 mg), 3-(hydroxymethyl) piperidine (539 mg), potassium carbonate (646 mg),
10 and dimethylsulfoxide (4.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (560 mg)
15 (Compound 19).

^1H -NMR (300 Hz, CDCl_3) δ : 1.20-1.32 (1H, m), 1.59 (1H, br.s), 1.86-1.96 (3H, m), 2.09-2.20 (1H, m), 2.66 (1H, t, J=10.5 Hz), 2.77-2.86 (1H, m), 3.38-3.42 (1H, m), 3.54-3.68 (3H, m), 7.01 (1H,
20 d, J=7.8 Hz), 7.56 (1H, ddd, J=8.1, 6.9 and 1.2 Hz), 7.62 (1H, ddd, J=8.1, 6.9 and 1.2 Hz), 7.79 (1H, d, J=7.8 Hz), 8.13-8.18 (2H, m).

IR (KBr) 2932, 2216, 1572 cm^{-1}

【0154】

25 Example 20 (Preparation of Compound 20)

To 4-[3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (560 mg) was added 4 N hydrogen chloride - ethyl acetate (2.0 mL), and the mixture was stirred at room temperature for 5 minutes and concentrated. The obtained residue was processed with diethyl
30 ether to obtain 4-[3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile hydrochloride (631 mg) (Compound 20).

^1H -NMR (300 Hz, DMSO-d_6) δ : 1.10-1.24 (1H, m), 1.74-2.04 (4H, m), 2.54 (1H, t, J=10.8 Hz), 2.76-2.84 (1H, m), 3.29-3.52 (4H, m), 7.14 (1H, d, J=8.1 Hz), 7.67 (1H, ddd, J=8.1, 6.9 and 1.5 Hz),
35 7.75 (1H, ddd, J=8.1, 6.9 and 1.5 Hz), 8.02-8.06 (2H, m), 8.14-

8.17 (1H, m).

【0155】

Example 21 (Preparation of Compound 21)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), (S)-3-(hydroxymethyl)piperidine (135 mg), potassium carbonate (161 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[(3S)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (133 mg) (Compound 21).

$[\alpha]_D^{25} = +4.9^\circ$ (c=0.460, MeOH).

$^1\text{H-NMR}$ (300 Hz, CDCl_3) δ : 1.20-1.32 (1H, m), 1.59 (1H, br.s), 1.86-1.96 (3H, m), 2.09-2.20 (1H, m), 2.66 (1H, t, $J=10.5$ Hz), 2.77-2.86 (1H, m), 3.38-3.42 (1H, m), 3.54-3.68 (3H, m), 7.01 (1H, d, $J=7.8$ Hz), 7.56 (1H, ddd, $J=8.1, 6.9$ and 1.2 Hz), 7.62 (1H, ddd, $J=8.1, 6.9$ and 1.2 Hz), 7.79 (1H, d, $J=7.8$ Hz), 8.13-8.18 (2H, m).

Compound 21 was obtained using optical resolution as shown in Example 23 as an alternative method.

【0156】

Example 22 (Preparation of Compound 22)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), (R)-3-(hydroxymethyl)piperidine (135 mg), potassium carbonate (161 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[(3R)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (139 mg) (Compound 22).

$[\alpha]_D^{25} = -4.4^\circ$ (c=0.460, MeOH).

$^1\text{H-NMR}$ (300 Hz, CDCl_3) δ : 1.20-1.32 (1H, m), 1.59 (1H, br.s), 1.86-1.96 (3H, m), 2.09-2.20 (1H, m), 2.66 (1H, t, $J=10.5$ Hz),

2.77-2.86 (1H, m), 3.38-3.42 (1H, m), 3.54-3.68 (3H, m), 7.01 (1H, d, J=7.8 Hz), 7.56 (1H, ddd, J=8.1, 6.9 and 1.2 Hz), 7.62 (1H, ddd, J=8.1, 6.9 and 1.2 Hz), 7.79 (1H, d, J=7.8 Hz), 8.13-8.18 (2H, m).

5 Compound 22 was obtained using optical resolution as shown in Example 23 as an alternative method.

【0157】

Example 23 (preparation of compounds 21 and 22)

4-[3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (3.53
10 g) was optically resolved by CHILALCEL OD (50 x 500 mm), to obtain 4-[(3S)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (Compound 21, 1.77 g) and 4-[(3R)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (Compound 22, 1.77 g).

【0158】

15 Example 24 (Preparation of Compound 23)

To 4-[(3S)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (1.66 g) was added 4 N hydrogen chloride - ethyl acetate (2.0 mL), and the mixture was stirred at room temperature for 5 minutes. The precipitated compound was filtered off, which was washed with
20 ethyl acetate to obtain 4-[(3S)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile hydrochloride (1.71 g) (Compound 23).
mp 179 - 180°C.

$[\alpha]_D^{25} = +1.3^\circ$ (c=0.535, MeOH).

¹H-NMR (300 Hz, DMSO-d₆) δ : 1.10-1.24 (1H, m), 1.74-2.04 (4H, m),
25 2.54 (1H, t, J=10.8 Hz), 2.76-2.84 (1H, m), 3.29-3.52 (4H, m),
7.14 (1H, d, J=8.1 Hz), 7.67 (1H, ddd, J=8.1, 6.9 and 1.5 Hz),
7.75 (1H, ddd, J=8.1, 6.9 and 1.5 Hz), 8.02-8.06 (2H, m), 8.14-
8.17 (1H, m).

Anal. Calcd. for C₁₇H₁₈N₂O·HCl: C, 67.43; H, 6.32; N, 9.25.

30 Found: C, 67.21; H, 6.40; N, 9.07.

【0159】

Example 25 (Preparation of Compound 24)

To 4-[(3R)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (1.66 g) was added 4 N hydrogen chloride - ethyl acetate (2.0 mL),
35 and the mixture was stirred at room temperature for 5 minutes.

The precipitated compound was filtered off, which was washed with ethyl acetate to obtain 4-[(3R)-3-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile hydrochloride (1.72 g) (Compound 24).

mp 178 - 179°C.

5 $[\alpha]_D = -0.45^\circ$ (c=0.520, MeOH).

$^1\text{H-NMR}$ (300 Hz, DMSO- d_6) δ : 1.10-1.24 (1H, m), 1.74-2.04 (4H, m), 2.54 (1H, t, J=10.8 Hz), 2.76-2.84 (1H, m), 3.29-3.52 (4H, m), 7.14 (1H, d, J=8.1 Hz), 7.67 (1H, ddd, J=8.1, 6.9 and 1.5 Hz), 7.75 (1H, ddd, J=8.1, 6.9 and 1.5 Hz), 8.02-8.06 (2H, m), 8.14-
10 8.17 (1H, m).

Anal. Calcd. for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O} \cdot \text{HCl}$: C, 67.43; H, 6.32; N, 9.25.

Found: C, 67.32; H, 6.30; N, 9.01.

【0160】

Example 26 (Preparation of Compound 25)

15 A mixture of 4-fluoro-1-naphthonitrile (500 mg), tert-butyl 3-pyrrolidinyl carbamate (1.09 g), potassium carbonate (808 mg), and dimethylsulfoxide (10 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were
20 washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain tert-butyl 1-(4-cyano-1-naphthyl)-3-pyrrolidinyl carbamate (765 mg) (Compound 25).

mp 157 - 158°C.

25 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.46 (9H, s), 1.92-2.08 (1H, m), 2.26-2.43 (1H, m), 3.41-3.61 (2H, m), 3.72-3.87 (2H, m), 4.35-4.45 (1H, m), 4.78 (1H, br.s), 6.74 (1H, d, J=8.0 Hz), 7.48 (1H, ddd, J=8.8, 6.8 and 1.2 Hz), 7.62 (1H, ddd, J=8.8, 6.8 and 1.2 Hz), 7.75 (1H, d, J=8.0 Hz), 8.15-8.22 (2H, m).

30 IR (KBr) 2978, 2209, 1694 cm^{-1}

Anal. Calcd. for $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}_2$: C, 71.19; H, 6.87; N, 12.45.

Found: C, 70.56; H, 6.93; N, 12.20.

【0161】

Example 27 (Preparation of Compound 26)

35 To a mixture of 4-amino-2-bromo-1-naphthonitrile (70 mg) and

N,N-dimethylformamide (3.5 mL) was added sodium hydride (60% in oil, 134 mg) at room temperature, the mixture was stirred for 20 minutes. After adding 1,5-dibromopentane (93 mg), the mixture was stirred for 30 minutes. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 2-bromo-4-(1-piperidinyl)-1-naphthonitrile (58 mg) (Compound 26).
mp 179 - 180°C.

¹H-NMR (300 MHz, CDCl₃) δ: 1.67-1.74 (2H, m), 1.82-1.90 (4H, m), 3.12-3.16 (4H, m), 7.13 (1H, s), 7.55 (1H, ddd, J=8.4, 7.2 and 1.5 Hz), 7.64 (1H, ddd, J=8.4, 7.2 and 1.5 Hz), 8.07-8.10 (1H, m), 8.12-8.16 (2H, m).

IR (KBr) 2938, 2218, 1570 cm⁻¹

Anal. Calcd. for C₁₆H₁₅BrN₂: C, 60.97; H, 4.80; N, 8.89.

Found: C, 60.89; H, 4.70; N, 8.90.

【0162】

Example 28 (Preparation of Compound 27)

To a mixture of dimethylsulfoxide (0.10 mL) and dichloromethane (3.0 mL) was added oxalyl chloride (60 μL) at -78°C. Five minutes later, a mixture of 4-(3-hydroxy-1-pyrrolidinyl)-1-naphthonitrile (150 mg), dichloromethane (3.0 mL), and dimethylsulfoxide (0.20 mL) was added, and the mixture was stirred for 15 minutes. Triethylamine (0.44 mL) was added thereto, and the resulting mixture was stirred for 30 minutes with elevating the temperature to room temperature. The reaction solution was poured into water, and extracted with ethyl acetate. The extracts were washed with 1 N hydrochloric acid, a sodium carbonate solution and brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(3-oxo-1-pyrrolidinyl)-1-naphthonitrile (83 mg) (Compound 27).

mp 153 - 154°C.

¹H-NMR (300 MHz, CDCl₃) δ: 2.76 (2H, t, J=7.2 Hz), 3.73 (2H, t, J=7.2 Hz), 3.77 (2H, s), 7.04 (1H, d, J=8.1 Hz), 7.61 (1H, ddd,

J=8.4, 6.9 and 1.2 Hz), 7.69 (1H, ddd, J=8.4, 6.9 and 1.2 Hz), 7.85 (1H, d, J=8.1 Hz), 8.16-8.18 (1H, m), 8.22-8.25 (1H, m).

IR (KBr) 2215, 1759, 1572 cm^{-1}

Anal. Calcd. for $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}$: C, 76.25; H, 5.12; N, 11.86.

5 Found: C, 75.89; H, 5.13; N, 11.69.

【0163】

Example 29 (Preparation of Compound 28)

To tert-butyl 1-(4-cyano-1-naphthyl)-3-pyrrolidinyl carbamate (600 mg) was added 4 N hydrogen chloride - ethyl acetate (3.0 mL) at room temperature, and the mixture was stirred for 30 minutes. The produced precipitate was filtered off, which was washed with ethyl acetate to obtain 4-(3-amino-1-pyrrolidinyl)-1-naphthonitrile dihydrochloride (558 mg) (Compound 28).

15 mp 161 - 163°C.

^1H -NMR (300 MHz, DMSO-d_6) δ : 2.11-2.21 (1H, m), 2.29-2.40 (1H, m), 3.48-3.55 (1H, m), 3.67 (1H, dd, J=10.8 and 3.6 Hz), 3.82-3.96 (3H, m), 6.89 (1H, d, J=8.4 Hz), 7.57-7.62 (1H, m), 7.71-7.76 (1H, m), 7.95 (1H, d, J=8.4 Hz), 8.01-8.04 (1H, m), 8.38 (1H, d, J=8.4 Hz), 8.58 (3H, br.s).

20 IR (KBr) 2209, 1518 cm^{-1}

【0164】

Example 30 (Preparation of Compound 29)

Sodium hydride (60% in oil, 40 mg) was washed with hexane and suspended in N,N-dimethylformamide (1.0 mL). 4-(3-hydroxy-1-pyrrolidinyl)-1-naphthonitrile (100 mg) was added, and the mixture was stirred for 10 minutes. After adding methyl iodide (78 μL), the mixture was stirred for 40 minutes. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(3-methoxy-1-pyrrolidinyl)-1-naphthonitrile (102 mg) (Compound 29).

35 ^1H -NMR (300 MHz, CDCl_3) δ : 2.10-2.24 (2H, m), 3.37 (3H, s), 3.52 (1H, ddd, J=12.0, 7.5 and 4.5 Hz), 3.57-3.62 (1H, m), 3.76-3.85

(2H, m), 4.09-4.14 (1H, m), 6.72 (1H, d, $J=8.1$ Hz), 7.46 (1H, ddd, $J=8.7$, 6.9 and 1.5 Hz), 7.60 (1H, ddd, $J=8.7$, 6.9 and 1.5 Hz), 7.73 (1H, d, $J=8.1$ Hz), 8.14-8.18 (1H, m), 8.22-8.25 (1H, m).

IR (KBr) 2205, 1563, 1518 cm^{-1}

5 **【0165】**

Example 31 (Preparation of Compound 30)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), 4-(hydroxymethyl) piperidine (135 mg), potassium carbonate (161 mg), and dimethylsulfoxide (1.0 mL) was stirred at 100°C for 3 hours.

10 After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[4-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (150 mg)

15 (Compound 30).

mp 135 - 136°C.

^1H -NMR (300 MHz, CDCl_3) δ : 1.47 (1H, t-like), 1.58-1.80 (3H, m), 1.93-1.98 (2H, m), 2.79-2.87 (2H, m), 3.55 (1H, d.t-like, $J=12.3$ Hz), 3.65 (2H, t, $J=5.4$ Hz), 7.01 (1H, d, $J=7.8$ Hz), 7.56 (1H, ddd, $J=8.4$, 6.9 and 1.5 Hz), 7.64 (1H, ddd, $J=8.4$, 6.9 and 1.5 Hz), 7.81 (1H, d, $J=7.8$ Hz), 8.13-8.20 (2H, m).

IR (KBr) 2915, 2216, 1572 cm^{-1}

Anal. Calcd. for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}$: C, 76.66; H, 6.81; N, 10.52.

Found: C, 76.35; H, 6.88; N, 10.42.

25 **【0166】**

Example 32 (Preparation of Compound 31)

A mixture of 4-fluoro-1-naphthonitrile (300 mg), (S)-ethyl nipecotate (551 mg), potassium carbonate (485 mg), and dimethylsulfoxide (3.0 mL) was stirred at 100°C for 3 hours.

30 After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain ethyl (3S)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (508 mg)

35 (Compound 31).

$[\alpha]_D = +49.6^\circ$ ($c=0.580$, MeOH).

$^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.26 (3H, t, $J=7.0$ Hz), 1.70-2.03 (3H, m), 2.14-2.20 (1H, m), 2.79-2.95 (2H, m), 3.07 (1H, t, $J=10.6$ Hz), 3.35-3.41 (1H, m), 3.57-3.62 (1H, m), 4.17 (2H, q, $J=7.0$ Hz),
 5 7.06 (1H, d, $J=8.2$ Hz), 7.54-7.70 (2H, m), 7.84 (1H, d, $J=8.2$ Hz), 8.13-8.23 (2H, m).

IR (KBr) 2216, 1730, 1574 cm^{-1}

【0167】

Example 33 (Preparation of Compound 32)

10 A mixture of 4-fluoro-1-naphthonitrile (300 mg), (R)-ethyl nipecotate (551 mg), potassium carbonate (485 mg), and dimethylsulfoxide (3.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were
 15 washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain ethyl (3R)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (451 mg) (Compound 32).

$[\alpha]_D = -56.4^\circ$ ($c=0.475$, MeOH).

20 $^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.26 (3H, t, $J=7.0$ Hz), 1.70-2.03 (3H, m), 2.14-2.20 (1H, m), 2.79-2.95 (2H, m), 3.07 (1H, t, $J=10.6$ Hz), 3.35-3.41 (1H, m), 3.57-3.62 (1H, m), 4.17 (2H, q, $J=7.0$ Hz), 7.06 (1H, d, $J=8.2$ Hz), 7.54-7.70 (2H, m), 7.84 (1H, d, $J=8.2$ Hz), 8.13-8.23 (2H, m).

25 IR (KBr) 2216, 1730, 1574 cm^{-1}

【0168】

Example 34 (Preparation of Compound 33)

A mixture of ethyl (3S)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (396 mg), a 1 N sodium hydroxide solution
 30 (2.6 mL), and tetrahydrofuran (4.4 mL) was stirred at room temperature for 20 hours. The mixture was acidified with 1 N hydrochloric acid, and extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated to obtain (3S)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (351 mg)
 35 (Compound 33).

$[\alpha]_D^{25} = +60.9^\circ$ ($c=0.495$, MeOH).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.74-2.24 (4H, m), 2.86-3.00 (2H, m), 3.04-3.14 (1H, m), 3.29-3.36 (1H, m), 3.58-3.62 (1H, m), 7.05 (1H, d, $J=7.8$ Hz), 7.55-7.68 (2H, m), 7.83 (1H, d, $J=7.8$ Hz), 8.12-
5 8.15 (1H, m), 8.18-8.21 (1H, m).

IR (KBr) 2947, 2216, 1705, 1474 cm^{-1}

【0169】

Example 35 (Preparation of Compound 34)

A mixture of ethyl (3S)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (340 mg), a 1 N sodium hydroxide solution (2.2 mL), and tetrahydrofuran (4.0 mL) was stirred at room temperature for 20 hours. The mixture was acidified with 1 N hydrochloric acid, and extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated to obtain
10 (3R)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (287 mg)
15 (Compound 34).

$[\alpha]_D^{25} = -63.9^\circ$ ($c=0.500$, MeOH).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.74-2.24 (4H, m), 2.86-3.00 (2H, m), 3.04-3.14 (1H, m), 3.29-3.36 (1H, m), 3.58-3.62 (1H, m), 7.05 (1H, d, $J=7.8$ Hz), 7.55-7.68 (2H, m), 7.83 (1H, d, $J=7.8$ Hz), 8.12-
20 8.15 (1H, m), 8.18-8.21 (1H, m).

IR (KBr) 2947, 2216, 1705, 1474 cm^{-1}

【0170】

Example 36 (Preparation of Compound 35)

25 A mixture of 4-fluoro-1-naphthonitrile (400 mg), 2-(methoxymethoxymethyl)piperidine (744 mg), potassium carbonate (646 mg), and dimethylsulfoxide (4.0 mL) was stirred at 100°C for 60 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The
30 extracts were washed with water, dried and concentrated, to obtain a yellowish-brown oily matter. A mixture of the obtained matter and trifluoroacetic acid (2.0 mL) was stirred at room temperature for 10 hours. The reaction solution was alkalified with a 1 N sodium hydroxide solution, and extracted with diethyl
35 ether. The extracts were washed with brine, dried and

concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[2-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile (37 mg) (Compound 35).

¹H-NMR (300 MHz, CDCl₃) δ: 1.42-1.92 (6H, m), 1.96-2.06 (1H, m),
5 2.88-2.96 (1H, m), 3.30-3.37 (1H, m), 3.52-3.62 (3H, m), 7.21 (1H, d, J=8.1 Hz), 7.55-7.67 (2H, m), 7.82 (1H, d, J=8.1 Hz), 8.17 (1H, d, J=8.1 Hz), 8.29 (1H, d, J=8.1 Hz).

IR (KBr) 2935, 2216, 1570, 1508 cm⁻¹

【0171】

10 Example 37 (Preparation of Compound 36)

A mixture of 7-hydroxy-4-nitro-1-indanone (1.02 g), triethylamine (2.21 mL), and dichloromethane (20 mL) was cooled to -25°C, and a mixture of trifluoromethanesulfonic anhydride (1.33 mL) and dichloromethane (5.0 mL) was added for 15 minutes.
15 After stirring at the same temperature for 10 minutes, the temperature was elevated to room temperature. The reaction solution was concentrated. The obtained residue was processed with silica gel column chromatography to obtain a brown solid matter (1.42 g). A mixture of the obtained solid (140 mg), 3-
20 (hydroxymethyl)piperidine (99 mg), potassium carbonate (119 mg), and dimethylsulfoxide (1.5 mL) was stirred at room temperature for 30 minutes. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified
25 by silica gel column chromatography to obtain 7-[3-(hydroxymethyl)-1-piperidinyl]-4-nitro-1-indanone (95 mg) (Compound 36).

¹H-NMR (300 MHz, CDCl₃) δ: 1.13-1.18 (1H, m), 1.76-1.91 (4H, m), 2.03-2.18 (1H, m), 2.69-2.73 (2H, m), 2.94 (1H, dd, J=12.6 and
30 9.6 Hz), 3.11 (1H, ddd, J=12.6, 9.6 and 3.3 Hz), 3.52-3.70 (5H, m), 3.77-3.83 (1H, m), 6.85 (1H, d, J=9.0 Hz), 8.28 (1H, d, J=9.0 Hz).

IR (KBr) 1699, 1586, 1319 cm⁻¹

【0172】

35 Example 38 (Preparation of Compound 37)

To a mixture of 7-[3-(hydroxymethyl)-1-piperidinyl]-4-nitro-1-indanone (91 mg) and methanol (2.0 mL) was added sodium borohydride (5.9 mg) at room temperature. After stirring for 30 minutes, the reaction solution was concentrated. The residue was
5 purified by silica gel column chromatography to obtain 7-[3-(hydroxymethyl)-1-piperidinyl]-4-nitro-1-indanol (92 mg)
(Compound 37).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.19-1.31 (1H, m), 1.64-2.18 (6H, m), 2.49-2.81 (2H, m), 2.93-3.04 (1H, m), 3.16-3.67 (6H, m), 4.28 (1H,
10 br.s), 5.51 (1H, t, $J=6.6$ Hz), 6.94 (1H, d, $J=9.0$ Hz), 8.09 (1H, d, $J=9.0$ Hz).

【0173】

Example 39 (preparation of compounds 38 and 39)

A mixture of 7-[3-(hydroxymethyl)-1-piperidinyl]-4-nitro-1-indanol (79 mg), 0.5 N hydrochloric acid (9.0 mL), and ethanol (4.0 mL) was stirred at 100°C for 6 hours. After cooling to room temperature, the reaction solution was concentrated. The residue was neutralized with a sodium hydrogen carbonate solution, and extracted with ethyl acetate. The extracts were washed with
20 water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain [1-(7-nitro-1H-inden-4-yl)-3-piperidinyl]methanol (37 mg) (Compound 38) and [1-(4-nitro-1H-indene-7-yl)-3-piperidinyl]methanol (20 mg) (Compound 39).

25 Compound 38

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.21-1.33 (1H, m), 1.71-2.07 (5H, m), 2.77 (1H, dd, $J=12.0$ and 9.6 Hz), 2.87-2.96 (1H, m), 3.49-3.70 (4H, m), 3.89 (2H, t, $J=1.8$ Hz), 6.64 (1H, dt, $J=5.7$ and 1.8 Hz), 6.86 (1H, d, $J=8.7$ Hz), 6.97 (1H, dt, $J=5.7$ and 1.8 Hz), 8.02 (1H,
30 d, $J=8.7$ Hz).

IR (KBr) 2928, 1582, 1327 cm^{-1}

Compound 39

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.24-1.35 (1H, m), 1.68-2.04 (5H, m), 2.81 (1H, dd, $J=12.3$ and 9.6 Hz), 2.93-3.01 (1H, m), 3.49 (2H, t,
35 $J=1.8$ Hz), 3.56-3.71 (3H, m), 3.75-3.80 (1H, m), 6.78 (1H, d,

J=9.0 Hz), 6.81 (1H, dt, J=5.7 and 1.8 Hz), 7.68 (1H, dt, J=5.7 and 1.8 Hz), 8.09 (1H, d, J=9.0 Hz).

IR (KBr) 2936, 1584, 1318 cm^{-1}

【0174】

5 Example 40 (Preparation of Compound 40)

A mixture of 4-fluoro-1-naphthonitrile (200 mg), 3-hydroxypiperidine (236 mg), potassium carbonate (322 mg), and dimethylsulfoxide (2.5 mL) was stirred at 100°C for 3 hours.

After cooling to room temperature, the reactant was poured into
10 water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(3-hydroxy-1-piperidinyl)-1-naphthonitrile (259 mg) (Compound 40).

^1H -NMR (300 MHz, CDCl_3) δ : 1.66-2.28 (5H, m), 3.02-3.16 (3H, m),
15 3.22-3.36 (1H, m), 4.08-4.15 (1H, m), 7.03 (1H, d, J=7.8 Hz), 7.59 (1H, ddd, J=8.1, 6.6 and 1.5 Hz), 7.66 (1H, ddd, J=8.1, 6.6 and 1.5 Hz), 7.82 (1H, d, J=7.8 Hz), 8.18-8.21 (2H, m).

IR (KBr) 2216, 1572 cm^{-1}

【0175】

20 Example 41 (Preparation of Compound 41)

Sodium hydride (60% in oil, 84 mg) was washed with hexane and suspended to N,N-dimethylformamide (2.5 mL). 4-(3-hydroxy-1-piperidinyl)-1-naphthonitrile (220 mg) was added thereto, and the mixture was stirred for 10 minutes. After adding methyl iodide
25 (160 μl), the resulting mixture was stirred for 40 minutes. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(3-methoxy-1-piperidinyl)-1-naphthonitrile (220 mg)
30 (Compound 41).

mp 92 - 93°C.

^1H -NMR (300 MHz, CDCl_3) δ : 1.48-1.60 (1H, m), 1.79-2.03 (2H, m),
2.14-2.27 (1H, m), 2.82-2.90 (2H, m), 3.28-3.34 (1H, m), 3.44 (3H, s), 3.51-3.64 (2H, m), 7.02 (1H, d, J=7.8 Hz), 7.57 (1H, ddd,
35 J=8.4, 6.6 and 1.5 Hz), 7.65 (1H, ddd, J=8.4, 6.6 and 1.5 Hz),

7.82 (1H, d, J=7.8 Hz), 8.17-8.20 (2H, m).

IR (KBr) 2215, 1574 cm^{-1}

Anal. Calcd. for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}$: C, 76.66; H, 6.81; N, 10.52.

Found: C, 76.44; H, 6.73; N, 10.44.

5 **【0176】**

Example 42 (Preparation of Compound 42)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), N-pyrrolidin-3-yl acetamide (240 mg), potassium carbonate (87 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 16 hours.
10 After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate) and crystallized from hexane : ethyl acetate = 4 : 1, to obtain
15 N-[1-(4-cyano-1-naphthyl)pyrrolidin-3-yl]acetamide (136 mg) (Compound 42).

mp 154 - 155°C.

^1H -NMR (200 MHz, CDCl_3) δ : 1.90-2.15(1H, m), 2.02 (3H, s), 2.35-2.48(1H, m), 3.40-3.60(2H, m), 3.70-3.92(2H, m), 4.55-
20 4.78(1H, m), 5.90(1H, d, J=5.0 Hz), 6.72(1H, d, J=5.0Hz), 7.42-7.68(2H, m).

IR (KBr) 2203, 1649, 1563, 1518 cm^{-1}

Anal. Calcd. for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}$: C, 73.10; H, 6.13; N, 15.04.

Found: C, 72.92; H, 6.04; N, 14.85.

25 **【0177】**

Example 43 (Preparation of Compound 43)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), (2S)-pyrrolidin-2-yl methanol (177 mg), potassium carbonate (87 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 16 hours.
30 After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 2 : 1). The residue was dissolved in ethyl acetate. A
35 4N-hydrochloric acid / ethyl acetate solution (0.3 mL) was added,

and the resulting mixture was crystallized to obtain 4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-1-naphthonitrile hydrochloride (148 mg) (compound 43).

mp 123 - 125°C.

5 $[\alpha]_D = +119.7^\circ$ (c=0.870, MeOH).

$^1\text{H-NMR}$ (200 MHz, DMSO- d_6) δ : 1.60-2.05(3H, m), 2.15-2.32(1H, m), 3.25-3.57(3H, m), 3.90-4.20(2H, m), 7.02(1H, d, J=8.4Hz), 7.48-7.55(2H, m), 7.89(1H, d, J=8.4Hz), 7.98(1H, d, J=8.4Hz), 8.26(1H, d, J=8.4Hz).

10 IR (KBr) 2225, 1522, 772 cm^{-1}

Anal. Calcd. for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}\cdot\text{HCl}$: C, 66.55; H, 5.93; N, 9.70.

Found: C, 66.27; H, 5.88; N, 9.58.

【0178】

Example 44 (Preparation of Compound 44)

15 A mixture of 4-fluoro-1-naphthonitrile (100 mg), (2R)-pyrrolidin-2-yl methanol (117 mg), potassium carbonate (87 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 16 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were
20 washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 2 : 1). The residue was dissolved in ethyl acetate and a 4N-hydrochloric acid / ethyl acetate solution (0.3 mL) was added thereto. The resulting solution was concentrated and dried.
25 The obtained residue was crystallized from hexane : ethyl acetate = 1 : 2, to obtain 4-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]-1-naphthonitrile hydrochloride (148 mg) (Compound 44).

mp 125 - 127°C.

$[\alpha]_D = -117.5^\circ$ (c=0.922, MeOH).

30 $^1\text{H-NMR}$ (200 MHz, DMSO- d_6) δ : 1.60-2.09(3H, m), 2.14-2.34(1H, m), 3.25-3.55(3H, m), 3.85-4.20(2H, m), 7.01(1H, d, J=8.4Hz), 7.48-7.74(2H, m), 7.89(1H, d, J=8.4Hz), 7.98(1H, dd, J=1.2 and 8.4Hz), 8.26(1H, d, J=8.4Hz).

IR (KBr) 2225, 1522, 772 cm^{-1}

35 Anal. Calcd. for

$C_{16}H_{16}N_2O \cdot HCl \cdot 0.2H_2O$: C, 65.73; H, 6.00; N, 9.58.

Found: C, 65.96; H, 5.93; N, 9.52.

【0179】

Example 45 (Preparation of Compound 45)

5 A mixture of 4-fluoro-1-naphthonitrile (100 mg), (2R)-2-(methoxymethyl)pyrrolidine (200 mg), potassium carbonate (87 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 16 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were
10 washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 2 : 1). The residue was dissolved in ethyl acetate and a 4N-hydrochloric acid / ethyl acetate solution (0.3 mL) was added thereto. The resulting solution was concentrated and dried.
15 The obtained residue was crystallized from hexane : ethyl acetate = 1 : 1, to obtain 4-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]-1-naphthonitrile hydrochloride (63 mg) (Compound 45).
mp 88 - 89°C.

$[\alpha]_D = -136.6^\circ$ (c=0.696, MeOH).

20 1H -NMR (200 MHz, DMSO- d_6) δ : 1.65-2.05 (3H, m), 2.12-2.34 (1H, m), 3.15 (3H, s), 3.20-3.46 (2H, m), 3.93-4.05 (1H, m), 4.15-4.36 (1H, m), 7.06 (1H, d, J=8.4Hz), 7.50-7.76 (2H, m), 7.90 (1H, d, J=8.4Hz), 8.00 (1H, dd, J=1.0 and 8.4Hz), 8.23 (1H, d, J=8.4Hz).

IR (KBr) 2218, 1598, 1519, 1386, 773 cm^{-1}

25 Anal. Calcd. for

$C_{17}H_{18}N_2O \cdot HCl \cdot 0.1H_2O$: C, 67.03; H, 6.35; N, 9.20.

Found: C, 66.97; H, 6.35; N, 9.05.

【0180】

Example 46 (Preparation of Compound 46)

30 A mixture of 4-fluoro-1-naphthonitrile (100 mg), L-prolinamide (200 mg), potassium carbonate (87 mg), and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 15 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were
35 washed with water, dried and concentrated. The obtained residue

was purified by silica gel column chromatography (hexane : ethyl acetate = 1 : 2) and crystallized from hexane : ethyl acetate = 1 : 2, to obtain 1-(4-cyano-1-naphthyl)-L-prolinamide (101 mg) (Compound 46).

5 mp 177 - 178°C.

$[\alpha]_D^{25} = +218.7^\circ$ (c=0.608, MeOH).

$^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.80-2.30 (3H, m), 2.30-2.72 (1H, m), 3.28-3.46 (1H, m), 4.10-4.30 (1H, m), 4.38 (1H, t, $J=8.0\text{Hz}$), 5.32 (1H, brs), 6.39 (1H, brs), 6.97 (1H, d, $J=8.0\text{Hz}$), 7.52-7.75 (2H, m),
10 7.78 (1H, d, $J=8.0\text{Hz}$), 8.18-8.32 (2H, m).

IR (KBr) 2210, 1691, 1323 cm^{-1}

Anal. Calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}$: C, 72.43; H, 5.70; N, 15.84.

Found: C, 72.25; H, 5.52; N, 15.68.

【0181】

15 Example 47 (Preparation of Compound 47)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), 2-methylpyrrolidine (150 mg), potassium carbonate (87 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 15 hours. After cooling to room temperature, the reactant was poured into
20 water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 8 : 1). The residue was dissolved in ethyl acetate and a 4N-hydrochloric acid / ethyl acetate solution (0.3 mL) was
25 added thereto. The resulting solution was concentrated and dried, to obtain 4-(2-methylpyrrolidin-1-yl)-1-naphthonitrile hydrochloride (150 mg) as a hygroscopic amorphous matter (Compound 47).

$^1\text{H-NMR}$ (200 MHz, DMSO-d_6) δ : 1.13 (3H, d, $J=5.8\text{Hz}$), 1.58-2.10 (3H, m), 2.20-2.40 (1H, m), 3.20-3.60 (1H, m), 3.95-4.20 (2H, m), 6.92 (1H, d, $J=8.4\text{Hz}$), 7.49-7.76 (2H, m), 7.90 (1H, d, $J=8.4\text{Hz}$), 7.99 (1H, d, $J=8.4\text{Hz}$), 8.25 (1H, d, $J=8.4\text{Hz}$).

IR (KBr) 2209, 1566, 1515, 1328, 764 cm^{-1}

【0182】

35 Example 48 (Preparation of Compound 48)

A mixture of 4-fluoro-1-naphthonitrile (400 mg), 2-methylpyrrolidine (410 mg), potassium carbonate (350 mg) and dimethylsulfoxide (8.0 mL) was stirred at 100°C for 5 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 8 : 1), to obtain 4-(2-methylpyrrolidin-1-yl)-1-naphthonitrile (516 mg) (Compound 48).

¹H-NMR (200 MHz, CDCl₃) δ: 1.18(3H, d, J=6.0Hz), 1.62-1.92(2H, m), 1.93-2.15(1H, m), 2.20-2.40(1H, m), 3.25-3.40(2H, m), 6.82(1H, d, J=8.4Hz), 7.40-7.68(2H, m), 7.76(1H, d, J=8.4Hz), 8.18(2H, t, J=7.9Hz).

IR (KBr) 2209, 1565, 1514, 1327, 763 cm⁻¹

15 **【0183】**

Example 49 (Preparation of Compound 49)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), N-methyl-N-pyrrolidin-3-yl acetamide (249 mg), potassium carbonate (87 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 15 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 1 : 2) and crystallized from hexane : ethyl acetate = 1 : 1, to obtain N-[1-(4-cyano-1-naphthyl)pyrrolidin-3-yl]-N-methylacetamide (130 mg) (Compound 49).
mp 144 - 145°C.

¹H-NMR (200 MHz, CDCl₃) δ: 2.00-2.40(2H, m), 2.15(2.1H, s), 2.20(0.9H, s), 3.03(0.9H, s), 3.08(2.1H, s), 3.40-3.78(4H, m), 4.52-4.62(0.3H, m), 5.28-5.50(0.7H, m), 6.80(0.7H, d, J=8.4Hz), 6.84(0.3H, d, J=8.4Hz), 7.45-7.70(2H, m), 7.77(0.7H, J=8.4Hz), 7.79(0.3H, d, J=8.4Hz), 8.12(2H, d, J=8.4Hz).

IR (KBr) 2199, 1655, 1565 cm⁻¹

Anal. Calcd. for C₁₈H₁₉N₃O: C, 73.69; H, 6.53; N, 14.32.

35

Found: C, 73.48; H, 6.56; N, 14.12.

【0184】

Example 50 (Preparation of Compound 50)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), pyrrolidin-3-yl methanol hydrochloride (240 mg), potassium carbonate (330 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 1 : 1). The residue was dissolved in ethyl acetate and a 4N-hydrochloric acid / ethyl acetate solution (0.3 mL) was added thereto. The resulting solution was concentrated and dried to obtain 4-[3-(hydroxymethyl)pyrrolidin-1-yl]-1-naphthonitrile hydrochloride (153 mg) as hygroscopic amorphous matter (Compound 50).

¹H-NMR (200 MHz, CDCl₃ + CD₃OD + D₂O) δ: 1.75-2.00(1H, m), 2.05-2.38(1H, m), 2.45-2.80(1H, m), 3.40-3.90(6H, m), 6.81(1H, d, J=8.4Hz), 7.40-7.80(3H, m), 8.14(1H, d, J=8.4Hz), 8.29(1H, d, J=8.4Hz).

IR (KBr) 2205, 1561 cm⁻¹

【0185】

Example 51 (Preparation of Compound 51)

4-(3-(hydroxymethyl)pyrrolidin-1-yl)-1-naphthonitrile hydrochloride (85 mg) was dissolved in N,N-dimethylformamide (2.0 mL), sodium hydride (60% in oil, 28 mg) was added at room temperature, and the mixture was stirred for 1 hour. After adding methyl iodide (0.1 mL), the mixture was stirred at room temperature for 2 hours. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography (hexane : ethyl acetate = 1 : 2) to obtain 4-[3-(methoxymethyl)pyrrolidin-1-yl]-1-naphthonitrile (77 mg) (Compound 51).

¹H-NMR (200 MHz, CDCl₃) δ: 1.70-1.96(1H, m), 2.06-2.30(1H, m), 3.39(3H, s), 3.42-3.78(6H, m), 6.72(1H, d, J=8.2Hz), 7.40-7.68(2H,

m), 7.73(1H, d, J=8.2Hz), 8.12-8.30(2H, m).

IR (KBr) 2206, 1569 cm^{-1}

【0186】

Example 52 (Preparation of Compound 52)

5 A mixture of 4-fluoro-1-naphthonitrile (100 mg), cis-(5-methylpyrrolidin-3-yl) methanol hydrochloride (220 mg), potassium carbonate (330 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl
10 acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain cis-4-[4-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-1-naphthonitrile (139 mg) (Compound 52).
 $^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.25(3H, d, J=6.2Hz), 1.40-1.70(1H, m),
15 2.28-2.58(2H, m), 3.30-3.45(1H, m), 3.62-4.20(4H, m), 6.85(1H, d, J=8.4Hz), 7.44-7.68(2H, m), 7.77(1H, d, J=8.4Hz), 8.18(2H, t, J=8.4Hz).

IR (KBr) 2209, 1566, 1514, 1327 cm^{-1}

【0187】

20 Example 53 (Preparation of Compound 53)

A mixture of 4-fluoro-1-naphthonitrile (100 mg), trans-(5-methylpyrrolidin-3-yl) methanol hydrochloride (220 mg), potassium carbonate (330 mg) and dimethylsulfoxide (2.0 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the
25 reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain trans-4-[4-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-1-naphthonitrile (148 mg) (Compound 53).
30 $^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.10(3H, d, J=5.8Hz), 1.18-1.99(1H, m), 2.10-2.30(1H, m), 2.40-2.70(1H, m), 3.10-3.20(1H, m), 3.40-3.70(2H, m), 4.00-4.20(2H, m), 6.86(1H, d, J=8.0Hz), 7.48-7.70(2H, m), 7.76(1H, d, J=8.0Hz), 8.12-8.24(2H, m).

IR (KBr) 2210, 1566, 1514, 1327 cm^{-1}

35 【0188】

Example 54 (Preparation of Compound 54)

Cis-4-[4-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-1-naphthonitrile (120 mg) was dissolved in N,N-dimethylformamide (3.0 mL), sodium hydride (60% in oil, 35 mg) was added at room temperature, and the mixture was stirred for 1 hour. After adding methyl iodide (0.2 mL), the mixture was stirred at room temperature for 15 hours. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain cis-4-[4-(methoxymethyl)-2-methylpyrrolidin-1-yl]-1-naphthonitrile (78 mg) (Compound 54).

$^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.36(3H, d, $J=6.2\text{Hz}$), 1.60-1.82(1H, m), 2.44-2.76(2H, m), 3.44-3.78(3H, m), 3.56(3H, s), 4.01(1H, t, $J=8.8\text{Hz}$), 4.10-4.34(1H, m), 7.01(1H, d, $J=8.4\text{Hz}$), 7.60-7.86(2H, m), 7.94(1H, d, $J=8.0\text{Hz}$), 8.28-8.42(2H, m).

IR (KBr) 2210, 1567, 1514, 1330 cm^{-1}

【0189】

Example 55 (Preparation of Compound 55)

Trans-4-[4-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-1-naphthonitrile (129 mg) was dissolved in N,N-dimethylformamide (3.0 mL), sodium hydride (60% in oil, 32 mg) was added at room temperature, and the mixture was stirred for 1 hour. After adding methyl iodide (0.2 mL), the mixture was stirred at room temperature for 15 hours. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain trans-4-[4-(methoxymethyl)-2-methylpyrrolidin-1-yl]-1-naphthonitrile (100 mg) (Compound 55).

$^1\text{H-NMR}$ (200 MHz, CDCl_3) δ : 1.12(3H, d, $J=5.8\text{Hz}$), 1.80-1.97(1H, m), 2.08-2.22(1H, m), 2.55-2.75(1H, m), 3.03-3.40(3H, m), 3.29(3H, s), 4.00-4.20(2H, m), 6.86(1H, d, $J=8.6\text{Hz}$), 7.42-7.64(2H, m), 7.77(1H, d, $J=8.0\text{Hz}$), 8.12-8.24(2H, m).

IR (KBr) 2211, 1566, 1515, 1332 cm^{-1}

【0190】

Example 56 (Preparation of Compound 56)

A mixture of 4-fluoro-1-naphthonitrile (200 mg), 3-(hydroxymethyl)-3-methylpiperidine (301 mg), potassium carbonate (322 mg) and dimethylsulfoxide (2.5 mL) was stirred at 100°C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[3-(hydroxymethyl)-3-methyl-1-piperidinyl]-1-naphthonitrile (264 mg) (Compound 56).

¹H-NMR (300 MHz, CDCl₃) δ: 1.13 (3H, s), 1.40-1.48 (1H, m), 1.63-2.04 (4H, m), 2.86-3.20 (4H, m), 3.63-3.76 (2H, m), 7.03 (1H, d, J=8.1 Hz), 7.54-7.67 (2H, m), 7.81 (1H, d, J=8.1 Hz), 8.17-8.22 (2H, m).

IR (KBr) 2216, 1572 cm⁻¹

【0191】

Example 57 (Preparation of Compound 57)

Sodium hydride (60% in oil, 34 mg) was washed with hexane and suspended in N,N-dimethylformamide (1.0 mL). 4-[3-(hydroxymethyl)-3-methyl-1-piperidinyl]-1-naphthonitrile (100 mg) was added thereto, and the mixture was stirred for 10 minutes. After adding methyl iodide (66 μl), the resulting mixture was stirred for 40 minutes. The reactant was poured into water, and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[3-(methoxymethyl)-3-methyl-1-piperidinyl]-1-naphthonitrile (100 mg) (Compound 57).

¹H-NMR (300 MHz, CDCl₃) δ: 1.14 (3H, s), 1.37-1.45 (1H, m), 1.62-1.70 (1H, m), 1.84-1.94 (2H, m), 2.78-2.82 (1H, m), 3.04-3.14 (3H, m), 3.31 (1H, d, J=9.0 Hz), 3.37 (3H, s), 3.48 (1H, d, J=9.0 Hz), 7.02 (1H, d, J=7.8 Hz), 7.57 (1H, ddd, J=8.4, 6.9 and 1.5 Hz), 7.64 (1H, ddd, J=8.4, 6.9 and 1.5 Hz), 7.80 (1H, d, J=7.8 Hz), 8.16-8.19 (1H, m), 8.21-8.24 (1H, m).

IR (KBr) 2934, 2216, 1574 cm^{-1}

【0192】

Example 58 (Preparation of Compound 58)

A mixture of 4-fluoro-1-naphthonitrile (150 mg), 3,5-
5 dimethylpiperidine (198 mg), potassium carbonate (362 mg), and
dimethylsulfoxide (2.0 mL) was stirred at 100°C for 3 hours.
After cooling to room temperature, the reactant was poured into
water, and then extracted with ethyl acetate. The extracts were
washed with water, dried and concentrated. The obtained residue
10 was purified by silica gel column chromatography to obtain 4-
(3,5-dimethyl-1-piperidinyl)-1-naphthonitrile (223 mg) (Compound
58).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 0.72-0.84 (1H, m), 0.95 (6H, d, $J=6.6$
Hz), 1.91-2.12 (3H, m), 2.32 (2H, t, $J=11.4$ Hz), 3.39-3.44 (2H,
15 m), 6.98 (1H, d, $J=7.8$ Hz), 7.55 (1H, ddd, $J=8.4$, 6.6 and 1.5 Hz),
7.63 (1H, ddd, $J=8.4$, 6.6 and 1.5 Hz), 7.80 (1H, d, $J=7.8$ Hz),
8.11-8.14 (1H, m), 8.16-8.19 (1H, m).

IR (KBr) 2953, 2216, 1574 cm^{-1}

【0193】

20 Example 59 (Preparation of Compound 59)

To a mixture of pyrrolidine (16 μL), palladium acetate (1.9
mg), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (15 mg),
sodium t-butoxide (22 mg) and toluene (1.5 mL) was added a
mixture of 4-cyano-5,6,7,8-tetrahydro-1-naphthalenyl
25 trifluoromethanesulfonate (50 mg) and toluene (0.5 mL) at 80°C
for 50 minutes. After stirring for 1 hour, the mixture was
cooled to room temperature and poured into water, and extracted
with ethyl acetate. The extracts were washed with water, dried
and concentrated. The obtained residue was purified by silica
30 gel column chromatography to obtain 4-(1-pyrrolidinyl)-5,6,7,8-
tetrahydro-1-naphthalenecarbonitrile (12 mg) (Compound 59).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.66-1.75 (2H, m), 1.78-1.87 (2H, m),
1.92-1.96 (4H, m), 2.61 (2H, t, $J=6.6$ Hz), 2.95 (2H, t, $J=6.6$ Hz),
3.25-3.29 (4H, m), 6.65 (1H, d, $J=8.4$ Hz), 7.33 (1H, d, $J=8.4$ Hz).

35 IR (KBr) 2938, 2209, 1588 cm^{-1}

【0194】

Example 60 (Preparation of Compound 60)

To a mixture of piperidine (39 μ L), palladium acetate (3.7 mg), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (33 mg),
5 sodium t-butoxide (44 mg) and toluene (3.0 mL) was added a mixture of 4-cyano,5,6,7,8-tetrahydro-1-naphthalenyl trifluoromethanesulfonate (100 mg) and toluene (1.0 mL) at 80°C for 50 minutes. After stirring for 2 hours, the mixture was cooled to room temperature, poured into water, and then extracted
10 with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-(1-piperidinyl)-5,6,7,8-tetrahydro-1-naphthalenecarbonitrile (5.0 mg) (Compound 60).
 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.56-1.63 (2H, m), 1.67-1.77 (6H, m),
15 1.81-1.89 (2H, m), 2.67 (2H, t, $J=6.0$ Hz), 2.84-2.87 (4H, m), 2.96 (2H, t, $J=6.0$ Hz), 6.83 (1H, d, $J=8.4$ Hz), 7.41 (1H, d, $J=8.4$ Hz).

IR (KBr) 2934, 2220, 1587 cm^{-1}

【0195】

20 Example 61 (preparation of compounds 61 and 62)

A mixture of 4-(3-oxo-1-pyrrolidinyl)-1-naphthonitrile (159 mg), hydroxylamine hydrochloride (70.1 mg), sodium acetate (99.4 mg), ethanol (4.0 mL) and water (2.0 mL) was stirred at room temperature for 1.5 hours. The reactant was concentrated and the
25 residue was distributed between ethyl acetate and water. The organic layer was washed with brine, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 4-[3-(hydroxyimino)-1-pyrrolidinyl]-1-naphthonitrile (76.5 mg) (Compound 61) providing a high R_f value and 4-[3-(hydroxyimino)-1-pyrrolidinyl]-1-naphthonitrile (20.4 mg)
30 (Compound 62) providing a low R_f value.

Compound 61

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 2.94 (2H, t, $J=6.9$ Hz), 3.57 (2H, t, $J=6.9$ Hz), 4.03 (2H, s), 7.00 (1H, d, $J=8.1$ Hz), 7.37 (1H, br.s),
35 7.58 (1H, ddd, $J=8.4$, 6.9 and 1.5 Hz), 7.67 (1H, ddd, $J=8.4$, 6.9

and 1.5 Hz), 7.82 (1H, d, J=8.1 Hz), 8.17-8.23 (2H, m).

IR (KBr) 2216, 1572 cm^{-1}

Compound 62

^1H -NMR (300 MHz, CDCl_3) δ : 2.86-2.90 (2H, m), 3.57 (2H, t, J=6.9 Hz), 4.22 (2H, s), 7.01 (1H, d, J=8.1 Hz), 7.23 (1H, br.s), 7.58 (1H, ddd, J=8.4, 6.9 and 1.5 Hz), 7.67 (1H, ddd, J=8.4, 6.9 and 1.5 Hz), 7.82 (1H, d, J=8.1 Hz), 8.17-8.23 (2H, m).

IR (KBr) 2215, 1572 cm^{-1}

【0196】

10 Example 62 (Preparation of Compound 63)

To a mixture of pyrrolidine (31 μL), palladium acetate (3.5 mg), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (29 mg), sodium t-butoxide (42 mg) and toluene (1.5 mL) was added a mixture of 7-cyano-2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl trifluoromethanesulfonate (100 mg) and toluene (0.8 mL) at 80°C for 30 minutes. After after stirring for 1.5 hours, the mixture was cooled to room temperature, poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain 2,2-dimethyl-4-(1-pyrrolidinyl)-2,3-dihydro-1-benzofuran-7-carbonitrile (30 mg) (Compound 63).

^1H -NMR (300 MHz, CDCl_3) δ : 1.49 (6H, s), 1.93-1.98 (4H, m), 3.27 (2H, s), 3.45-3.49 (4H, m), 6.03 (1H, d, J=8.7 Hz), 7.13 (1H, d, J=8.7 Hz).

IR (KBr) 2201, 1613 cm^{-1}

【0197】

Experimental Example 1: AR-binding inhibition test (wild type and LNCaP type)

30 To a solution of wild type or LNCaP type mutant androgen receptor (AR) was added 3 nM radio-labeled Mibolerone and 100 nM of the compound. The mixture was incubated at 4°C for 3 hours, and B (Bound) and F (Free) Mibolerones were separated by the dextran/charcoal method. The radioactivity of B was measured and inhibition rate of the compound was calculated. The results are

35

shown in Table 1.

[Table 1]

Compound No.	Inhibition rate (%) at 100 nM	
	Wild type	LNCaP type
1	88	78
3	97	97
8	92	96
10	112	144
18	96	79
19	75	91
30	105	113
45	105	110
47	116	116
50	91	102
56	80	91

【0198】

Experimental Example 2: Evaluation of a compound in reporter
5 assay system using Cos-7 cells

Cos-7 cells were inoculated in a 150 cm² flask at 5,000,000 cells, and incubated in a culture solution (DMEM medium containing 10% Dextran Charcoal (DCC)-Fetal Bovine Serum (FBS) and 2 mM glutamine) for 24 hours. A vector DNA containing AR
10 gene and a vector DNA ligated with luciferase gene downstream of the androgen-responsive promoter, which was constructed by ligating two PSA promoter regions in tandem, were cotransfected by the liposome method. Two hours later, the culture medium was replaced and incubation was further carried out for 3 hours. 1
15 μ M of 5 α -dihydrotestosterone or 100 nM of the compound were added, and incubation was further carried out for 24 hours. By measuring luciferase activity, induction rate (%) of the compound was calculated, based on the luciferase activity induced is 100 when 1 μ M of 5 α -dihydrotestosterone was added. The results are
20 shown in Table 2.

[Table 2]

Compound No.	Induction rate (%) at 100 nM	
	Wild type	LNCaP type
1	97	88
3	119	112

【0199】

Experimental Example 3: PSA production test in Human prostate
 5 cancer cells strain

Human prostate cancer cell strain LNCaP-FGC was inoculated in 96 well plate at 5,000 cells/100 μ L/well. The next day, the test Compound (100 nM of final concentration), or vehicle or testosterone as control (0.35 to 350 nM of final concentration)
 10 was added thereto. 3 days after the drug addition, the culture supernatant was collected. Concentration of androgen-dependently produced PSA (Prostate Specific Antigen) in the culture supernatant was measured by ELISA. The promotion rate on PSA production by the test compound was calculated, based that
 15 the vehicle-addition group is 0 and the 350 nM testosterone-addition group is 100. The results are shown in Table 3.

[Table 3]

Compound No.	Promotion rate (%) on PSA production at 100 nM
3	90
8	71
10	75
19	70
30	100
47	88
50	88
56	96

20 【0200】

Experimental Example 4: Influence of an androgen receptor agonist
on growth rate of hormone-resistant cancer cell

1) Establishment of hormone-resistant cell strain (LNCaP-hr
and MDA PCa 2b-hr cell strains)

LNCaP-FGC and MDA PCa 2b cell strains were incubated in a culture solution free of androgen (RPMI1640+10% Dextran Charcoal (DCC)-Fetal Bovine Serum (FBS) for LNCaP-FGC, Ham's F-12K + 25 ng/ml cholera toxin + 10 ng/ml EGF + 0.005 mM phosphoethanol amine + 100 pg/ml hydrocortisone + 45 nM selenious acid + 0.005 mg/ml insulin + 20% DCC-FBS for MDA PCa 2b). Initially, no growth was observed, but 3 to 8 months of continuous incubation led to growth. The cells were designated as LNCaP-hr and MDA PCa 2b-hr.

10 **【0201】**

2) Influence of an androgen receptor agonist on growth rate of hormone-resistant cancer cell

(Method) LNCaP-hr (incubated for 60 weeks in androgen-free culture solution) cells were inoculated in 24 well plate at 40,000 cells/ml/well. The next day, 0.01 to 10 nmol/L of the test compound was added thereto. 3 days after the addition, cell number was counted. Furthermore, MDA PCa 2b-hr (incubated for 61 weeks in androgen-free culture solution) cells were inoculated in 24 well plate at 40,000 cells/ml/well. The next day, 0.01 to 10 μ mol/L of the test compound was added thereto. 4 days after the addition, cell number was counted.

(Results) The compound of the present invention inhibited the growth of LNCaP-hr and MDA PCa 2b-hr cells.

25 **【0202】**

Formulation Example 1: Microcapsules containing leuprorelin acetate

5.8 g of leuprorelin acetate was dissolved in 6.7 ml of distilled water. To this was added 138 g of dichloromethane solution containing polylactic acid (weight average molecular weight: 15000) (51.6 g) which had been separately dissolved and filtered, and the mixture was stirred and emulsified with an auto-mini mixer for 9 minutes (rotation number: about 6000 rpm), and adjusted to 15°C. This mixture was added to 13.5 L aqueous solution of 0.1% polyvinyl alcohol (PVA) which had been

previously dissolved, filtered and adjusted to the same temperature, to emulsify it. For emulsification, HOMOMIC LINE FLOW (Tokushu Kika Kogyo Co., Ltd.) was used, and the rotation number of the mixer was about 7,000 rpm. Solvent was removed
 5 from this W/O/W emulsion with light stirring for about 3 hours (drying method in water).

The obtained microcapsules were put through a sieve of 74 μm to remove coarse particles, and separated by filtration or centrifugation. Those were washed with distilled water, free
 10 drug and PVA were removed, and re-dispersed with small amount of water. 8.7 g of D-mannitol was dissolved therein, and the mixture was sieved and lyophilized. The rack temperature was gradually elevated in the drying process, and the microcapsules were dried finally at 52°C for 69 hours. The microcapsules were
 15 sieved and crushed to give microcapsule powders. From this process, 58 g of microcapsule powders containing 15% D-mannitol was obtained.

【0203】

Formulation Example 2: Injections containing the compound of
 20 Example 1

- | | |
|---|---------|
| (1) Compound of Example 1 | 5.0 mg |
| (2) Sodium chloride | 20.0 mg |
| (3) Distilled water to make total volume 2 ml | |

The compound of Example 1 (5.0 mg) and sodium chloride (20.0
 25 mg) are dissolved in distilled water, and to the solution is added water to make the total volume 2 ml. The solution is filtered, and filled into an ampoule (content: 2 ml) under sterilized conditions. The ampoule is sterilized and sealed to obtain an injectable solution.

30 【0204】

Formulation Example 3: Tablets containing testosterone

- | | |
|------------------------------------|---------|
| (1) Testosterone | 50 mg |
| (2) Lactose | 34 mg |
| (3) Corn starch | 10.6 mg |
| 35 (4) Corn starch (in paste form) | 5 mg |

(5) Magnesium stearate	0.4 mg
(6) Carboxymethyl cellulose calcium	20 mg
Total	120 mg

In accordance with conventional methods, the above (1) to
5 (6) were mixed and tabletted by means of a tablet machinee to
obtain a tablet.

【0205】

Formulation Example 4

The preparation obtained in Formulation Example 1 and the
10 preparation obtained in Formulation Example 2 are combined.

Formulation Example 5

The preparation obtained in Formulation Example 1 and the
preparation obtained in Formulation Example 3 are combined.

Formulation Example 6

15 The preparation obtained in Formulation Example 1, the
preparation obtained in Formulation Example 2 and the preparation
obtained in Formulation Example 3 are combined.

【0206】

【Effect of the Invention】


20 The compound of the present invention has excellent actions
as an androgen receptor modulator (especially an agonist), and is
useful for preventing and/or treating hypogonadism, osteoporosis
or hormone-resistant cancer (especially LHRH derivative-resistant
prostate cancer) for which androgen administration is effective.

【Document】 Abstract

【Summary】

【Problem】 Provision of a compound represented by the following formula (I).

5 【Solving Means】 A compound represented by the general formula:



[wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X¹ represents a carbon atom, X² represents a carbon atom, etc., Y¹ represents a group represented by the formula CR²R³ (wherein R² and R³ are the same or different and each represents a hydrogen atom, a cyano group, etc.), Y² represents a group represented by the formula CR⁴R⁵ (wherein R⁴ and R⁵ are the same or different and each represents a hydrogen atom, a cyano group, etc.), etc., and R¹ represents an electron-withdrawing group, or a salt thereof.

15 【Main Drawing】 none